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SUMMARY 
 
This study describes: 
• the influence of a methanolic extract of unfermented Rooibos and five major 
Rooibos flavonoids, aspalathin, nothofagin, rutin, orientin and vitexin, on the 
activities of key adrenal steroidogenic enzymes - cytochrome P450 17β-
hydroxylase/17,20-lyase (CYP17A1), 3β-hydroxysteroid dehydrogenase 
(3βHSD2), cytochrome P450 21-hydroxylase (CYP21A2) and cytochrome 
P450 11β-hydroxylase (CYP11B1), expressed in non-steroidogenic COS-1 
cells; 
 
• the development of a novel UPLC-MS/MS method for the separation and 
quantification of 21 adrenal steroid metabolites; 
 
• the influence of Rooibos and aforementioned flavonoids on adrenal steroid 
hormone production in H295R cells - a human adrenal carcinoma cell line 
expressing the enzymes catalysing the production of mineralocorticoids, 
glucocorticoids and adrenal androgens, assayed under both basal (normal) 
and forskolin-stimulated (stressed) conditions; 
 
• the influence of Rooibos on the inter-conversion between cortisol and 
cortisone by 11βHSD1 and 11βHSD2 expressed in CHO-K1 cells; 
 
• the influence of Rooibos consumption on circulating steroid hormone levels 
and ratios in male Wistar rats; 
 
• the influence of Rooibos consumption on circulating steroid hormone levels 
and ratios in male and female human test subjects at risk for developing 
cardiovascular disease. 
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OPSOMMING 
 
Hierdie studie beskryf: 
• die invloed van metanoliese ekstrakte van ongefermenteerde Rooibos en vyf 
van die hoof flavonoïedverbindings in Rooibos, aspalatien, notofagien, rutien, 
oriëntien en viteksien, op die aktiwiteite van  ensieme wat steroïedbiosintese 
in die bynier kataliseer – sitochroom P450 17α-hidroksilase/17,20-liase 
(CYP17A1), 3β-hidroksisteroïed dehidrogenase (3βHSD2), sitochroom P450 
21-hidroksilase (CYP21A2) en sitochroom P450 11β-hidroksilase (CYP11B1), 
uitgedruk in nie-steroïed produserende COS-1 selle; 
 
• die ontwikkeling van ‘n geskikte UPLC-MS/MS metode vir die skeiding en 
kwantifisering van 21 steroïedmetaboliete in  die bynier; 
 
• die invloed van Rooibos en die bg. flavonoïede op steroïedproduksie in 
H295R selle – ‘n menslike bynier kanker sellyn gekenmerk deur die 
ekspressie van die steroidogeniese ensieme wat die produksie van 
mineralokortikoïede, glukokortikoïede en bynierandrogene kataliseer, ge-
analiseer onder beide basale (normale) en forskoliengestimuleerde 
(gestresde) kondisies; 
 
• die invloed van Rooibos op die omeenskakeling tussen kortisol en kortisoon 
deur 11βHSD1 and 11βHSD2 in CHO-K1 selle; 
 
• die invloed van Rooibosinname op vlakke van sirkulerende steroïed hormone 
en relatiewe verhoudings in die bloed van manlike Wistarrotte; 
 
• die invloed van Rooibosinname op sirkulerende steroïed hormoon vlakke en 
relatiewe verhoudings in die bloed van mans en vrouens met ‘n hoë risiko vir 
die ontwikkeling van kardiovaskulêre siektes. 
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CHAPTER 1 
General Introduction 
 
Rooibos (Aspalathus linearis), a fynbos plant unique to the Western Cape 
region of South Africa, has traditionally been used for the alleviation of anxiety, 
sleeplessness and nervous tension – ailments generally associated with stress and 
abnormal glucocorticoid levels. Rooibos is a rich source of dietary polyphenols and 
while exhibiting potent anti-oxidant, anti-diabetic and cardio-protective properties, 
numerous in vivo studies have reported that its consumption also improves glucose 
homeostasis, insulin resistance and lipid profiles significantly. (Mose Larsen et al. 
2008; Marnewick et al. 2011; Son et al. 2013; Ajuwon et al. 2014; Dludla et al. 2014). 
These clinical conditions are generally associated with abnormal glucocorticoid 
levels. Glucocorticoids are synthesized in the adrenal cortex by P450 11β-
hydroxylase (CYP11B1), which catalyzes the conversion of deoxycorticosterone 
(DOC) and deoxycortisol to corticosterone (CORT) and cortisol, respectively. 
Glucocorticoid biosynthesis in the adrenal is, however, not only dependent the 
activity of CYP11B1, but also on the activities of upstream enzymes which include 
cytochrome P450 (P450) 17α-hydroxylase/17,20 lyase (CYP17A1), 3β-
hydroxysteroid dehydrogenase (3βHSD2) and P450 21-hydroxylase (CYP21A2), 
catalysing a network of reactions to yield substrates for CYP11B1. In addition, 
glucocorticoids are also produced by 11β-hydroxysteroid dehydrogenase type 1 
(11βHSD1), which catalyses the regeneration of CORT and cortisol from their 
respective inactive keto-metabolites, 11-dehydrocorticosterone (11-DHC) and 
cortisone, in peripheral tissues such as the liver and adipose tissue. Glucocorticoids 
regulate a wide range of physiological processes including carbohydrate, protein and 
lipid metabolism, immune and inflammatory processes, while also playing a key role 
in the stress response (Miller and Auchus 2011). 
Stress is often symptomatic of an unhealthy lifestyle, and while it is also the 
consequence of a physical threat or the perception thereof, stress is generally 
defined as a state of threatened homeostasis — resulting in the activation of various 
physiological and behavioral adaptive compensatory responses in order to re-
establish homeostasis (Pacák and Palkovits 2001; Chrousos 2009). The body 
responds to stress via activation of the hypothalamic-pituitary-adrenal (HPA) axis — 
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a complex system consisting of the hypothalamus, anterior pituitary and adrenal 
cortex. Activation of the HPA axis involves the release of corticotropin-releasing 
hormone (CRH) from the hypothalamus, which in turn stimulates the anterior pituitary 
to release adrenocorticotropic hormone (ACTH). ACTH subsequently stimulates the 
adrenal cortex to release glucocorticoids - cortisol in humans and CORT in rodents. 
Glucocorticoids released in response to stress exert inhibitory effects on the 
hypothalamus and pituitary to reduce the secretion of CRH and ACTH, respectively, 
thereby forming a negative feedback regulatory system. During chronic stress, 
however, this negative feedback regulatory system is overridden, resulting in 
elevated basal glucocorticoid levels (Chrousos and Gold 1998; Huizenga et al. 1998). 
Chronically elevated glucocorticoid levels play a central role in the development of 
hyperglycemia, type 2 diabetes (T2D), insulin resistance, visceral obesity, 
dyslipidemia, atherosclerosis, hypertension and cardiovascular diseases (CVDs), 
which are characteristic of clinical conditions such as metabolic syndrome (MetS) 
and Cushing’s syndrome. (Chrousos and Gold 1998; Arnaldi et al. 2003; Faggiano et 
al. 2003; Dekkers et al. 2007; Feelders et al. 2012).  
Since Rooibos appears to have the potential to aid in the treatment of 
metabolic diseases associated with elevated glucocorticoid levels, the aim of this 
thesis was to determine the influence of Rooibos on adrenal steroid hormone 
production in vitro and in vivo, and in particular, on the levels of the glucocorticoids, 
cortisol and CORT. 
In Chapter 2, Rooibos is discussed in terms of its unique flavonoid profile and 
the impact that processing has on flavonoid levels, however, the main focus of this 
chapter is the bioavailability and health-promoting properties of Rooibos.  
Chapter 3 provides an overview of adrenal steroidogenesis in terms of the 
enzymes catalysing adrenal steroid hormone production as well as the physiological 
roles of these steroid hormones. While the physiological relevance of the 
mineralocorticoids and adrenal androgen precursors will be discussed briefly, the 
enzymes involved in glucocorticoid biosynthesis and the clinical conditions 
associated with chronically elevated glucocorticoid levels will be discussed in detail.  
The aims of this thesis will be addressed in Chapter 4 and can be summarized as 
follows: 
• to determine the influence of Rooibos and five major Rooibos flavonoids (the 
dihydrochalcones, aspalathin and nothofagin, their flavone analogues, orientin 
Stellenbosch University  https://scholar.sun.ac.za
! 3!
and vitexin, and the flavonol, rutin) on the activities of key adrenal 
steroidogenic enzymes - CYP17A1, 3βHSD2, CYP21A2 and CYP11B1, 
expressed in COS-1 cells; 
• to develop of a novel ultra performance liquid chromatography/tandem mass 
spectrometry (UPLC-MS/MS) method for the separation and quantification of 
the adrenal steroid metabolites produced by adrenal H295R cells  - a human 
adrenal cell model expressing the steroidogenic enzymes involved in the 
production of the mineralocorticoids, glucocorticoids and adrenal androgens; 
• to determine the influence of Rooibos and aforementioned flavonoids on 
overall  steroid hormone production in H295R cells under basal and forskolin-
stimulated conditions; 
• to investigate the influence of Rooibos on the inter-conversion between 
cortisol and cortisone by 11βHSD1 and 11β-hydroxysteroid dehydrogenase 
type 2 (11βHSD2), expressed in CHO-K1 cells; 
• to investigate the influence of Rooibos consumption on circulating steroid 
hormone levels and ratios in male Wistar rats; 
• to investigate the influence of Rooibos consumption on circulating steroid 
hormone levels and ratios in human test subjects at risk for developing CVD. 
 
The experimental procedures, results and discussions of this thesis are presented 
in the form of three published manuscripts. The first manuscript (Schloms et al. 2012) 
describes the influence of Rooibos and two major Rooibos flavonoids, aspalathin and 
nothofagin, on the activities of two key adrenal steroidogenic enzymes, CYP17A1 
and CYP21A2, expressed in COS-1 cells. The influence of Rooibos, aspalathin and 
nothofagin was subsequently investigated on steroid hormone production in H295R 
cells, assayed under both basal and forskolin-stimulated conditions. Due to the 
complex mixture of steroid metabolites produced by the H295R cell line, a novel 
UPLC-MS/MS method was developed for the separation and quantification of 21 
adrenal steroid metabolites. This method enabled the quantification of not only the 
end metabolites of adrenal steroidogenesis, but also the intermediate steroid 
metabolites within the mineralocorticoid-, glucocorticoid-, and adrenal androgen 
precursor pathways. In this manuscript, we also report, for the first time, that 11β-
hydroxyandrostenedione (11OHA4), a major product of steroidogenesis in H295R 
cells, is a product of the hydroxylation of androstenedione (A4) by human CYP11B1. 
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In the second manuscript (Schloms and Swart 2014), the influence of Rooibos 
and the five major Rooibos flavonoids was investigated on the catalytic activities of 
key adrenal steroidogenic enzymes - CYP17A1, 3βHSD2, CYP21A2 and CYP11B1, 
expressed in COS-1 cells. The influence of the dihydrochalcones, flavones and the 
flavonol was subsequently investigated on steroid metabolism in H295R cells, under 
both basal and forskolin stimulated conditions. The structure-activity relationships of 
these flavonoid compounds are discussed, focusing on the structural differences of 
these compounds influencing their ability to inhibit individual steroidogenic enzymes 
and the steroid flux through the mineralocorticoid-, glucocorticoid- and adrenal 
androgen precursor pathways. 
The third manuscript (Schloms et al. 2014) describes the influence of Rooibos 
consumption on circulating glucocorticoid levels and steroid ratios in male Wistar rats 
and human subjects at risk for CVD. In addition, the influence of Rooibos was 
investigated on the inter-conversion between cortisol and cortisone by 11βHSD1 and 
11βHSD2 in CHO-K1 cells. 
Chapter 5 presents a general discussion of the results described in Chapter 4 
and highlights the main conclusions that were drawn from these findings. 
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CHAPTER 2 
Rooibos (Aspalathus linearis) 
 
2.1 Introduction 
 
Rooibos is a popular herbal tea, or more correctly, a tisane, which is prepared 
from the stems and leaves of the fynbos plant, Aspalathus linearis, which is 
indigenous to the Western Cape region of South Africa. Rooibos is gaining popularity 
worldwide and is consumed mostly as a healthy alternative to oriental tea (Camellia 
sinensis) or coffee due to the low tannin levels, high polyphenol content and it being 
caffeine free. Rooibos is currently being consumed in more than 37 countries and in 
a recent report by the Swiss Business Hub South Africa, it was predicted to become 
the second most popular tea in the world after Camellia sinensis (Anon 2007; Joubert 
and de Beer 2011). Rooibos has been reported to exhibit potent anti-oxidant (Joubert 
et al., 2008; Yoshikawa et al., 1990), anti-inflammatory (Baba et al. 2009; Hendricks 
and Pool 2010; Mueller et al. 2010; Ajuwon et al. 2014), anti-carcinogenic (Petrova 
2009), anti-hyperlipidemic (Beltrán-Debón et al. 2011), hypoglycemic (Joubert and de 
Beer 2011; Muller et al. 2012), and anti-diabetic (Mose Larsen et al. 2008; Kawano et 
al. 2009) properties, amongst others, suggesting a potential role for Rooibos in the 
overall management of metabolic diseases. In this chapter, Rooibos will be 
discussed in terms of the processing methods involved in the production of 
unfermented and fermented Rooibos tea; the unique flavonoid profile of Rooibos and 
how it is altered during fermentation; the bioavailability of Rooibos flavonoids and the 
bioactivity attributed to Rooibos extracts and some of its major flavonoid compounds. 
2.2 Rooibos processing methods 
Rooibos is available commercially either as a fermented or unfermented 
product, depending on the method by which it is processed. Traditional, fermented 
Rooibos is typically processed by shredding the shoots, bruising the plant material, 
adding water to the fermentation heap and finally, further mixing and bruising of the 
plant material. Shredding of the Rooibos shoots initiates enzymatic oxidation 
(fermentation) of the polyphenol compounds, which subsequently leads to browning 
of the plant material. Bruising of the plant material and the addition of water is 
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required to accelerate the fermentation process. Since the oxidation of the plant 
material requires aeration, the fermentation heap is turned over several times during 
the fermentation process, which lasts between 8 and 24 h, depending on the climate, 
composition of the plant material and processing conditions. Fermented Rooibos has 
a characteristic reddish-brown color and a sweet honey-like aroma.  
During the production of unfermented or “green” Rooibos, oxidative changes 
are minimised in order to retain the green leaf color and polyphenol content, 
especially that of aspalathin, the principal flavonoid in unfermented Rooibos. 
Oxidization is minimised by inactivation of oxidative enzymes in one of the following 
ways: (a) by drying the plant material under vacuum; (b) by drying the shoots to a 
specified moisture content prior to shredding; or (c) by steaming the shoots to 
denature oxidative enzymes prior to shredding. Even though these techniques are 
very effective, there are considerable cost implications and therefore unfermented 
Rooibos is currently being produced by drying the shredded plant material in thin 
layers in the sun. This technique, however, still leads to reduced aspalathin levels 
and if the plant material is not correctly dried, slow browning will result in 
unfermented Rooibos of inferior quality. Prior to packaging, Rooibos is steam-
pasteurized to ensure a low microbial content. (Joubert and Schulz 2006; Joubert et 
al. 2008; Joubert and de Beer 2011). 
2.3 Rooibos polyphenols 
 
Polyphenols are bioactive compounds present in a variety of dietary plant 
sources including fruit, vegetables and tea, amongst others. Polyphenols are 
generally classified as flavonoids or non-flavonoids, based on the number and 
structural components of their phenolic rings. Flavonoids are the largest group of 
polyphenols and to date, more than 9000 structurally distinct flavonoids have been 
identified. Based on their structural differences, flavonoids are subdivided into 
different classes such as the flavanols, flavanones, flavones, isoflavones, flavonols 
and anthocyanins (Ignat et al. 2011; Lima et al. 2014). 
Rooibos contains two unique flavonoids, namely aspalathin, a 
dihydrochalcone C-glucoside (Koeppen and Roux 1965), and aspalanin, a cyclic 
dihydrochalcone (Shimamura et al. 2006). Another rare flavonoid present in Rooibos 
is the dihydrochalcone C-glucoside, nothofagin, which has only been identified in two 
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other plant species, Nothofagus fusca (Hillis and Inoue 1967) and Schoepfia 
chinensis (Huang et al. 2008). In addition to the dihydrochalcones, other major 
polyphenols identified in Rooibos include the flavones (orientin, iso-orientin, vitexin, 
iso-vitexin, luteolin, luteolin-7-O-glucoside and chrysoeriol), flavonols (quercetin, iso-
quercetin, hyperoside, rutin and quercetin-3-O-robinobiocide), and flavanones 
(dihydro-orientin, dihydro-iso-orientin and hemiphlorin). Other phenolic compounds 
identified in Rooibos include phenolic acids, lignans, flavone diglycosides, (+)-
catechin, coumarins (esculetin and esculin) and phenylpyruvic acid glucoside 
(PPAG) (Joubert et al. 2008; Joubert and de Beer 2011; Beelders et al. 2012). The 
complex polyphenol content of Rooibos is clearly illustrated in a study by Beltrán-
Debón et al. (2011), in which twenty-five polyphenol compounds were identified. The 
structures of the major Rooibos dihydrochalcones, flavones and flavonols, as well as 
their relative quantities in unfermented and fermented Rooibos extracts, are shown in 
Table 2.1. 
 
Table 2.1: Major flavonoids in green (unfermented) and fermented Rooibos 
Three individual plants were divided into two equal parts to prepare green (dried whole for 12h at 
40°C) and fermented (shredded, fermented for 12h at 38°C and dried for 12h at 40°C) Rooibos 
(means ± SD; g/100g dry matter). Reproduced from Joubert and De Beer (2011) with permission from 
Elsevier. 
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Rooibos has a unique flavonoid profile that is altered during fermentation due 
to the oxidation of these compounds. Fermented Rooibos therefore has a lower 
flavonoid content, while also exhibiting less anti-oxidant activity compared to 
unfermented Rooibos (De Beer and Joubert 2002). The dihydrochalcones, aspalathin 
and nothofagin, are most affected by the fermentation process, with their levels being 
roughly 6-fold lower in fermented Rooibos compared to the unfermented product, as 
shown in Table 2.1 (Joubert and de Beer 2011). The significant reduction in the 
levels of aspalathin during fermentation is due to the enzymatic oxidation of this 
compound to its corresponding flavone analogues, iso-orientin and orientin, and it 
has been suggested that nothofagin would be converted to the flavones, isovitexin 
and vitexin, in a similar manner (Koeppen and Roux 1965; Joubert and de Beer 
2011). During fermentation, aspalathin is converted to (R)/(S)-eriodictyol-6-C-
glucoside and (R)/(S)-eriodictyol-8-C-glucoside. (R)/(S)-eriodictyol-6-C-glucoside, 
which is preferentially formed from aspalathin, is oxidized to iso-orientin. The 
conversion of iso-orientin to orientin occurs via an irreversible reaction in which the 
vinyl ester structure of iso-orientin opens, yielding a chalcone intermediate, which is 
subsequently converted to orientin (Krafczyk et al. 2009; Joubert and de Beer 2011) 
(Fig. 2.1). These oxidative changes could potentially account for the reduced levels 
of aspalathin and nothofagin following fermentation, although one would then expect 
that this decrease would be reflected in increased levels of their corresponding 
flavones. Since the levels of orientin, iso-orientin, vitexin and isovitexin remain 
relatively constant following fermentation, it is assumed that these compounds 
undergo further oxidative changes. These compounds could possibly be oxidized to 
the hydroxybenzoic acid derivatives 3,4-dihydroxybenzoic acid, caffeic acid, ferulic 
acid and vanillic acid, as these compounds have been reported to be present in 
higher concentrations in fermented Rooibos than in unfermented Rooibos (Richfield 
2008).  
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Figure 2.1: Schematic representation of aspalathin oxidation. Reproduced from 
Joubert and De Beer (2011) with permission from Elsevier. 
 
In addition to the fermentation process altering the flavonoid content of 
Rooibos, the genetic composition of the seedling, geographical location and the 
particular plantation also significantly influences the flavonoid content of Rooibos 
(Joubert and Schulz 2006). Joubert and De Beer (2011) demonstrated considerable 
variations in the levels of aspalathin and orientin in unfermented Rooibos plant 
material obtained from 21 separate plants, which were harvested simultaneously 
from the same plantation. In addition, the harvest date also influenced the phenolic 
composition of Rooibos (Joubert and de Beer 2011). Beelders et al. (2012) 
subsequently developed a novel HPLC-DAD method which enables the 
quantification1 of 15 of the major Rooibos polyphenols, which can be used to test the 
quality and authenticity of Rooibos products. The authors also clearly demonstrated !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Quantification of the flavonoid content of the Rooibos extracts used in the present study is shown in  
Addendum A.!
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the variation in polyphenol content between Rooibos plant material obtained from 
different suppliers (Beelders et al. 2012). 
2.4 Bioavailability 
 
The consumption of dietary polyphenols has been linked with a reduced risk 
for various diseases including T2D (Scalbert et al. 2005; Ong et al. 2011), CVD (Holt 
et al. 2009; Hodgson and Croft 2010), cancer (Thomasset et al. 2007; Yang et al. 
2007), neurodegenerative diseases (Singh et al. 2008; Chen et al. 2009) and 
osteoporosis (Hagiwara et al. 2011), amongst others. In order for flavonoid 
compounds to exert their bioactivity, absorption in the gastrointestinal (GI) tract and 
transportation into circulation is crucial for these compounds to reach the target 
tissues. The bioavailability of a compound is the fraction of the ingested dose that is 
absorbed and reaches the systemic circulation. Before compounds are absorbed in 
the GI tract, they must become bioaccessible, which refers to the amount of ingested 
compound that is released from the food matrix and is available for absorption 
through the intestinal barrier (Velderrain-Rodríguez et al. 2014). Bioavailability can be 
influenced by exogenous factors such as the composition of the ingested food, the 
chemical formulation and dose of the ingested compound as well as the interaction 
and competition with co-ingested compounds. Endogenous factors influencing the 
bioavailability include mucosal mass, intestinal transit time, the availability of suitable 
receptors, metabolism, conjugation, protein binding in blood and tissues, as well as 
the rate of gastric emptying. Both endogenous and exogenous factors result in great 
inter- and intra-individual variability in bioavailability (Scholz and Williamson 2007; 
Holst and Williamson 2008). The intra-individual variation was clearly demonstrated 
in a study by Breiter et al. (2011), in which Rooibos was consumed by twelve healthy 
volunteers. Despite consuming equal amounts of Rooibos, the flavonoid levels 
detected in plasma and urine samples differed significantly between these 
individuals. 
Following ingestion, flavonoids undergo extensive metabolism in the small 
intestine.  Dietary flavonoids are often bound to sugar moieties in the form of beta-
glycosides and deglycosylation is known to play a fundamental role in the absorption 
of these compounds. Within the small intestine, deglycosylation of flavonoid 
glycosides primarily relies on the actions of lactase-phlorizin hydrolase (LPH) and 
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cytosolic β-glucosidase. Following enzymatic deglycosylation, flavonoid aglycones 
(free flavonoids) passively diffuse across the intestinal epithelium, since the loss of 
the sugar moieties increases their lipophilicity (Walgren et al. 1998; Day et al. 2000; 
Murota et al. 2000). 
Within the small intestine and liver, flavonoid aglycones are metabolized to 
glucuronidated-, sulfated- and methylated conjugates via the enzymatic actions of 
uridine-5’diphosphate glucuronosyl-transferases (UGTs), sulfotransferases (SULTs) 
and catechol-O-methyltransferases (COMTs), respectively. Conjugation of flavonoid 
aglycones first occurs in the small intestine, after which these metabolites are 
transported to the liver where they undergo further metabolism. Metabolites that 
reach the liver are either transported in circulation to target cells and tissues, 
secreted to bile and re-absorbed in the small intestine, or excreted via the urine 
and/or feces. The compounds that are not absorbed in the small intestine reaches 
the colon where colonic microflora degrades the compounds to phenolic acids, which 
are subsequently either excreted or re-absorbed and transported to the liver for 
further metabolism (Crozier et al. 2010; Thilakarathna and Rupasinghe 2013; 
Velderrain-Rodríguez et al. 2014). A schematic representation of human flavonoid 
metabolism is shown in Figure 2.2.  
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Figure 2.2.  Schematic representation of flavonoid metabolism. LPH, lactase-phlorin 
hydrolase. Reproduced from Thilakarathna and Rupasinghe (2013). 
 
The bioavailability of flavonoids can be assessed in one of three ways. Firstly, 
an increase in the total antioxidant capacity (TAC) of blood plasma after consuming 
polyphenol-rich foods can serve as an indirect measure of their absorption through 
the gut wall. This method, however, does not provide any compositional information 
and it has been shown that various macro- and micronutrients can also affect the 
TAC of plasma, either directly or through their metabolism. A more direct and 
accurate measurement of bioavailability is obtained via the quantification of 
polyphenol concentrations in plasma and urine samples following consumption of 
individual polyphenols or foodstuffs with known polyphenol concentrations (Scalbert 
and Williamson 2000; Tapiero et al. 2002; Sies 2007). Although plasma analyses are 
effective for the identification of circulating metabolites, it is not necessarily an 
accurate determination of flavonoid uptake from the GI tract. Urine analyses, on the 
other hand, provide a more realistic indication of GI uptake. However, these analyses 
do not account for metabolites absorbed at cellular level, and therefore, would not 
provide a true indication of absorption, and would rather reflect underestimated 
values (Crozier et al. 2010). A third, and the most preferred method to measure 
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bioavailability, includes the investigation of flavonoid uptake and distribution in 
tissues. The time of sampling, however, is believed to play a crucial role in the 
polyphenol concentration within tissues due to the kinetics involved in the absorption 
and elimination of polyphenols from tissues (Manach et al. 2004). 
The first in vivo study to investigate the bioavailability of Rooibos was 
performed by Kreuz et al. (2008). In this study, aspalathin metabolism was assayed 
in pigs following oral administration of an unfermented Rooibos extract over a period 
of 11 days. Six metabolites were identified in the urine which included: intact 
aspalathin, methylated aspalathin, glucuronidated aspalathin, methylated- and 
glucuronidated aspalathin, a glucuronidated aglycone of aspalathin and a metabolite 
of eriodictyol. The data obtained from this study indicated that aspalathin is either 
absorbed in the small intestine as a C-glycoside, or cleaved into an aglycone. The 
major metabolite detected in the urine was methylated aspalathin. Only 0.1% to 0.9% 
of the administered dose of aspalathin was detected in urinary samples, while no 
metabolites were detected in the plasma (Kreuz et al. 2008).  
In a subsequent study by Courts and Williamson (2009), the bioavailability of 
Rooibos was investigated in human subjects following the consumption of an 
unfermented Rooibos extract. Glucuronidated- and methylated metabolites of 
aspalathin were observed in the urine following Rooibos ingestion, confirming that 
aspalathin is absorbed, methylated and glucuronidated in vivo. In addition, 
methylated metabolites of intact (glycosylated) aspalathin were identified in urine 
samples, suggesting that C-glycosyl flavonoids does not have to be deglycosylated in 
order to be absorbed in humans (Courts and Williamson 2009). These data 
corroborated previous findings by Kreuz et al. (2008). 
In the same year, Stalmach et al. (2009) detected eight metabolites of 
aspalathin in the urinary samples of humans following a single intake (500 ml) of 
either an unfermented or fermented Rooibos tea beverage. These metabolites 
included O-linked methylated-, sulfated- and glucuronidated metabolites of aspalathin 
and eriodictyol-O-sulfate. The main compound excreted following the consumption of 
the unfermented and fermented drink was O-methyl-aspalathin-O-glucuronide and 
eriodictyol-O-sulfate, respectively. The majority of aspalathin metabolites were 
detected within the first 5 h following intake, which is suggestive of small intestine 
absorption. However, further analyses of the samples showed that aspalathin 
metabolites and eriodictyol-O-sulfate comprised only 0.22% of the 159 µmol total 
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polyphenols consumed in the unfermented Rooibos beverage, while these 
metabolites comprised 0.09% of the 84 µmol total polyphenols consumed in the 
fermented Rooibos beverage. The unfermented and fermented Rooibos beverage 
contained 90 µmol and 8 µmol aspalathin, respectively, with only 317 nmol and 14 
nmol aspalathin metabolites being excreted over a 24 h period. No flavonoid 
compounds were detected in the plasma (Stalmach et al. 2009).  
Even though the levels of aspalathin ingested by pigs during the study 
conducted by Kreuz et al. (2008) was roughly 400 times higher than the single dose 
administered in the study performed by Stalmach et al. (2009), the urinary recovery 
rates of aspalathin metabolites in these two studies would seem to suggest that 
limited aspalathin absorption occurred, regardless of the administered dose. 
However, taking into account the significantly low recovery rates of aspalathin 
obtained in both studies, it is possible that these low levels could be attributed to 
inadequate extraction procedures. In the studies conducted by both Kreuz et al. 
(2008) and Stalmach et al. (2009), polyphenol compounds bound to serum proteins 
were not considered, and protein-polyphenol complexes had not been denatured 
prior to extraction.  
These protein-polyphenol complexes were, however, taken into account in a 
subsequent human study by Breiter et al. (2011), investigating the bioavailability of 
flavonoids following the consumption unfermented Rooibos tea. In contrast to the 
previous studies, this was the first group to detect intact flavonoids in the plasma of 
humans following Rooibos consumption. The compounds identified in plasma 
samples included aspalathin, orientin, iso-orientin, vitexin, (S)-eriodictyol-8-C-
glucoside, eriodictyol-7-O-glucoside and quercetin-O-rutinoside. The recovery rates 
of these flavonoids were, however, also very low, ranging between 0.2% and 2.3%. 
Intact aspalathin and nothofagin as well as seven of their metabolites were identified 
in urinary samples. These metabolites included sulfated-, glucuronidated-, 
methylated-, both methylated- and glucuronidated metabolites, as well as the 
aglycone metabolites of aspalathin and nothofagin (Breiter et al. 2011). 
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2.5 Biological activity 
Even though Rooibos flavonoids have been reported to have poor 
bioavailability in vivo, consumption of water extracts of Rooibos has been linked to 
anti-oxidant, anti-inflammatory, anti-tumor, anti-carcinogenic, hepatoprotective, 
phyto-estrogenic, immune-modulatory, anti-hyperlipidemic and hypoglycemic effects, 
amongst others (Joubert et al. 2008; Joubert and de Beer 2011). Studies reporting on 
the biological properties of Rooibos have been extensively reviewed by Joubert et al. 
(2008) and Joubert & De Beer (2011). The main focus of this section will be on the 
health promoting properties of Rooibos associated with reduced risks for metabolic 
related diseases such as diabetes and CVDs. 
2.5.1 Anti-oxidative properties of Rooibos 
 
Free radicals, including reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), are implicated in cellular signaling systems, receptor activation and 
gene expression, and can have both beneficial and harmful biological properties. 
Oxidative damage, also termed ‘oxidative stress’ occurs when excessive free radical 
production is not prevented by endogenous anti-oxidant mechanisms. Elevated 
levels of free radicals cause damage to nucleic acids, membrane lipids, as well as 
structural and functional proteins. Oxidative stress can therefore be defined as an 
imbalance between pro-oxidant and anti-oxidant levels in the body, with elevated pro-
oxidant levels leading to oxidative damage (Halliwell 2006, 2007; Darvesh et al. 
2010). Various studies have confirmed that oxidative stress resulting from excessive 
free radical production plays a crucial role in the development of age-related 
diseases such as neurodegenerative diseases, CVDs, diabetes and cancer (Rao and 
Balachandran 2002; Emerit et al. 2004; Halliwell 2006; Valko et al. 2006; Wang et al. 
2006).  
Polyphenols are known to exhibit potent anti-oxidant properties and the use of 
these compounds in the treatment of several chronic diseases has proved to be 
successful (Linseman 2009). Glutathione (GSH) is the most potent intracellular 
antioxidant, and the ratio between reduced GSH and oxidized GSH (GSH:GSSG) is 
used as a marker to determine the anti-oxidative capacity of the cell, with low GSH 
levels and GSH:GSSH ratios being indicative of oxidative stress (Exner et al. 2000; 
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Franco et al. 2007). GSH has been reported to counteract ageing, various cancers 
and heart diseases (Townsend et al. 2003; Exner et al. 2000; Locigno and 
Castronovo 2001; Franco et al. 2007; Ballatori et al. 2009). It has, however, been 
shown that GSH levels decrease with age (Marí et al. 2009) and due to smoking 
(Teramoto et al. 1996). In addition, GSH cannot be taken as a supplement since it 
degrades in the gut (Witschi et al. 1992).  
In a study by Marnewick et al. (2003), it was shown that rats consuming 
Rooibos tea as their only source of liquid for 10 weeks had a 5-fold increase in the 
GSH:GSSG ratio (Marnewick et al. 2003). These results were corroborated in a more 
recent study by Ajuwon et al. (2014), investigating the effect of Rooibos on 
lipopolysaccharide (LPS)-induced oxidative stress in Wistar rats. Rooibos 
consumption was shown to significantly suppress LPS-induced oxidative stress and 
inflammatory responses in the livers of rats by reducing liver damage, lipid-
peroxidation, the secretion of pro-inflammatory cytokines, tumor necrosis factor-α 
(TNF-α) and interleukin-6 (IL-6), and by preventing the LPS-induced reduction of 
GSH:GSSH ratios (Ajuwon et al. 2014). In a study by Hong et al. (2014), the 
protective action of Rooibos was clearly demonstrated in rats subjected to chronic 
immobilization stress. Rooibos was shown to regulate GSH metabolism by 
counteracting the reduction in GSH levels and GSH:GSSG ratios caused by 
immobilization-induced oxidative stress. In addition, Rooibos reversed the increase in 
stress related metabolites, prevented lipid-peroxidation and stress-induced protein 
degradation, while also modulating changes in anti-oxidative enzyme activities (Hong 
et al. 2014). 
The impact of dietary choices on oxidative stress is underscored in the study 
by Francisco (2010), in which the consumption of sucrose with a meal containing 
oxidized and/or oxidizabIe lipids was shown to increase oxidative stress, also 
referred to as post-pranadial oxidative stress. In this study, a single oral dose of 
Rooibos containing sucrose, together with a high fat meal, inhibited post-pranadial 
oxidative stress in healthy humans. Rooibos reduced lipid-oxidation biomarkers, 
increased the anti-oxidant capacity and restored the redox status as reflected in the 
increased plasma GSH levels (Francisco 2010). These findings were supported in a 
subsequent study by Marnewick et al. (2011), reporting that the consumption of six 
cups of Rooibos tea per day over a period of six weeks reduced oxidative stress by 
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decreasing lipid-peroxidation and increasing the GSH:GSSG ratio in humans at risk 
for CVD (Marnewick et al. 2011). 
2.5.2 Anti-diabetic properties of Rooibos 
 
Diabetes mellitus is a metabolic disorder characterized by chronically elevated 
glucose levels (hyperglycemia) – either due to a deficiency in insulin secretion and/or 
the body’s resistance to insulin, a hormone that regulates glucose utilization. Type 1 
diabetes (T1D) is associated with insulin deficiency as a result of autoimmune-
mediated deletion of pancreatic β-cells, while T2D is characterized by the inability of 
tissues to respond to insulin (insulin resistance), even if insulin levels are normal. 
Pancreatic β-cells mediate glucose uptake via the glucose transporter, GLUT2, when 
blood glucose levels rise, which ultimately leads to insulin secretion (Braun et al. 
2008; Leto and Saltiel 2012). The secretion of insulin results in a number of 
regulatory processes: GLUT4-dependent glucose uptake in various tissues including 
skeletal muscle and adipose tissue is increased, glycogenesis in the liver is 
stimulated, while lipogenesis is promoted and lipolysis is inhibited in adipose tissue. 
As circulating glucose levels start to decline, pancreatic α-cells are stimulated to 
release glucagon, which promotes gluconeogenesis and glycogenolysis in the liver 
and lipolysis in adipose tissue. In patients with T2D, defects in the regulation of these 
hormones lead to sustained elevated blood glucose levels, which have a wide range 
of pathological consequences. Insulin is used for the treatment of T1D, while drugs 
that target glucose-regulating processes in the pancreas, gut, skeletal muscle, 
adipose tissue or liver is used for the treatment of T2D (Mohler et al. 2009).  
Natural plant products are often included in the treatment of non-insulin 
dependent diabetes, particularly within traditional medicines in developing countries. 
The first study investigating the anti-diabetic properties of fermented Rooibos found 
that diabetic parameters tested in streptozotocin2 (STZ) - induced diabetic rats were 
unaffected by Rooibos extracts. Rooibos was, however, suggested to aid diabetic 
complications such as ocular pathological changes (Uličná et al. 2006). In a 
subsequent study by Kawano et al. (2009), it was shown that aspalathin, the major 
flavonoid compound in unfermented Rooibos, exhibited hypoglycemic effects. In !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!2!STZ is used to reduce/deplete insulin producing cell numbers and induce hyperglycemia to levels 
typically found during T1D or late stage T2D.!
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vitro, aspalathin significantly and dose-dependently increased the uptake of glucose 
by L6 myotubes (rat skeletal muscle-derived cell line) while also significantly 
increasing insulin secretion from RIN-5F cells (rat-derived pancreatic β-cell line). In 
vivo, aspalathin ameliorated impaired glucose tolerance in T2D model db/db mice, 
while also reducing increased fasting plasma glucose levels (Kawano et al. 2009). 
These results were corroborated in a more recent study by Son et al. (2013), 
investigating the mechanisms of action to which the anti-diabetic effects of aspalathin 
could be attributed. Aspalathin dose-dependently increased glucose uptake by L6 
myotubes through GLUT4 translocation to the plasma membrane, via the activation 
of AMP-activated protein kinase (AMPK). In RIN-5F cells, aspalathin reduced the 
advanced glycation end product-induced increase in ROS due to its radical 
scavenging capabilities. In vivo, aspalathin improved hyperglycemia and impaired 
glucose intolerance in diabetic ob/ob mice, while also reducing hypertriglyceridemia. 
The expression of genes encoding enzymes catalyzing gluconeogenesis, 
glycogenolysis and lipogenesis were suppressed by aspalathin. In addition, 
aspalathin reversed the reduced expression of genes encoding enzymes catalysing 
glycogenesis in the liver, thus possibly contributing towards reducing blood glucose 
and serum triglyceride (TG) levels (Son et al. 2013).  
In an earlier study by Muller et al. (2012), the hypoglycemic potential of an 
unfermented Rooibos extract, as well as that of aspalathin and rutin was investigated 
(Muller et al. 2012). Rutin (quercetin-3-O-rutinoside) levels are significantly higher in 
unfermented Rooibos than in fermented Rooibos extracts and it has been shown to 
inhibit β-glucosidase activity (Li et al. 2009), increase plasma insulin levels and 
reduce plasma glucose levels in STZ-induced diabetic rats (Kamalakkannan and 
Prince 2006). In their study, Muller et al. (2012) showed glucose uptake to be 
stimulated in C2C12 cells (murine myoblast cell model) in a dose-dependent manner 
by the unfermented Rooibos extract, while stimulation of glucose uptake was not 
detected at lower concentrations in the Chang liver (HeLa derivative) cell line 
expressing negligible GLUT4. In C2C12 cells, aspalathin and rutin did not result in 
dose-dependent increases in glucose uptake, with rutin stimulating glucose uptake 
only at 100 µM, while aspalathin stimulated glucose uptake significantly from 1 – 100 
µM. The increases in glucose uptake detected in Chang cells were not shown to be 
significant. In STZ-induced diabetic rats, the Rooibos extract reduced glucose levels 
to a similar extent as in the presence of metformin, while a glucose tolerance test 
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indicated that Rooibos was significantly better at lowering circulating glucose levels 
than vildagliptin, a dipeptidyl peptidase-4 inhibitor. Analyses of the synergistic 
combined effects of an equimolar aspalathin:rutin mixture  showed that maximal 
glucose lowering effects were obtained 4 h after administration, with a ± 3-fold 
greater reduction compared to single administrations of aspalathin and rutin. After 4 
h, the extract exhibited similar glucose lowering effects at concentrations ranging 
between 5 - 50 mg/kg body weight. It is interesting to note that neither compound 
was capable of stimulating glucose uptake in vitro or in vivo as significantly as the 
Rooibos extract, even though aspalathin and rutin levels were significantly lower in 
the extract. The highest stimulation of glucose uptake in C2C12 cells was achieved 
at 5 µg extract/mL, which contained 2.2 µM aspalathin and 0.04 µM rutin (Muller et 
al. 2012). These data indicate the presence of more potent compounds or synergistic 
interactions within the complex mixture of Rooibos polyphenols.  
Following various in vivo studies reporting on the hypoglycemic properties of 
fermented Rooibos extracts as well as the Rooibos flavonoids, aspalathin and rutin, 
Rooibos was patented as an anti-diabetic agent in 2011. The patent3 claims the use 
of Rooibos extract, aspalathin and rutin in the prevention and treatment of diabetes, 
based on the ability of the extract and flavonoid compounds to improve impaired 
glucose tolerance and to reduce plasma glucose levels in STZ-induced diabetic rats 
and diet-induced T2D monkeys. Interestingly, when aspalathin and rutin were 
administered to diabetic rats, similar results were obtained as those in the presence 
of the Rooibos extract. It was also reported that aspalathin and rutin were most 
effective when used in combination. Aspalathin alone, or in particular when used 
together with rutin, significantly lowered plasma glucose levels, while also generally 
alleviating diabetic symptoms in both type 1- and type 2 diabetic rats. As anti-diabetic 
agents, a human dosage of aspalathin, or aspalathin in combination with rutin, was 
suggested to be administered between 0.1 – 50 mg/kg/day, while the dosage of 
fermented Rooibos extract should range between 1 – 2.5 mg/kg/day (Mose Larsen et 
al. 2008). 
In addition to aspalathin, rutin and Rooibos extracts exhibiting hypoglycemic 
properties, Mathijs et al. (2014) recently showed that phenylpropenoic acid glucoside !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3 European Patent No. EP 2 120 980 B1 (WO 2008/110551). !
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(PPAG), a polyphenol compound isolated from Rooibos, also exhibited hypoglycemic 
properties in mice consuming a high-fat, fructose-containing diet to induce obesity 
and hyperglycemia. Treatment with PPAG prevented diet-induced hyperglycemia in 
these mice, while also leading to a 3-fold increase of β-cell mass. In addition, PPAG 
protected pancreatic β-cells against apoptosis (Mathijs et al. 2014). Rooibos 
flavonoids including quercetin, rutin and luteolin, have also been shown to protect 
pancreatic β-cells from experimental agents that induce diabetes. In a study by 
Coskun et al. (2005), it was shown that quercetin prevented and protected rat 
pancreas against β-cell damage and STZ-induced oxidative stress (Coskun et al. 
2005). In a similar way, rutin and apigenin (aglycone of vitexin) also prevented STZ-
induced oxidative stress and increased insulin release in rat pancreas islets (Esmaeili 
et al. 2009). Furthermore, it was shown that apigenin, quercetin and luteolin inhibited 
cytokine-induced pancreatic β-cell damage in vitro (Kim et al. 2007). The 
enhancement of insulin secretion from pancreatic β-cells is a standard approach for 
the treatment of diabetes and various studies have reported that quercetin and rutin 
both increase insulin secretion (Hii and Howell 1985; Pinent et al. 2008; Yang et al. 
2010). 
Numerous studies have indicated a link between diabetes and oxidative stress 
(Kesavulu et al. 2000; Tinahones et al. 2009; Hoehn et al. 2010). As the severity of 
diabetes progresses, the formation of ROS increases and it is now widely accepted 
that oxidative stress plays a prominent role in the development of diabetes and 
associated complications (Schleicher and Weigert 2000; Brownlee 2005; Houstis et 
al. 2006). Adipose tissue includes a variety of cell types such as adipocytes, 
preadipocytes, endothelial cells and immune cells, which consist of lymphocytes and 
bone marrow-derived macrophages. The number of macrophages present in adipose 
tissue has been shown to correlate with the degree of obesity, as the levels of 
macrophages are significantly higher in obese individuals compared to lean 
individuals (Weisberg et al. 2003). Macrophages that accumulate in the adipose 
tissue are a major source of the pro-inflammatory cytokines, TNF-α and IL-6. TNF-α 
levels are elevated in the blood and adipose tissue of obese animals, and 
neutralization of TNF-α has been shown to improve insulin sensitivity (Hotamisligil 
1999; Shoelson et al. 2006). Furthermore, TNF-α and IL-6 released by adipocytes 
and macrophages were shown to be elevated in diabetic and insulin resistant 
patients (Senn et al. 2002). Consistent with the findings showing that inflammatory 
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markers are upregulated in individuals with diabetes, insulin has also been shown to 
downregulate free fatty acid (FFA) release and numerous inflammatory markers (Kim 
et al. 2006; Dandona et al. 2009). The crosstalk between inflammation and ROS in 
diabetes is also apparent, since ROS has been shown to promote macrophage 
infiltration, adipocyte senescence as well as the production of TNF-α and IL-6 
(Rahman et al. 2002). It is therefore likely that agents capable of suppressing 
inflammation by reducing pro-inflammatory cytokine levels and/or their biological 
actions may have beneficial effects in the treatment of insulin resistance and/or 
diabetes (Kim et al. 2004; Larsen et al. 2007; Sears and Ricordi 2012; Gómez-Zorita 
et al. 2013; Siriwardhana et al. 2013). Besides the antioxidant and hypoglycemic 
properties attributed to Rooibos, it has also been reported to exhibit anti-inflammatory 
effects both in vitro (Hendricks and Pool 2010; Mueller et al. 2010) and in vivo (Baba 
et al. 2009). Preliminary results from studies in our group have shown that Rooibos 
decreased IL-6 production in rat adrenal tissue, while significantly increasing the 
levels of interleukin-10 (IL-10), an anti-inflammatory cytokine (P<0.05) (unpublished 
data). It is therefore possible that the anti-diabetic properties of Rooibos could, in 
part, also be ascribed to its anti-inflammatory properties. 
2.5.3 Cardio-protective properties of Rooibos 
 
CVDs are the leading cause of death in the world and the main risk factors 
contributing to CVDs include an unhealthy diet, a lack of physical activity, smoking,  
obesity, hypertension, diabetes and elevated lipid levels4. Although Rooibos has 
been anecdotally reported to aid hypertension, studies investigating the cardio-
protective properties of Rooibos are limited. The first scientific study investigating the 
effect of Rooibos on angiotensin-converting enzyme (ACE) - a crucial enzyme 
involved in the rennin-angiotensin aldosterone system (RAAS), and commonly 
targeted in the treatment of hypertension and CVD, was carried out by Persson et al. 
(2006). In comparison to green tea (Japanese Sencha) and black tea (Indian Assam 
Broken Orange Pekoe), Rooibos did not inhibit ACE significantly at the !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 WHO, 2014 - Cardiovascular diseases: Fact sheet No.317. 
http://www.who.int/mediacentre/factsheets/fs317/en/ (Updated March 2013). !
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concentrations assayed in HUVEC cells (cultured human umbilical endothelial cells). 
However, nitric oxide production was significantly lower in these cells when exposed 
to Rooibos compared to green and black tea (Persson et al. 2006). In a subsequent 
in vivo study investigating the inhibition of ACE by green tea, black tea and Rooibos 
in human subjects, a single oral dose of Rooibos or green tea significantly inhibited 
the activity of ACE, suggesting that both teas may have cardio-protective properties. 
No effect was, however, observed on blood pressure after tea consumption (Persson 
et al. 2010). The authors subsequently showed mixed inhibition of ACE by both 
Rooibos and green tea, however, neither were as efficient as enalaprilat (Persson 
2012). 
As previously discussed, the investigation by Francisco (2010) showed that a 
single oral dose of Rooibos extract containing sucrose, together with a high fat meal, 
decreased the levels of plasma insulin, glucose, total cholesterol, low density lipid 
(LDL) cholesterol, TGs and inflammatory biomarkers (Francisco 2010). These 
findings were confirmed in a subsequent human study by Marnewick et al. (2011), 
reporting that Rooibos consumption significantly improved the lipid profiles by 
reducing LDL cholesterol and TG levels, while increasing the levels of high density 
lipid (HDL) cholesterol in humans at risk for CVD (Marnewick et al. 2011). In a more 
recent study by Dludla et al. (2014) investigating diabetic cardiomyopathy (DCM), a 
disorder of the heart muscle associated with diabetes, Rooibos was shown to have 
cardio-protective effects in primary cardiomyocytes cultures isolated from diabetic 
rats. Rooibos reduced intracellular ROS and cell death under experimentally induced 
oxidative-stress and ischemic conditions. In addition, Rooibos maintained normal 
intracellular ATP and GSH levels, which if depleted, are strongly associated with 
oxidative stress and metabolic dysfunction. It was suggested that by maintaining the 
balance between ROS and antioxidants, Rooibos was able to protect cardiomyocytes 
from cell damage associated with disease states such as diabetes (Dludla.2014).  
Going hand in hand with T2D, hypertension and CVD, is obesity, a chronic 
disease commonly associated with poor lifestyle. The beneficial properties of 
Rooibos regarding metabolic conditions such as hyperglycemia, hyperlipidemia, and 
CVDs, as discussed above, is suggestive of Rooibos exhibiting anti-obesity potential. 
However, only two studies have been reported to date.  In the first study by Beltrán-
Debón et al. (2011), the effect of Rooibos on dietary-induced hyperlipidemia in male 
LDLr−/− mice, a mouse model representing aspects resembling MetS, was 
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investigated. Continuous Rooibos consumption resulted in significant reductions in 
the levels of serum cholesterol, TGs and FFAs in rats consuming a high fat diet. In 
addition, the effects of Rooibos were more prominent than in the chow fed rats and 
resulted in significantly improved VLDL:LDL:HDL ratios. Analysis of adipose tissue 
showed that Rooibos promoted lipid accumulation in adipocytes of rats consuming 
standard rat chow, however, in rats consuming a high fat diet, Rooibos protected the 
liver from lipid storage without the accumulation of fat in adipocytes. Analyses of liver 
tissue showed that Rooibos prevented dietary-induced hepatic steatosis in 
hyperlipidemic mice, which was also associated with a significant decrease in 
macrophage recruitment, a reduction not detected in the rats fed a normal diet. In the 
3T3-L1 pre-adipocyte cell line, Rooibos was shown to decrease TG levels in a dose-
dependent manner in differentiated cells, while not affecting differentiation of pre-
adipocytes (Beltrán-Debón et al. 2011). In a subsequent study, a fermented Rooibos 
extract was shown to modulate adipocyte differentiation in 3T3-L1 cells. Rooibos 
exhibited anti-adipogenic effects in differentiating 3T3-L1 preadipocytes, while also 
reducing lipid accumulation in these cells, possibly by inhibiting the expression of 
enzymes involved in adipogenesis and lipid metabolism. In addition, glucose uptake 
and ATP levels were increased in differentiating 3T3-L1 adipocytes. Interestingly, 
leptin levels in 3T3-L1 adipocytes were reduced in the presence of Rooibos 
(Sanderson et al. 2014).  
2.5.4 Modulation of adrenal steroidogenic enzymes by Rooibos 
 
Adrenal steroid hormones, which include the mineralocorticoids, 
glucocorticoids and adrenal androgens, are responsible for the regulation of a variety 
of physiological processes in the body. These steroid hormones are produced in the 
adrenal gland by P450 enzymes and hydroxysteroid dehydrogenases (HSDs). 
Abnormal adrenal steroid hormone levels due to altered enzyme activities impact a 
number of clinical conditions such as hypertension, MetS, T2D and heart failure, to 
name but a few, and will be discussed in greater detail in Chapter 3. 
P450 enzymes and flavonoids have been reported to interact with each other 
in at least three ways − flavonoids have been shown to induce the biosynthesis of 
P450 enzymes; alter (inhibit / stimulate) the enzymatic activities of P450 enzymes, 
while also serving as substrates for several P450 enzymes. Besides the effect on the 
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catalytic activity of steroidogenic enzymes, flavonoids have also been shown to 
influence physiological processes by interfering at the receptor level. In addition, 
flavonoids are often referred to as phytoestrogens due to the structural similarity to 
estrogen and the ability to bind to the estrogen receptor (ER). Various flavonoids 
have been reported to inhibit the activity of cytochrome P450 aromatase (CYP19), a 
key enzyme involved in estrogen biosynthesis and a target for the treatment of breast 
cancer (Hodek et al. 2002). Luteolin, a flavonoid compound present in Rooibos, has 
for example, been shown to inhibit estrogen biosynthesis by reducing the expression 
of CYP19 (Lu et al. 2012). 
The influence of flavonoids on adrenal steroidogenesis has been investigated 
by several groups. Previous studies in our laboratory by Richfield (2008) and Perold 
(2009) showed that Rooibos extracts significantly inhibited the binding of substrates, 
progesterone (PROG) and 17OH-progesterone (17OH-PROG), to enzymes in ovine 
adrenal microsomal preparations. These preparations contain both CYP17A1 and 
CYP21A2, which catalyze the conversion of pregnenolone (PREG) and PROG in 
adrenal steroidogenesis. Subsequent substrate conversion assays in COS-1 cells 
showed that Rooibos significantly reduced PROG conversion by CYP17A1 and 
CYP21A2, with CYP21A2 being inhibited to a greater extent than CYP17A1. In 
addition, it was also shown that the inhibitory effect of an unfermented Rooibos 
extract was greater than that of a fermented Rooibos extract (Richfield 2008; Perold 
2009). 
Although assays in COS-1 cells yield data regarding the interaction between 
flavonoids and individual steroidogenic enzymes, studies conducted in H295R cells, 
an adrenal carcinoma cell line expressing all of the adrenal steroidogenic enzymes, 
provide a broader perspective as these analyses are indicative of the effect of 
flavonoids on overall adrenal steroid production. In a study by Mesiano et al. (1999), 
it was shown that both genistein and daidzein inhibit cortisol production in cAMP-
stimulated H295R cells as well as in ACTH-stimulated cultured fetal and postnatal 
adrenal cortical cells. The authors proposed that the reduction observed in cortisol 
levels was due to inhibition of CYP21A2, since both genistein and diadzein inhibited 
cortisol production when PROG and 17OH-PROG were added to the medium. 
However, when deoxycortisol was added, no inhibition on cortisol production was 
detected, indicating that the compounds do not inhibit CYP11B1 (Mesiano et al. 
1999). In a subsequent study by Ohno et al. (2002), the flavonoids, daidzein, 
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genistein and 6-hydroxyflavone was shown to selectively inhibit the activities of 
CYP17A1, 3βHSD2, CYP21A2 and CYP11B1 in H295R cells. In addition, these 
flavonoids also significantly inhibited cortisol production in cAMP stimulated H295R 
cells (Ohno et al. 2002). The authors subsequently showed that genistein 
significantly reduced serum CORT and testosterone levels in rats (Ohno et al. 2003). 
In a more recent study, Ohlsson et al. (2010) showed that daidzein and genistein 
inhibited cortisol and testosterone production in H295R cells, while an equimolar 
mixture of diadzein, genistein and vitexin inhibited the production of cortisol, 
testosterone and aldosterone (ALDO) in an additive manner (Ohlsson et al. 2010).  
Although the aforementioned Rooibos flavonoids, luteolin and vitexin, was 
shown to inhibit CYP19 as well as the production of end products in H295R cells, 
respectively, the former compound was identified in fermented Rooibos only and is 
present at very low levels. Vitexin, on the other hand, appears to be relatively stable 
and is present at similar levels in both fermented and unfermented Rooibos (Richfield 
2008). In our studies, we have shown that vitexin’s interaction with key adrenal 
steroidogenic enzymes is complex in terms of substrate preference. The interaction 
of Rooibos extracts and the major flavonoids in Rooibos with adrenal steroidogenic 
enzymes in vitro and in vivo will be discussed in Chapter 4 and is presented as three 
published manuscripts. The relevant literature regarding the interaction between 
flavonoid compounds and steroidogenic enzymes will also be addressed.  
2.6 Summary 
 
From the data presented in this chapter it is evident that Rooibos exhibits 
various health promoting properties that impact metabolic disorders. It is also clear 
that oxidative stress plays a critical role in the etiology of metabolic diseases. 
Changes in the redox status that occur during oxidative stress as a result of 
excessive free radical production can be counteracted by polyphenols exhibiting 
potent anti-oxidant properties. The anti-oxidant properties of Rooibos have been 
widely reported and its ability to restore the redox imbalance is reflected in positive 
changes in GSH:GSSH ratios in rats and humans. It is thus possible that decreased 
GSH:GSSH ratios may impact on diabetes, since the link between oxidative stress 
and diabetes has been clearly established. Rooibos flavonoids are able to protect 
pancreatic β-cells against oxidative stress and cell damage, while also exhibiting 
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hypoglycemic effects in vitro and in vivo, as reflected in increased glucose uptake, 
improved glucose tolerance and the stimulation of insulin secretion. The protective 
role of Rooibos is also evident in heart muscle disorders associated with diabetes, 
with Rooibos protecting cardiomyocytes by maintaining the balance between ROS 
and antioxidants.  The cardio-protective effects of Rooibos are demonstrated both in 
vitro and in vivo, with in vivo studies reporting reductions in plasma levels of total 
cholesterol, LDL cholesterol and TGs, while the levels of HDL cholesterol is 
increased following Rooibos consumption. Although the anti-obesity properties of 
Rooibos appear to be less apparent, extracts were able to modulate adipocyte 
differentiation, enzyme expression and lipid metabolism. However, the anti-diabetic 
and cardio-protective properties of Rooibos as discussed above are all factors that 
would also impact on obesity parameters. 
The properties of Rooibos discussed in this chapter therefore suggest a 
therapeutic role for Rooibos in the overall management of endocrine-related 
disorders. In addition, Rooibos extract, as well as specific Rooibos flavonoids have 
been shown to alter the activities of key enzymes in adrenal steroidogenesis, which 
also plays a fundamental role in the regulation of the endocrine system. It therefore 
seems plausible that Rooibos extract and/or Rooibos flavonoid compounds could 
modulate adrenal steroidogenic enzyme activities and reduce the levels of the 
glucocorticoids, which would further add to the anti-diabetic and cardio-protective 
properties of Rooibos. Since the aim of the present study is to investigate the 
influence of Rooibos on adrenal steroidogenesis, the next chapter will provide an 
overview of adrenal steroidogenesis in terms of the enzymes involved in adrenal 
steroid production, as well as the physiological roles of these hormones in normal 
and diseased states. 
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CHAPTER 3 
Adrenal steroidogenesis 
 
3.1  Introduction 
 
Adrenal steroid hormones regulate a variety of essential developmental and 
physiological processes in the body. These hormones are synthesised in the adrenal 
cortex from the common precursor, cholesterol, through a network of enzyme-
catalysed reactions within the adrenal steroidogenic pathway. Based on their 
physiological functions, adrenal steroid hormones can be divided into three classes, 
namely the glucocorticoids, mineralocorticoids and adrenal androgen precursors. The 
adrenal androgen precursors are involved in sexual growth and development, while 
the mineralocorticoids regulate sodium and water homeostasis. Glucocorticoids play 
a key role in the regulation of carbohydrate-, protein- and lipid metabolism, immune 
and inflammatory responses and the stress response. Abnormal steroid hormone 
levels, due to altered enzyme activities and/or expression levels, have been 
implicated in numerous clinical conditions. Elevated glucocorticoid levels due to 
chronic stress, for instance, have been linked with the development of visceral 
obesity, hypertension, T2D and CVDs, amongst others. In this chapter, adrenal 
steroidogenesis will be discussed in terms of the enzymes catalyzing adrenal steroid 
hormone production, as well as the physiological effects of the mineralocorticoids, 
glucocorticoids and adrenal androgens and their role in disease. The main focus, 
however, will be on the glucocorticoids and clinical conditions that are associated 
with stress-induced elevation of glucocorticoids. In order to understand how stress 
can cause disease, it is necessary to first understand the mechanisms by which 
adrenal steroid hormones are produced and regulated. 
3.2  Anatomy and morphology of the adrenal gland 
The adrenals are small endocrine glands situated on the upper pole of each 
kidney. The mammalian adrenal gland consists of two structurally and functionally 
distinct types of endocrine tissue, namely the outer adrenal cortex and the inner 
adrenal medulla (Fig. 3.1). The adrenal medulla consists of catecholamine producing 
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chromaffin cells, while the adrenal cortex contain steroid producing cortical cells. This 
is, however, rather an oversimplification, since, chromaffin cells are also found in the 
cortex, either in the form of islets or extending from the medulla through the cortex, 
while cortical cells are also present in the medulla as islets surrounded by chromaffin 
cells (Palacios and Lafarga 1975; Bornstein et al. 1991; Bornstein and Ehrhart-
Bornstein 1992). The medullary chromaffin cells, which originate from neural crest 
material, mainly secrete the catecholamines, epinephrine (adrenaline) and 
norepinephrine (noradrenaline), along with various other neurotransmitters and 
neuropeptides (Winkler et al. 1986). Since these two endocrine tissues are 
morphologically interwoven, their functions have also been shown to interact with 
each other – chromaffin cells are able to regulate steroid release from the adrenal 
cortex, while adrenal steroids can induce the production of catecholamines in the 
medulla (Ehrhart-Bornstein and Bornstein 2008). 
The adrenal cortex consists of three distinct adrenal zones namely the zona 
glomerulosa, zona fasciculata and zona reticularis, which differ from each other with 
regards to their morphological features as well as the steroid hormones that they 
secrete (Fig. 3.1) (Ehrhart-Bornstein et al. 1998). 
 
 
Figure 3.1: Schematic cross-section of the adrenal gland showing the capsule, 
adrenal cortex and medulla. The adrenal cortex consists of the zona glomerulosa, 
zona fasciculata and zona reticularis, which produce the mineralocorticoids, 
glucocorticoids and adrenal androgen precursors, respectively. Reproduced from 
Mescher et al. (2010) with permission from McGraw Hill. 
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The outer zona glomerulosa cells, which comprise ± 15% of the adrenal cortex 
volume, secrete the mineralocorticoid, ALDO. The zona glomerulosa is situated 
directly beneath the fibrous connective tissue capsule and the cells of this highly 
vascularised region are arranged in irregular clusters and arcades. Cells of the zona 
glomerulosa are capable of regenerating cells of the zona fasciculata and zona 
reticularis via a progenitor cell population situated between the zona glomerulosa and 
fasciculata (Neville and O’Hare 1985; Teebken and Scheumann 2000).  
The zona fasciculata, which lies between the zona glomerulosa and zona 
reticularis, comprises ± 75% of the total cortex volume. Cells in this region consist of 
columns of polyhedral cells, surrounded by straight capillaries angled at the same 
position as the cells. Cells in the zona fasciculata produce the glucocorticoids, 
cortisol and CORT, as well as trace amounts of dehydroepiandrosterone (DHEA) 
(Ehrhart-Bornstein et al. 1998; Young and Heath 2002).  
The innermost region, the zona reticularis, encircles the medulla and consists 
of irregular branching cords and cell clusters separated by capillaries. The zona 
reticularis comprises ± 10% of the cortex volume and produces the adrenal androgen 
precursors, DHEA, dehydroepiandrosterone-sulfate (DHEAS) and A4 (Arlt and 
Stewart, 2005; Mescher, 2010). 
3.3 Cholesterol as precursor for adrenal steroid hormone biosynthesis 
 
Cholesterol, the common precursor for adrenal steroid hormone production, is 
mainly derived from circulating lipoproteins including LDL- and HDL cholesterol 
esters. Cholesterol can also be synthesized de novo from acetate in the endoplasmic 
reticulum of steroid producing cells or it can be mobilized from other intracellular 
sources. LDL cholesterol ester uptake is mediated by the LDL-receptor via receptor-
mediated endocytosis. The endosome fuses with lysosomes containing acid lipase, 
which hydrolyses the LDL cholesterol to release free cholesterol. Cholesterol is 
subsequently transported to the endoplasmic reticulum where it is either used for 
adrenal steroid hormone production or converted to cholesterol esters by acyl-
coenzyme A:cholesterol acyltransferase (ACAT) and stored in lipid droplets. These 
cholesterol esters can be converted back to free cholesterol by hormone-sensitive 
lipase (HSL) on demand (Faust et al. 1977; Brown et al. 1979; Gwynne and Strauss 
1982; Mason and Rainey 1987; Ungewickell and Hinrichsen 2007; Rone et al. 2009; 
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Miller and Auchus 2011). HDL cholesterol ester uptake is mediated by the scavenger 
receptor class B, type-I receptor (SRBI), which forms a hydrophobic channel allowing 
for direct incorporation into the plasma membrane. HDL cholesterol esters are either 
converted to free cholesterol by HSL or stored in lipid droplets (Fig. 3.2) (Kraemer 
and Shen 2002; Connelly and Williams 2003; Rone et al. 2009). The transport of free 
cholesterol across the aqueous cytosol towards the outer mitochondrial membrane 
(OMM) is mediated by binding proteins which contain steroidogenic acute regulatory 
protein (StAR)-related lipid transfer (START) domains (Soccio and Breslow 2003; 
Miller and Auchus 2011). The transport of free cholesterol from the OMM to the inner 
mitochondrial membrane (IMM) by StAR is the rate-limiting step in adrenal steroid 
hormone production and is directly dependent on the availability of free cholesterol. 
At the IMM, P450 side chain cleavage (CYP11A1), also known as P450 scc, 
catalyses the conversion of cholesterol to PREG (Fig. 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Principal pathways involved in intracellular cholesterol transport 
pathways. LDL, low-density lipoprotein; SRB1, scavenger receptor class B type-I; 
ACAT, acyl-coenzyme A:cholesterol acyltransferase; HSL, hormone-sensitive lipase; 
StAR, steroidogenic acute regulatory protein; StarD4, StAR-related lipid transfer 
domain; OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; 
P450scc, cytochrome P450 side chain cleavage. Reproduced from Miller and Auchus 
(2011) with permission from Endocrine Society. 
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PREG subsequently enters the endoplasmic reticulum, where it serves as the 
precursor steroid metabolite to adrenal steroid hormone production through a 
network of enzyme-catalysed reactions. Adrenal steroid hormones therefore possess 
closely related chemical structures to that of cholesterol, based on the common 
cyclopentanoperhydrophenanthrene ring structure (You 2004) as shown in Figure 
3.3.  
 
 
 
 
 
 
 
 
 
Figure 3.3: Cyclopentanoperhydrophenanthrene ring representing the backbone 
structure of all adrenal steroid hormones. Reproduced from You (2004) with 
permission from Elsevier.  
 
3.4 Enzymes catalysing adrenal steroid hormone production 
 
Adrenal steroid hormones are biosynthesized in the adrenal cortex from 
cholesterol via two distinct groups of enzymes - the P450 enzymes and the HSD 
enzymes. Adrenal P450 enzymes include CYP11A1, CYP17A1, CYP21A2, 
CYP11B1 and aldosterone synthase (CYP11B2), while the HSD enzymes include 
3βHSD2, several isoforms of 17β-hydroxysteroid dehydrogenase (17βHSD) as well 
as 11βHSD1 and 11βHSD2 (Miller and Auchus, 2011). The 17βHSDs and 11βHSDs 
are, however, expressed at much lower levels compared to 3βHSD2 (Rege et al., 
2013). Within the adrenal cortex, steroid production catalyzed by 3βHSD2, CYP17A1 
and CYP21A2 occur in the endoplasmic reticulum, while reactions catalysed by 
CYP11A1, CYP11B1 and CYP11B2 occur in the mitochondria.  
The mitochondrial enzymes require an electron shuttle system, 
adrenodoxin/adrenodoxin reductase, in order to hydroxylate or oxidize steroid 
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metabolites, while the enzymes located in the endoplasmic reticulum, also known as 
microsomal P450 enzymes, require electrons from NADPH via the enzymatic action 
of P450 oxidoreductase (POR) (Miller and Auchus, 2011). CYP17A1 lyase activity is 
dependant on an additional cofactor, namely cytochrome b5 (Cyt-b5), which is a 
flavoprotein functioning as an allosteric facilitator between CYP17A1 and POR 
(Storbeck et al. 2013). 
P450 enzymes are functionally unidirectional, resulting in the accumulation of 
steroid products without driving the flux back to precursor steroid metabolites (Miller 
and Auchus 2011). Reactions catalysed by the HSDs, on the other hand, are 
reversible under certain in vitro conditions, with the reaction direction being 
dependent on substrate-, product- and co-factor availability. In vivo, however, the 
HSD enzymes catalyse one reaction only — either the oxidation or reduction of 
steroid metabolites (Agarwal and Auchus, 2005). 
3.4.1 P450 enzymes  
 
P450 enzymes are membrane bound proteins belonging to a superfamily of 
heme-containing proteins, and are present in all eukaryotic and some prokaryotic 
organisms. The “P450” annotation is derived from “pigment 450” due to the enzyme’s 
unique spectral property of absorbing light maximally at 450 nm when the reduced 
form of the enzyme is complexed with carbon monoxide in vitro. In addition, it was 
shown that P450-containing microsomes treated with detergent were converted to a 
solubilized form which, under reduced conditions and in the presence of carbon 
monoxide, resulted in an absorption maximum at 420 nm. This form of P450, referred 
to as “P420”, represented the inactive form of P450 (Miller and Auchus, 2011; Omura 
and Sato, 1962).  
The P450 enzymes, also referred to as monooxygenases, function as strong 
oxidants since they catalyse oxidative reactions using molecular oxygen. P450 
enzymes utilize NADPH as an electron donor to incorporate one oxygen atom into 
the substrate in the form of a hydroxyl group, while the other atom is reduced to 
water. The general P450 catalysed reaction can be written as follows: 
 
                              RH + O2 + NADPH + H+ ⟶  ROH + H2O + NADP+ 
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A general mechanism for P450 catalysed hydroxylation reactions has been 
established over many years (Fig. 3.4) and consists of the following steps: Initially, 
the enzyme is in a resting low spin (LS) ferric (Fe3+) state with a water molecule as 
the sixth ligand (1). Substrate (RH) binding in the active pocket displaces the water 
molecule and generates a high-spin (HS) substrate bound complex (2). The higher 
positive reduction potential of the HS Fe3+ complex leads to a single electron transfer 
from the redox partner, and the complex is subsequently reduced to the ferrous 
(Fe2+) state (3). Molecular oxygen binds to the ferrous enzyme-substrate complex to 
form an oxygen-P450-substrate complex (4), which in turn results in the transfer of 
the second electron from the redox partner, leading to the formation of a Fe3+-dioxo 
complex (5a). Protonation of this complex results in the formation of a peroxo-Fe3+ 
intermediate (5b), which undergoes a second protonation reaction, resulting in the 
splitting of molecular oxygen. One of the oxygen atoms are transferred to water, 
while the other atom remains bound to the ferric iron to form the reactive species (6), 
which subsequently transfers the distal oxygen atom to the substrate (7). Once the 
substrate is hydroxylated, it is released from the complex and replaced by water, 
regenerating the resting ferric state (1). In addition to various intermediate states, the 
P450 reaction cycle also involves three abortive reactions. The first reaction includes 
the autoxidation of the oxy-ferrous complex (4), with the subsequent production of a 
superoxide, while the enzyme returns to the resting state (2). The second reaction 
involves a peroxide shunt in which the hydroperoxide anion (5b) dissociates from the 
iron-producing hydrogen peroxide, while the enzyme returns to the resting state. 
Finally, an oxidase uncoupling can occur, in which the ferryl-oxo intermediate is 
oxidized, yielding water instead of the hydroxylated substrate (6) (Denisov et al. 
2005). 
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Figure 3.4: Cytochrome P450 reaction cycle. The substrate is indicated as RH and 
the hydroxylated product as ROH. Reprinted with permission from Denisov et al. 
(2005). Copyright 2005, American Chemical Society. 
 
P450 enzymes are divided into different classes based on their intracellular 
localization and the mechanism by which they receive electrons. There are two 
classes of P450s involved in mammalian steroid hormone production, namely type-1 
and type-2 P450 enzymes, which are localized in the mitochondria and endoplasmic 
reticulum, respectively. Type-1 mitochondrial enzymes (CYP11A1, CYP11B1 and 
CYP11B2) utilize NADPH as an electron donor, which transfers a high potential 
electron via the flavoprotein, adrenodoxin reductase, and then via adrenodoxin, a 
nonheme iron-sulfur protein. Adrenodoxin subsequently transfers the electron to the 
substrate via the P450 heme centre (Fig. 3.5A). Type-2 microsomal enzymes 
(CYP17A1, CYP21A2 and CYP19) receive electrons from NADPH via the single 2-
flavin protein, POR. The electrons from NADPH are firstly transferred to a 
flavinadenine dinucleotide (FAD), secondly to flavinmononucleotide (FMN), and 
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finally to the substrate via the P450 heme centre (Fig. 3.5B) (Hannemann et al., 
2007; Miller and Auchus, 2011; Payne and Hales, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Schematic representation of mitochondrial (A) and microsomal (B) 
electron transfer systems. FAD, flavinadenine dinucleotide; Adr, adrenodoxin 
reductase; Ado, adrenodoxin; FMN, flavinmononucleotide; S, substrate. Reproduced 
from Payne and Hales (2004) with permission from Endocrine Society. 
 
3.4.2 Hydroxysteroid dehydrogenases 
 
The HSDs are non-metallic enzymes belonging to the short-chain alcohol 
dehydrogenase reductase superfamily. These enzymes catalyse the reduction and 
oxidation of steroid hormones and require NADH/NADPH as donors and 
NAD+/NADP+ as acceptors of reducing equivalents. There are three main types of 
HSDs that catalyse reactions within the adrenal cortex, namely the 3βHSDs, 
17βHSDs and 11βHSDs. These enzymes have various isoforms, each being a 
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product of a different gene. Based on their physiological activities, HSDs can either 
be classified as dehydrogenases or reductases. Dehydrogenases utilize 
NAD+/NADP+ as cofactor, oxidizing hydroxy-steroids to keto-steroids, while the 
reductases mainly utilize NADH/NADPH to reduce keto-steroids to hydroxy-steroids. 
Although these enzymes can be bi-directional in vitro, they exhibit either reductase or 
dehydrogenase activity in vivo, with the direction being dependant on co-factor 
availability as well as the relative affinities of the HSDs for these cofactors (Agarwal 
and Auchus, 2005; Miller and Auchus, 2011; Penning, 1997). 
In humans, two distinct isoforms of 3βHSD have been identified, namely 
3βHSD1 and 3βHSD2, with only the latter isoform being expressed in the adrenal 
(Rhéaume et al. 1991). Within the adrenal, 3βHSD2 catalyses the conversion of the 
∆5-steroids, PREG, 17OH-pregnenolone (17OH-PREG) and DHEA to their respective 
∆4-steroid products, PROG, 17OH-PROG and A4, in two sequential reactions. Using 
PREG conversion by 3βHSD2 as an example, the first step involves a NAD+ 
dependant dehydrogenation reaction, in which the C3 hydroxyl-group is converted to 
a keto-group, yielding a ∆5-3-keto-intermediate and NADH, followed by a second 
reaction in which NADH subsequently activates the isomerisation of the ∆5-3-keto-
intermediate, yielding a ∆4-3-keto-steroid product (Payne and Hales, 2004; Thomas 
et al., 2003) (Fig. 3.6).  
 
 
 
 
 
Figure 3.6: Enzymatic reactions catalysed by human 3βHSD2 in the adrenal using 
the conversion of pregnenolone (PREG) to progesterone (PROG) as an example. 
Reproduced from Payne and Hales (2004) with permission from Endocrine Society. 
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17βHSDs catalyse the inter-conversion between inactive 17-keto-steroids, 
such as DHEA, A4 and estrone to their respective active 17β-hydroxy-forms, 
androstenediol, testosterone and estradiol. There are at least 14 human 17βHSD 
isoforms, which all vary in terms of their sites of expression, substrate specificity, 
cofactor utilization and physiological functions (Miller and Auchus, 2011). 
11βHSDs catalyse the inter-conversion between active glucocorticoids, 
(cortisol in humans and CORT in rodents) and their inactive keto-metabolites, 
(cortisone in humans and 11-DHC in rodents), respectively. There are two 11βHSD 
isoforms, viz. 11βHSD1 and 11βHSD2. 11βHSD1 is a NADPH-dependent 
microsomal oxo-reductase, which catalyzes the conversion of 11-DHC and cortisone, 
to their respective active glucocorticoids, CORT and cortisol (Cooper and Stewart, 
2009). NADPH required for the oxo-reductase activity of 11βHSD1 is produced by 
the microsomal NADPH regenerating enzyme, hexose-6-phosphate dehydrogenase 
(H6PDH). H6PDH catalyzes the first two reactions of the pentose phosphate pathway 
to regenerate NADPH from NADP+ via the conversion of glucose-6-phosphate (G6P) 
to 6-phosphogluconolactone within the endoplasmic reticulum lumen (Atanasov et al. 
2008; Dzyakanchuk et al. 2009). H6PDH is an isomer of glucose-6-phosphate 
dehydrogenase (G6PDH), which catalyses the first step of the pentose phosphate 
pathway in the cytoplasm. In contrast to G6PDH, H6PDH does not only utilize G6P 
as substrate, but also other hexose-6-phosphates and sugars (Hino and Minakami 
1982; Atanasov et al. 2008). In a study by Atanasov et al. (2004) it was shown that 
co-expresssion of 11βHSD1 and H6PDH in HEK-293 cells resulted in more than a 
20-fold increase in the ratio of reductase:dehydrogenase activity of 11βHSD1 
(Atanasov et al. 2004). The loss of NADPH production, as observed in H6PDH 
knockout mice, results in predominant dehydrogenase activity of 11βHSD1, which 
clearly indicates that H6PDH plays an indispensable role in 11βHSD1-depentant 
glucocorticoid production (Rogoff et al. 2007). In vitro, 11βHSD1 exhibits both 
dehydrogenase (oxidase) and oxo-reductase activity, due to the absence of H6PDH, 
and it is therefore able to catalyse the inter-conversion between active and inactive 
glucocorticoid metabolites. Co-transfection of 11βHSD1 and H6PDH changes the 
directionality of 11βHSD1 to mimic in vivo conditions in which the oxo-reductase 
activity of 11βHSD1 predominates. 11βHSD2, on the other hand, exhibits 
dehydrogenase activity only, and catalyses the conversion of the active 
glucocorticoids, cortisol and CORT to their respective inactive metabolites, cortisone 
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and 11-DHC (Fig 3.7). Besides from the inter-conversion between active 
glucocorticoids and their inactive keto-metabolites, we have recently shown that 
11βHSD1 also catalyses the conversion of 11-ketoandrostenedione (11KA4) and 11-
ketotestosterone (11KT) to 11OHA4 and 11β-hydroxytestosterone (11OHT), 
respectively, while 11βHSD2 catalyses the reverse reaction in which 11OHA4 and 
11OHT is converted to 11KA4 and 11KT, respectively (Swart et al. 2013).  
 
 
 
Figure 3.7: Inter-conversion between cortisol and cortisone by 11βHSD1 and 
11βHSD2.  
 
 
3.5  The adrenal steroidogenic pathway 
 
The first step of adrenal steroidogenesis occurs in the mitochondria where 
cholesterol is converted to PREG by CYP11A1. The conversion of cholesterol to 
PREG involves three sequential reactions, which include the hydroxylation of C22 
and C20 of cholesterol, followed by the cleavage of the C20-22 bond to yield PREG 
and isocaproaldehyde. PREG diffuses from the mitochondria to the endoplasmic 
reticulum, where it serves as a substrate for either CYP17A1 or 3βHSD2. Since 
CYP17A1 and 3βHSD2 are at the branch point in adrenal steroidogenesis, the 
relative catalytic activities and substrate specificities of these two enzymes toward 
their common substrates, PREG and 17OH-PREG, play a crucial role in the 
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determination of the steroid fluxes in the mineralocorticoid, glucocorticoid and 
adrenal androgen precursor pathways (Miller and Auchus, 2011).  
CYP17A1 catalyzes two distinct reactions – the 17α-hydroxylation of PREG 
and PROG, yielding the glucocorticoid precursors, 17OH-PREG and 17OH-PROG, 
respectively; followed by the subsequent 17,20-lyase reaction in which the 17,20 
bonds of 17OH-PREG and 17OH-PROG are cleaved to yield the adrenal androgen 
precursors, DHEA and A4, respectively. In humans, however, the 17,20-lyase 
reaction of CYP17A1 prefers 17OH-PREG as substrate and the conversion of 17OH-
PROG to A4 is negligible. In addition, human CYP17A1 also hydroxylates PROG at 
C16, yielding 16OH-progesterone (16OH-PROG), a dead-end product. 
As previously mentioned, 3βHSD2 catalyses the dehydrogenation of the ∆5-
steroids, PREG, 17OH-PREG and DHEA at C3 in two sequential reactions (Fig. 3.6) 
to yield their corresponding ∆4-steroid products, PROG, 17OH-PROG and A4, which 
are the precursor metabolites for the mineralocorticoid-, glucocorticoid- and adrenal 
androgen precursor pathways, respectively. Cyt-b5 is an electron transfer 
hemoprotein which influences the competition between CYP17A1 and 3βHSD2 by 
selectively promoting the 17,20-lyase activity of CYP17A1 by acting as an allosteric 
facilitator between CYP17A1 and POR. (Katagiri et al., 1995, 1982; Miller and 
Auchus, 2011). It was recently shown that Cyt-b5 also augments the activity of 
3βHSD by increasing the affinity of 3βHSD for NAD+, which subsequently results in 
an increase of the rate limiting dehydrogenase reaction of this enzyme (Goosen et al. 
2011, 2013). In addition to the activity of Cyt-b5, phosphorylation of CYP17A1 
serine/threonine residues has also been shown to promote the 17,20-lyase activity of 
CYP17A1 by facilitating the interaction between CYP17A1 and POR (Miller and Tee 
2014). 
CYP21A2 catalyzes the hydroxylation of PROG and 17OH-PROG at C21 to 
yield DOC and deoxycortisol, respectively, which are substrates for CYP11B2 and 
CYP11B1 in the mitochondria. CYP11B2, also known as aldosterone synthase, 
catalyzes three sequential reactions to yield the mineralocorticoid, ALDO. The first 
reaction involves the 11β-hydroxylation of DOC to yield CORT, which is hydroxylated 
at C18 to produce 18OH-corticosterone (18OH-CORT). CYP11B2 finally oxidizes the 
C18 hydroxyl group of 18OH-CORT, yielding ALDO. CYP11B1 catalyses the 
conversion of DOC and deoxycortisol to their respective glucocorticoids, CORT and 
cortisol, via hydroxylation at position 11β (Fig. 3.8).  
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 We recently showed that both CYP11B1 and CYP11B2 catalyse the 
hydroxylation of A4 and testosterone, yielding 11OHA4 and 11OHT, respectively. 
These data suggests that CYP11B1 and CYP11B2 not only play a role in the 
biosynthesis of the mineralocorticoids and glucocorticoids, but also in the production 
of adrenal androgen precursors (Swart et al. 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Major enzymes involved in human adrenal steroid hormone production. 
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As mentioned previously, the mineralocorticoids, glucocorticoids and adrenal 
androgen precursors are produced in three morphologically and biochemically 
distinct zones in the adrenal cortex, namely the zona glomerulosa, zona fasciculata 
and zona reticularis, respectively. Tissue specific expression of adrenal steroidogenic 
enzymes within these three zones, as well as their relative expression levels and 
catalytic activities, provide the biochemical basis for the differences in the steroid 
fluxes through the mineralocorticoid-, glucocorticoid- and adrenal androgen precursor 
pathways. Several enzymes are, however, expressed in more than one zone and 
defects in such enzymes can therefore affect the biosynthesis of various steroid 
hormones. Enzymes involved in the initial steps of adrenal steroidogenesis are 
expressed in all three zones of the adrenal cortex and they include StAR, CYP11A1, 
CYP21A2 and 3βHSD2, however, it has been shown that after the age of 8 years, 
the expression of 3βHSD2 in the zona reticularis decreases significantly. CYP17A1 is 
expressed in zona fasciculata and in the zona reticularis. The expression of Cyt-b5 
markedly rises in the zona reticularis after the age of 5 years and plateaus at the age 
of 13 years, whereas the levels in the zona glomerulosa and zona fasciculata remain 
extremely low at all ages. CYP11B2 is specific to the zona glomerulosa and 
CYP11B1 is specific to the zona fasciculata (Suzuki et al. 2000; Fallo et al. 2002; 
Enberg et al. 2003; Gomez-Sanchez et al. 2014; Rege et al. 2014).  
Under physiological conditions, mineralocorticoid biosynthesis is regulated 
primarily by angiotensin II (Ang II), while glucocorticoid and adrenal androgen 
biosynthesis is regulated by ACTH. ACTH has been shown to significantly alter 
enzyme expression levels in the adrenal, which subsequently leads to altered steroid 
hormone production, influencing the steroid fluxes through the adrenal steroidogenic 
pathways.  
The H295R cell line - a human adrenocortical carcinoma cell line, is an 
excellent model system for studying basal adrenal functions and the regulation of 
adrenal steroidogenesis (Rainey et al. 1994; Rehman et al. 2003). These cells are 
pluripotent and are capable of being directed to produce steroid metabolites from 
each of the three adrenal zones. H295R cells can be differentiated into ‘glomerulosa-
like’ cells by pre-treating the cells with Ang II or potassium, which leads to increased 
ALDO production (Rainey et al. 2004). Pretreatment with forskolin- a diterpene which 
mimics the effects of ACTH via the activation of cAMP pathways, results in the 
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formation of ‘zona fasciculata-like’ cells, which leads to increased cortisol and 
adrenal androgen biosynthesis (Laurenza et al. 1989; Rainey et al. 1993).  
In a study by Oskarsson et al. (2006), mRNA expression levels of 
steroidogenic enzymes were quantified in human adult adrenal glands as well as in 
H295R cells in the absence and presence of forskolin. Forskolin treatment in H295R 
cells significantly increased the expression levels of CYP11A1, CYP17A1, 3βHSD2, 
CYP21A2, CYP11B1, CYP11B2 and CYP19A1, with the most prominent increases 
being observed for CYP17A1 and CYP11B1, as their expression levels were 
upregulated between 5- and 6-fold following treatment. Interestingly, it was observed 
that the addition of forskolin changed the enzyme expression levels in the H295R 
cells to a steroidogenic transcript profile that was very similar to the profile of adult 
adrenal glands. Within the adult adrenal glands, CYP17A1 had the highest 
expression levels by far, followed by CYP11B1, StAR, CYP21A1, CYP11A1, 
3βHSD2, SULT2A1, CYP11B2 and CYP19A1 (Oskarsson et al. 2006).  
In a more recent study by Xing et al. (2011), the influence of ACTH on overall 
steroid production was assayed in adult adrenal primary cultures. ACTH treatment 
significantly increased the levels of the glucocorticoids, cortisol (63-fold), CORT (37-
fold), the glucocorticoid precursor, deoxycortisol (23-fold), as well as the adrenal 
androgen precursors, A4 (26-fold), DHEA (18-fold) and 11OHA4 (17-fold), confirming 
the stimulation of both glucocorticoid and adrenal androgen precursor biosynthesis 
by ACTH (Xing et al. 2011).  
3.6 Adrenal steroid hormones and their implications in disease 
 
The adrenal steroid hormones — glucocorticoids, mineralocorticoids and 
adrenal androgen precursors are characterized by different physiological functions 
and as such, specific hormonal imbalances will impact uniquely on disease states. In 
the following sections, the three steroid hormone classes will be discussed in terms 
of their implications in disease. While the role of the adrenal androgen precursors 
and the mineralocorticoids will be discussed briefly, the main focus will be on the 
glucocorticoids. 
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3.6.1 Adrenal androgen precursors 
 
Adrenal androgen precursors are C19 steroids produced in the zona reticularis 
of the adrenal cortex. The adrenal androgens precursors, DHEA and A4, only exhibit 
androgenic or estrogenic activity once converted by 3βHSD2, 17βHSD or CYP19 in 
peripheral target tissues to yield steroid metabolites such as testosterone and 
estrogen which are capable of activating steroid receptors. In women, roughly 75% of 
adrenal androgen precursors are utilized for peripheral estrogen production prior to 
menopause, while after menopause, it rises to 100%. In men, the contribution of 
adrenal androgen precursors is less significant (± 30-50%), since their primary 
source of androgens arise from the testes. DHEA secretion from the adrenal 
decreases over time and it is estimated that by the time women reach menopause, 
their DHEA secretion has decreased with about 60%. Due to significant inter-
individual variation, some post-menopausal women have normal DHEA levels, while 
others have very low levels. There is no negative feedback mechanism controlling 
the levels of DHEA, and therefore, women with low DHEA levels will have a 
deficiency for the remainder of their lifespan. Since the adrenal is the sole producer 
of androgens in women, low post menopausal DHEA levels, together with the ageing 
process, leads to a number of medical conditions such as osteoporosis, muscle loss, 
fat accumulation, hot flashes, T2D, memory loss and possibly Alzheimer’s disease. 
For most of these diseases, however, DHEA replacement therapy can be used to 
improve, correct, or even prevent some of these diseases. In men, on the other hand, 
adrenal androgen precursors have been implicated in prostate cancer, and both 
testicular- and adrenal androgen production need to be blocked in order to achieve 
optimal results during prostate cancer therapy (Arlt and Stewart, 2005; Labrie, 2010). 
 
3.6.2 Mineralocorticoids 
 
The principal mineralocorticoid, ALDO, is produced by CYP11B2 in the zona 
glomerulosa of the adrenal cortex and plays a key role in the regulation of sodium-, 
potassium- and water homeostasis. ALDO secretion is regulated by Ang II, 
potassium and, to a lesser degree, by ACTH. Ang II is produced via the RAAS, which 
regulates fluid and electrolyte balance. In response to low blood pressure, 
angiotensinogen is cleaved by renin to produce angiotensin I (Ang I), which has no 
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apparent biological activity. Ang I is subsequently converted by ACE to Ang II, a 
potent vaso-active peptide which cause blood vessels to constrict. Ang II increases 
the transcription of CYP11B2, stimulating the production of ALDO, which leads to 
increased sodium and water absorption, ultimately leading to an increase in blood 
pressure. Once the blood pressure has returned to normal, the secretion of renin is 
inhibited via a negative feedback mechanism (Ma et al. 2010; Beuschlein 2013). 
Excessive production of ALDO is implicated in the development of various 
clinical conditions including heart failure (Güder et al. 2007; Tsutamoto et al. 2007), 
fibrosis of the heart (Brilla 2000), myocardial infarction (Beygui et al. 2006), renal 
failure (Tylicki et al. 2005) and hypertension (Vasan et al. 2004). Anti-hypertensive 
drugs include mineralocorticoid receptor (MR) antagonists, ACE inhibitors, CYP11B2 
inhibitors and Ang II receptor blockers, amongst others (Hargovan and Ferro 2014). 
Spironolactone was the first MR agonist developed for the treatment of hypertension 
(Wolf et al. 1966). It was, however, shown to lack specificity for the MR, as it was 
able to also bind to progesterone and androgen receptors, resulting in a number of 
side effects including menstrual irregularities in women and sexual dysfunction in 
men (Parthasarathy et al. 2011). Another MR agonist, eplerenone, was subsequently 
developed, which had a reduced affinity for sex steroid receptors and was therefore 
less prone to cause sex hormone-related side effects. Both of these compounds 
have, however, been shown to cause electrolyte imbalances, in particular 
hyperkalemia, in up to 5% of patients (Weinberger et al. 2002). It was recently 
suggested that some of the adverse side effects of ALDO may occur through non-
genomic pathways independent of MR stimulation. If non-genomic pathways 
contribute substantially to the effects brought about by ALDO, drugs that inhibit 
CYP11B2 might offer an advantage over MR antagonists by preventing the activation 
of both genomic and non-genomic pathways (Amar et al. 2013). 
Since CYP11B2 catalyses the terminal steps in ALDO biosynthesis, selective 
inhibition of CYP11B2 is also of high pharmacological interest for the treatment of 
hypertension (Hakki and Bernhardt 2006; Baston and Leroux 2007; Schuster and 
Bernhardt 2007). However, selective inhibition of CYP11B2 has proved to be very 
challenging, since it shares 93% sequence identity with CYP11B1 (Curnow et al., 
1991; Denner et al., 1995.; Kawainoto et al., 1990). Preclinical studies have shown 
that FAD286, a dextroenantiomer of fadrozole, significantly inhibits the activity of 
CYP11B2. FAD286 dose-dependently reduced the levels of ALDO, lowered blood 
Stellenbosch University  https://scholar.sun.ac.za
! 45!
pressure and prevented end-organ damage. However, FAD286 was shown to lack 
selectivity for CYP11B2, since it also inhibited CYP11B1 to a large extent, which 
resulted in reduced cortisol biosynthesis. A second compound, LCI699 was 
subsequently developed and was the first orally active CYP11B2 inhibitor tested in 
clinical trials. Although LCI699 strongly and selectivity inhibited CYP11B2, it also 
inhibited CYP11B1 and impaired the plasma cortisol response to ACTH when 
administered at doses higher than 3 mg/day (Amar et al. 2013; Hargovan and Ferro 
2014). 
Due to the strong association between the RAAS and blood pressure 
regulation, blockade of this system is currently one of the key therapeutic targets for 
the treatment of hypertensive patients. Within this system, ACE inhibitors are 
currently the most clinically relevant pharmacological agents to block the activity of 
RAAS for the treatment of hypertension and CVD (Persson et al. 2010; van Vark et 
al. 2012). Numerous ACE inhibitors such as benazepril, catopril and perindopril have 
been developed and acute treatment with these ACE inhibitors was reported to 
significantly reduce circulating Ang II levels. Chronic treatment with ACE inhibitors, 
however, has been linked with the re-emergence of Ang II, which is referred to as 
“reactivation”, and it was shown to occur in one out of every six patients (Robles et 
al. 2014). 
3.6.3 Glucocorticoids 
 
The glucocorticoids, cortisol and CORT, are synthesised by CYP11B1 in the 
zona fasciculata of the adrenal cortex, which catalyses the conversion of DOC and 
deoxycortisol to CORT and cortisol, respectively (Miller and Auchus, 2011). In 
addition, cortisol and CORT are also regenerated from their respective inactive 
metabolites, cortisone and 11-DHC, via 11βHSD1 in peripheral tissues such as the 
liver, bone, adipose tissue, muscles and central nervous system (CNS). 11βHSD2 
catalyses the inactivation of glucocorticoids and is expressed in mineralocorticoid 
target tissues such as the kidneys, colon, sweat and salivary glands, where it 
protects the MR from cortisol, which binds with a high affinity (Agarwal and Auchus, 
2005; Cooper and Stewart, 2009; Tomlinson et al., 2004). Although both cortisol and 
CORT exhibit glucocorticoid activity, cortisol functions as the primary glucocorticoid 
in humans and it is produced in much higher levels than CORT. In rodents such as 
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rats and mice, however, CORT is the primary glucocorticoid due to the lack of 
CYP17A1 lyase activity (Miller and Auchus, 2011). 
In circulation, 95% of glucocorticoids are bound to proteins – mainly to 
corticosteroid binding globulins (CBGs) and albumin, with only the free, unbound 
glucocorticoids having access to the glucocorticoid receptor (GR). Local mechanisms 
for the release of glucocorticoids from their carrier proteins include interactions with 
CBG receptors on the cell surface and enzymatic cleavage of CBGs (Golan et al. 
2008).  
Intracellularly, glucocorticoids exert their actions via the GR, however, 
glucocorticoids are also able to bind to the MR. While the GR is selective for 
glucocorticoids, the MR has equal affinities for the mineralocorticoid, ALDO and the 
glucocorticoids, cortisol and CORT. Since circulating cortisol levels are significantly 
higher than that of ALDO, the inactivation of cortisol to cortisone via 11βHSD2 in MR 
expressing tissues such as the kidney, plays a crucial role in protecting the MR from 
inappropriate activation by cortisol (Gathercole 2013). 
Cortisol plays a vital role in the regulation of carbohydrate, protein and lipid 
metabolism; vascular responsiveness to catecholamines; maintenance of blood 
pressure; suppression of immune- and inflammatory responses; modulation of CNS 
function and regulation of the stress response. Cortisol regulates carbohydrate, 
protein and lipid metabolism in a coordinated fashion in order to increase circulating 
glucose levels at the expense of protein and fat stores. In the liver, cortisol promotes 
gluconeogenesis and glycogen synthesis, while simultaneously promoting protein 
catabolism in the muscle and lipolysis in adipose tissue in order to provide amino 
acids and glycerol for gluconeogenesis in the liver. In addition, cortisol reduces 
glucose utilization in tissues and decreases insulin sensitivity in adipose tissue. Low 
cortisol levels (hypocortisolism) is therefore characterised by low circulating glucose 
levels (hypoglycemia), while elevated cortisol levels (hypercortisolism) is 
characterised by high circulating glucose levels (hyperglycemia) (Costanzo 2014). 
The biosynthesis and release of cortisol is under the control of the HPA axis - 
a complex system consisting of the hypothalamus, anterior pituitary and adrenal 
cortex. Interplay between these organs through the endocrine, paracrine and 
autocrine actions of their hormones is crucial for the maintenance of hormonal 
homeostasis. In response to stress, acute activation of the HPA axis results in the 
stimulation of the hypothalamus to secrete CRH and arginine vasopressin (AVP). 
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The role of AVP is to increase the activity of CRH, while also enhancing 
cardiovascular function, mood, memory and selective attention. CRH released from 
the hypothalamus stimulates the anterior pituitary to release ACTH, which in turn 
stimulates the adrenal cortex to release glucocorticoids. Increased glucocorticoid 
levels following ACTH stimulation have a negative feedback effect on CRH and 
ACTH in the hypothalamus and pituitary, respectively, acting to downregulate both 
the biosynthesis and secretion of these hormones in order to maintain homeostasis. 
In addition, ACTH is also able to downregulate the secretion of CRH from the 
hypothalamus (Tsigos and Chrousos 2002; Chung et al. 2011; Gathercole et al. 
2013) (Fig. 3.9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Schematic representation of the HPA axis. GC, glucocorticoids; PVN, 
paraventricular nucleus. Reproduced from Chung et al. (2011) with permission from 
Elsevier. 
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During chronic stress, the negative feedback regulatory mechanism is, 
however, overridden and circulating glucocorticoid levels remain elevated. Long term 
exposure to elevated glucocorticoid levels, either due to chronic stress, altered 
expression/activity of enzymes involved in glucocorticoid biosynthesis or 
abnormalities at receptor level, have been associated with hyperglycemia, 
hypertension, osteoporosis, suppression of the immune system, visceral obesity, 
insulin resistance, dyslipidemia, atherosclerosis and CVDs, which are characteristic 
of clinical conditions such as MetS and Cushing’s syndrome (Chrousos and Gold 
1998; Sen et al. 2008; Feelders et al. 2012; Gathercole et al. 2013). CVDs are 
currently the number one leading cause of death globally, with obesity, hypertension, 
diabetes and increased lipid levels being major contributing risk factors for the 
development of CVDs5. 
It is therefore evident that the maintenance of normal glucocorticoid levels is 
critical to sustain homeostasis and prevent disease. Strategies employed in the 
treatment of these metabolic diseases could thus be aimed at decreasing 
glucocorticoid levels either by inhibiting the enzymes involved in glucocorticoid 
biosynthesis (CYP11B1 and 11βHSD1) or antagonist activity at steroid receptor level 
(GR and MR).  
Cushing’s syndrome is a clinical phenotype induced by chronically elevated 
glucocorticoid levels. It shares almost all of the features of MetS, such as visceral 
obesity, T2D, dyslipidemia, hypertension, psychological dysfunction and 
osteoporosis. Cushing’s syndrome is a rare disorder caused by a pituitary adenoma 
and is characterized by hyper-secretion of ACTH, which subsequently leads to 
excess glucocorticoid production (hypercortisolism) in the adrenal (Feelders et al., 
2012; Gathercole et al., 2013). Of all the adverse systemic effects associated with 
hypercortisolism, cardiovascular associated complications are the most serious, and 
are one of the leading causes of death among patients suffering from Cushing’s 
syndrome (Dekkers et al. 2007). The risk for CVDs in patients with Cushing’s 
syndrome is aggravated due to obesity, T2D, dyslipidemia, insulin resistance and 
hypertension resulting from hypercortisolism (Arnaldi et al., 2003; Faggiano et al., !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
5 WHO, 2014 - Cardiovascular diseases: Fact sheet No.317. 
http://www.who.int/mediacentre/factsheets/fs317/en/ (Updated March 2013) !
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2003; Feelders et al., 2012). The main difference between Cushing’s syndrome and 
MetS is that Cushing’s syndrome is associated with severe hypercortisolism, while 
patients with MetS do not necessarily have elevated circulating cortisol levels 
(Pasquali et al. 2006; Walker 2006; Gathercole and Stewart 2010). 
The first-line treatment for Cushing’s syndrome is surgery, with surgical 
remission being achieved for 65% - 100% of patients (Sudhakar et al. 2004; 
Prevedello et al. 2008). In contrast, individuals with comorbidities are twice as likely 
to have complications after surgery when compared with individuals without 
comorbidities (Patil et al. 2007). In severe cases, bilateral adrenalectomy offers a 
very effective treatment, provided that this is combined with permanent steroid 
replacement to prevent adrenal insufficiency (Smith et al. 2009). Other non-surgical 
treatments involve adrenal-blocking agents such as ketoconazole, metyrapone and 
mitotane. Although all of these agents lead to reduced cortisol secretion, none of 
these have been approved for the treatment of Cushing’s syndrome since they do not 
selectively inhibit CYP11B1, resulting in a number of adverse side effects (Feelders 
et al., 2012). Ketoconazole, for example, has been shown to trigger toxicological 
effects in vivo, decreasing A4 and testosterone levels by up to 60% below basal 
plasma levels, while increasing 17OH-PROG levels. Metyrapone, on the other hand, 
has been reported to cause hypokalemia due to inhibition of both CYP11B1 and 
CYP11B2 (Nishizato et al. 2010; Emmerich et al. 2013). 
As previously mentioned, CYP11B1 shares 93% homology with CYP11B2 and 
therefore, selective inhibition of these two enzymes is problematic. The compound, 
LCI699, selectivity inhibits CYP11B2 when administered at concentrations below 3 
mg/day, while higher concentrations leads to significant inhibition of CYP11B1 (Amar 
et al. 2013; Hargovan and Ferro 2014). In a recent study by Bertagna et al. (2014), 
LCI699 (10-20 mg/day) strongly inhibited CYP11B1 and normalized urinary cortisol 
levels in patients with Cushing’s syndrome during a 10-week proof-of concept study. 
Since patients with Cushing’s syndrome generally have high blood pressure, the 
reduction of blood pressure by LCI699 was beneficial rather than harmful. In general, 
LCI699 was well tolerated in all patients involved in this study, and a large scale 
study of longer duration is currently being undertaken to investigate the safety and 
efficacy of LCI699 in the treatment of Cushing’s syndrome (Bertagna et al. 2014). 
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Dysregulation of glucocorticoid action also plays a central role in the 
development of MetS, which refers to a cluster of abnormalities which include 
visceral obesity, dyslipidemia, hyperglycemia and hypertension (Obunai et al. 2007; 
Anagnostis et al. 2009; Athyros et al. 2010). MetS is associated with an increased 
risk for T2D, endothelial dysfunction, atherosclerosis, vascular morbidity and 
mortality (Lakka et al. 2002; Athyros et al. 2004; Kolovou et al. 2007; Obunai et al. 
2007) and it is estimated that roughly one out of every four adults world-wide suffer 
from MetS (Athyros et al. 2005, 2007; Kolovou et al. 2007). Elevated 11βHSD1 
expression in the liver and adipose tissue is one of the major causes of MetS and 
contributes substantially to the diabetic phenotype observed in db/db mice. Mice 
over-expressing 11βHSD1 in adipose tissue were shown to develop a 2-fold increase 
in intra-adipose glucocorticoid levels. Although plasma glucocorticoid levels remained 
unchanged, these mice nevertheless developed central obesity, hyperphagia, 
hyperinsulinemia and hyperglycemia (Masuzaki et al. 2001, 2003). Inhibition of 
11βHSD1 has also been shown to have beneficial effects on glucose homeostasis 
and weight reduction in diabetic and obese mouse models (Alberts et al. 2002). 
11βHSD1 knockout mice show reduced activation of key enzymes involved in 
gluconeogenesis such as glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK). In addition, these mice were 
protected from hyperglycemia, dyslipidemia and obesity, despite consuming a high-
fat diet (Kotelevtsev et al. 1997; Morton et al. 2004; Anagnostis et al. 2013). These 
findings were also reported in an earlier study by Dhanesha et al. (2012), in which 
inhibition of 11βHSD1 by carbenoxolone, a synthetic derivative of glycyrrhetinic acid, 
significantly affected obesity and glucose homeostasis in db/db mice, resulting in a 
dose-dependent improvement of energy expenditure, fat mass, serum lipid profiles, 
serum glucose tolerance and serum insulin tolerance. In addition, 11βHSD1 inhibition 
also reduced the activity of G6Pase and PEPCK in the liver, while improving 
glucokinase function in the pancreas and liver (Dhanesha et al. 2012).  
Since MetS and Cushing’s syndrome share numerous common features, with 
circulating glucocorticoid levels being significantly higher in patients with Cushing’s 
syndrome, it has been proposed that increased glucocorticoid action at peripheral 
level may play a key role in the pathogenesis of these diseases. Intracellular 
glucocorticoid levels are not only determined by plasma levels, but also via the 
activity of 11βHSD1, especially in the liver and adipose tissue. 11βHSD1 plays a key 
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role in glucocorticoid metabolism at peripheral level and overexpression of this 
enzyme has been linked with MetS, central obesity and dysregulation of glucose and 
lipid metabolism (Anagnostis et al., 2013; Cooper and Stewart, 2009). Several potent 
and selective inhibitors of 11βHSD1 have been identified and include 
adamantyltriazoles (Olson et al. 2005), arylsulfonamidothiazoles (Barf et al. 2002) 
and anilinothiazolones (Yuan et al. 2007), amongst others. Some of the in vivo 
effects brought about by these compounds include reductions in plasma glucose 
levels, body weight, central obesity and adipocyte size, as well as improved insulin 
sensitivity and lipid profiles (Anagnostis et al. 2013). Selective inhibition of 11βHSD1 
is crucial since non-selective inhibitors such as liquorice and its active metabolites, 
glycyrrhizic and glycyrrhetinic acids inhibit both 11βHSD1 and 11βHSD2, which 
result in an increased activation of the MR. In humans, ingestion of these compounds 
have been shown to result in “apparent mineralocorticoid excess” syndrome, 
hypertension encephalopathy, hypokalemia and suppression of the RAAS (Russo et 
al. 2000; Anagnostis et al. 2010, 2013; Pant et al. 2010). 
Although circulating biologically active glucocorticoids, CORT and cortisol, are 
primarily derived from the adrenal gland via the activity of CYP11B1, glucocorticoids 
can also be regenerated from their inactive metabolites, 11-DHC and cortisone, via 
the activity of 11βHSD1 in peripheral tissues such as the liver and adipose tissue. 
Local glucocorticoid regeneration within these tissues have been shown to promote 
hepatic insulin resistance and fat accumulation (Masuzaki et al. 2001; Paterson et al. 
2004). It is, however, still uncertain whether circulating glucocorticoid levels or 
glucocorticoids produced via 11βHSD1 in peripheral tissues plays the more 
prominent role in the development of MetS. These mechanisms were investigated in 
a recent study by Harno et al. (2013), in which the effect of 11-DHC administration 
was investigated in a liver-specific 11βHSD1 knockout (LKO) mouse model and 
compared to wild type (WT) mice. Following chronic administration of 11-DHC, WT 
mice had significantly increased circulating levels of CORT and displayed a MetS-like 
phenotype which included increased body weight gain, adiposity and the 
development of insulin resistance. In addition, reduced adrenal gland weight and 
decreased circulating ACTH levels in response to increased CORT levels suggest 
down-regulation of the HPA-axis. LKO mice, on the other hand, did not develop any 
of these adverse clinical side effects following administration of 11-DHC, despite 
having elevated circulating CORT levels, suggesting that 11βHSD1 activity in the 
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liver plays a central role in the development of insulin resistance and weight gain. 
The significant increase in CORT levels observed in LKO mice suggests that the 
major source of 11βHSD1-derived CORT that enters the circulation is generated 
elsewhere, most likely in the adipose tissue. Mice with complete deletion of 11βHSD1 
did not have increased circulating CORT levels and showed no adverse metabolic 
effects following 11-DHC administration. Taken together, these data indicate that 
intracellular glucocorticoids regenerated in the liver via 11βHSD1, rather than 
circulating glucocorticoids, contribute towards the development of MetS. Selective 
inhibition of 11βHSD1 therefore seems like a promising target for the treatment of 
MetS (Harno et al. 2013). 
 
3.7 Summary  
 
From this chapter it is clear that adrenal steroid hormones play a crucial role in 
the maintenance of homeostasis within a variety of physiological processes, since 
abnormal steroid hormone production has been linked to numerous clinical 
conditions. Of particular interest for this study are the glucocorticoids, which if 
chronically elevated, have been linked to MetS and Cushing’s syndrome, 
characterized by visceral obesity, insulin resistance, T2D, dyslipidemia, 
atherosclerosis, hypertension and CVDs. The maintenance of normal glucocorticoid 
levels therefore plays a central role in the prevention of these metabolic diseases. 
Strategies employed in the treatment of these disorders include, amongst others, 
inhibition of CYP11B1 and 11βHSD1. However, selective inhibition of CYP11B1 is 
difficult to achieve due to the enzyme’s homology with CYP11B2. In contrast to 
compounds such as ketoconazole and metyrapone, the compound, LCI699, was 
shown to normalize urinary cortisol levels in patients with Cushing’s syndrome 
without having any adverse side effects. Overexpression of 11βHSD1 plays a 
significant role in the development of MetS, and selective inhibition of 11βHSD1 has 
been reported to prevent hyperglycemia, dyslipidemia and obesity and to improve 
glucose homeostasis, lipid profiles and insulin tolerance.  
In the next chapter, presented in the form of three published manuscripts, the 
influence of Rooibos and major Rooibos flavonoid compounds, which were assayed 
on the activities of key adrenal steroidogenic enzymes, CYP11B1, 3βHSD2, 
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CYP17A1, CYP21A2, 11βHSD1 and 11βHSD2, as well as on overall steroid 
production in H295R cells, under both basal and forskolin stimulated conditions, will 
be presented and discussed. In addition, the in vivo effects of Rooibos on circulating 
steroid hormone levels in experimental rats and in human test subjects at risk for 
developing CVD will be discussed. 
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CHAPTER 4 
Published Manuscripts 
 
4.1 Introduction 
 
Chronically elevated glucocorticoid levels play a central role in the 
development of metabolic diseases. Numerous in vivo studies have reported that 
Rooibos consumption significantly improves glucose homeostasis, insulin resistance 
and lipid profiles, while also exhibiting potent anti-oxidant, anti-diabetic and cardio-
protective properties. In addition, Rooibos has also been reported to modulate the 
activities of CYP17A1 and CYP21A2, two key enzymes involved in adrenal 
steroidogenesis. The aim of this thesis was therefore to determine the influence of 
Rooibos on adrenal steroid hormone production in vitro and in vivo, and in particular, 
on the levels of the glucocorticoids, cortisol and CORT.  
The influence of an unfermented Rooibos extract and five of its major 
flavonoid compounds (the dihydrochalcones, aspalathin and nothofagin, their flavone 
analogues, orientin and vitexin and the flavonol, rutin) were firstly assayed on the 
activity of key adrenal steroidogenic enzymes - CYP17A1, 3βHSD2, CYP21A2 and 
CYP11B1, expressed in non-steroidogenic COS-1 cells. The influence of Rooibos 
and the aforementioned flavonoids on steroid hormone production was subsequently 
determined in H295R cells, a human adrenal cell model expressing the steroidogenic 
enzymes involved in the production of the mineralocorticoids, glucocorticoids and 
adrenal androgen precursors. Assays in H295R cells were conducted under both 
basal and forskolin stimulated conditions. Forskolin, a general inducer of adrenal 
steroidogenesis, was used to mimic the ACTH response in these cells, since H295R 
cells are insensitive to ACTH. 
Since the 11βHSD isozymes play a crucial role in cortisol regeneration from 
the inactive metabolite, cortisone, the influence of Rooibos on the inter-conversion 
between cortisol and cortisone by 11βHSD1 and 11βHSD2 was investigated in CHO-
K1 cells6. The influence of Rooibos on circulating glucocorticoid and testosterone 
levels was subsequently investigated in vivo, in male Wistar rats and in human !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
6 CHO-K1 cells were used since COS-1 cells have endogenous 11βHSD2 activity 
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subjects (males and females) at risk for CVD. These studies are presented in the 
three manuscripts included in this chapter. 
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a  b  s  t  r  a  c  t
The  steroid  hormone  output  of  the  adrenal  gland  is  crucial  in  the  maintenance  of  hormonal  homeostasis,
with  hormonal  imbalances  being  associated  with  numerous  clinical  conditions  which  include,  amongst
others,  hypertension,  metabolic  syndrome,  cardiovascular  disease,  insulin  resistance  and  type  2  diabetes.
Aspalathus  linearis  (Rooibos),  which  has  been  reported  to  aid  stress-related  symptoms  linked  to metabolic
diseases,  contains  a wide  spectrum  of  bioactive  phenolic  compounds  of  which  aspalathin  is  unique.  In
this  study  the  inhibitory  effects  of  Rooibos  and  the  dihydrochalcones,  aspalathin  and  nothofagin,  were
investigated  on  adrenal  steroidogenesis.  The  activities  of both  cytochrome  P450  17!-hydroxylase/17,20
lyase  and cytochrome  P450  21-hydroxylase  were  significantly  inhibited  in  COS-1  cells.  In  order  to  study
the  effect  of  these  compounds  in  H295R  cells,  a human  adrenal  carcinoma  cell  line,  a  novel  UPLC–MS/MS
method  was  developed  for  the detection  and  quantification  of  twenty-one  steroid  metabolites  using a sin-
gle  chromatographic  separation.  Under  both  basal  and  forskolin-stimulated  conditions,  the total  amount
of  steroids  produced  in  H295R  cells  significantly  decreased  in the  presence  of Rooibos,  aspalathin  and
nothofagin.  Under  stimulated  conditions,  Rooibos  decreased  the total  steroid  output  4-fold  and  resulted
in  a significant  reduction  of aldosterone  and  cortisol  precursors.  Dehydroepiandrosterone-sulfate  levels
were  unchanged,  while  the  levels  of androstenedione  (A4)  and  11"-hydroxyandrostenedione  (11"OH-
A4)  were  inhibited  5.5  and  2.3-fold,  respectively.  Quantification  of  11"OH-A4  showed  this  metabolite  to
be  a major  product  of  steroidogenesis  in  H295R  cells  and  we  confirm,  for  the  first  time,  that  this  steroid
metabolite  is  the  product  of  the  hydroxylation  of A4 by  human  cytochrome  P450  11"-hydroxylase.  Taken
together  our  results  demonstrate  that  Rooibos,  aspalathin  and  nothofagin  influence  steroid  hormone
biosynthesis  and  the  flux  through  the  mineralocorticoid,  glucocorticoid  and  androgen  pathways,  thus
possibly  contributing  to the  alleviation  of negative  effects  arising  from  elevated  glucocorticoid  levels.
© 2011 Elsevier Ltd. All rights reserved.
Abbreviations: P450, cytochrome P450; 3"HSD, 3"-hydroxysteroid
dehydrogenase II; CYP11A1, cytochrome P450 side-chain cleavage;
PREG,  pregnenolone; CYP17A1, P450 17!-hydroxylase/1720 lyase; 17OH-
PREG,  17-hydroxypregnenolone; DHEA, dehydroepiandrosterone; DHEA-S,
dehydroepiandrosterone-sulfate; PROG, progesterone; 17OH-PROG,
17!-hydroxyprogesterone; 16OH-PROG, 16!-hydroxyprogesterone; A4,
androstenedione;  CYP21, cytochrome P450 21-hydroxylase; CYP11B1, cytochrome
P450  11"-hydroxylase; CYP11B2, aldosterone synthase; ALDO, aldosterone; DOC,
deoxycorticosterone; CORT, corticosterone; 11-DHC, 11-dehydrocorticosterone;
11"OH-A4, 11"-hydroxyandrostenedione; 11"HSD, 11"-hydroxysteroid dehydro-
genases;  ACE, angiotensin-converting enzyme; UPLC–MS/MS, ultra performance
liquid  chromatography/tandem mass spectrometry.
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1. Introduction
In steroidogenesis, the steroid hormone output of the adrenal
plays a pivotal role in the maintenance of hormonal homeosta-
sis. Steroidogenic enzymes consisting of steroidogenic cytochrome
P450 (P450) enzymes and 3"-hydroxysteroid dehydrogenase II
(3"HSD) catalyse the biosynthesis of mineralocorticoids, glu-
cocorticoids and androgen precursors in the adrenal cortex
through multiple reactions (Fig. 1). Cytochrome P450 side-chain
cleavage (CYP11A1) catalyses the conversion of cholesterol to
pregnenolone (PREG) which is further metabolized by both
3"HSD and P450 17!-hydroxylase/17,20 lyase (CYP17A1) at a
branch point in the pathway, thus determining the steroido-
genic output of the adrenal. CYP17A1 catalyses the hydroxy-
lation of PREG to yield 17-hydroxypregnenolone (17OH-PREG),
which in turn is a substrate for the subsequent lyase reac-
tion, yielding the androgen precursor dehydroepiandrosterone
0960-0760/$ – see front matter ©  2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.jsbmb.2011.11.003
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Fig. 1. Human steroid biosynthesis. Major enzymes and steroids involved in mineralocorticoid, glucocorticoid, androgen and estrogen biosynthesis.
(DHEA). In addition, human CYP17A1 converts progesterone
(PROG) to 17!-hydroxyprogesterone (17OH-PROG) and 16!-
hydroxyprogesterone (16OH-PROG) [1]. The metabolism of the
!5-steroids, PREG, 17OH-PREG and DHEA to the respective
!4-steroids, PROG, 17OH-PROG and androstenedione (A4), is
catalysed by 3"HSD. Cytochrome P450 21-hydroxylase (CYP21)
hydroxylates PROG and 17OH-PROG to yield the substrates for
cytochrome P450 11"-hydroxylase (CYP11B1) and aldosterone
synthase (CYP11B2). The latter catalyses the biosynthesis of the
mineralocorticoid, aldosterone (ALDO), from deoxycorticosterone
(DOC), while CYP11B1 catalyses the conversion of DOC and deoxy-
cortisol to the glucocorticoids, corticosterone (CORT) and cortisol,
respectively [2]. In addition to the major steroid hormones, the
adrenal also produces, amongst others, sex steroids, albeit at low
levels, as well as cortisone, 11-dehydrocorticosterone (11-DHC)
and 11"-hydroxyandrostenedione (11"OH-A4), at significantly
higher levels [3]. The former two metabolites are products of reac-
tions catalysed by 11"-hydroxysteroid dehydrogenases (11"HSD
type 1 and 2) [4], while the latter has been reported to be the
product of the 11"-hydroxylation of A4 [5].
Glucocorticoids play a role in the maintenance of the homeo-
stasis of the central nervous system, glucose homeostasis and
immune modulation, and are considered stress hormones as
their secretion is strongly altered by exposure to environmen-
tal stressors. Stress, be it psychological or physical, activates
the hypothalamic–pituitary–adrenal (HPA) axis. Activation of the
HPA-axis involves the release of adrenocorticotropic hormone
(ACTH), resulting in the stimulation of the adrenal cortex with
the  subsequent elevation in circulating cortisol. Cortisol, released
in response to stress, also forms part of the negative feedback
system regulating the HPA-axis. During chronic stress, however,
the negative feedback regulatory mechanism is overridden, result-
ing in elevated basal cortisol levels [6,7]. Elevated glucocorticoid
levels, resulting from hormonal imbalances, have been associated
with numerous clinical conditions which include, amongst others,
hypertension, metabolic syndrome, cardiovascular disease, hyper-
glycemia, insulin resistance, type 2 diabetes, depressed immune
function, osteoporosis and suppression of the reproductive system
[7–10].
Maintaining normal cortisol levels is therefore critical to
endocrine function. Therapies aimed at alleviating negative effects
arising from the chronic stimulation of the HPA-axis could thus
be aimed at decreasing plasma glucocorticoid levels. Strategies
employed in the treatment of diseases associated with endocrine
disorders involve selective inhibitors of either the enzymes
catalysing adrenal steroid biosynthesis or antagonist activity at
steroid receptor level. Several compounds have been identified
which inhibit steroidogenesis by interfering with one or more
enzymes in the steroidogenic pathway [11,12]. One such com-
pound, ketoconazole, which is widely used to treat patients with
Cushing’s syndrome, inhibits CYP11A1 and CYP11B1 as well as
ACTH secretion at therapeutic doses. Ketoconazole, however, has
been found to trigger toxicological effects in vivo, decreasing A4 and
testosterone levels to 60% below basal plasma levels while increas-
ing 17OH-PROG levels. It is therefore critical in the development
of pharmaceutical drugs to ensure that the inhibition of specific
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steroidogenic enzymes is selective and that endocrine toxicity is
avoided [13,14].
In  recent years, the shift towards the use of natural and herbal
medicinal products has led to attention being placed on the
influence of, amongst others, polyphenolic compounds on steroido-
genesis. Polyphenolic compounds include the dihydrochalcones,
flavones, isoflavones and flavanols, and are commonly referred
to as flavonoids. These secondary plant metabolites, abundantly
present in soy and soy products, legumes and lentils, have been
shown to demonstrate potent anti-oxidant, anti-inflammatory,
anti-atherosclerotic and anti-mutagenic properties [15–19]. In
addition, numerous studies have shown that flavonoid compounds
exhibit phytoestrogenic activity and may  aid clinical conditions
such as osteoporosis, breast cancer and cardiovascular disease
[20–22]. However, it has been suggested that flavonoid compounds
may possibly be cytotoxic since they may  act as mutagens, pro-
oxidants and inhibitors of key enzymes [23]. High doses of genistein
have, for example, been shown to result in decreased fertility
and sexual dysfunction in experimental animals [24]. The over-
all health benefits of flavonoids therefore still remain uncertain
[25]. The effect of flavonoid compounds on adrenal steroidoge-
nesis has been investigated by various groups. Ohno et al. [26]
showed that flavonoid compounds such as diadzein, genistein and
6-hydroxyflavone selectively inhibits key steroidogenic enzymes
including 3!HSD, CYP17A1, CYP21 and CYP11B1 in H295R cells.
Mesiano et al. [27] demonstrated that both genistein and diadzein
inhibit cortisol production in ACTH-stimulated cultured fetal and
postnatal adrenal cortical cells as well as in cAMP-stimulated H295
cells. More recently, Ohlsson et al. [28] showed that the flavonoids
diadzein and genistein dose-dependently inhibit cortisol, ALDO and
testosterone production in H295R cells.
Rooibos (Aspalathus linearis) is consumed world-wide as a
herbal tea and is anecdotally reported to aid stress-related symp-
toms. It is a rich source of dietary polyphenols and as such,
possesses potent antioxidant activities [29,30]. In addition, Rooibos
extracts have been shown to exhibit anti-mutagenic, anti-cancer
and immune modulating properties [31–33]. Rooibos consumption
has been shown to significantly improve the lipid profiles and redox
status in humans at risk for developing cardiovascular disease [34].
In addition, it has been shown by Persson et al. [35] that Rooibos
significantly inhibits angiotensin-converting enzyme (ACE) activ-
ity after an oral intake of a single dose of Rooibos tea, supporting
the potential role of Rooibos in the overall management of cardio-
vascular and metabolic-related diseases. Rooibos has been shown
to have beneficial effects on glucose homeostasis and type 2 dia-
betes, with aspalathin stimulating glucose uptake in muscle tissues
as well as insulin secretion from pancreatic !-cells [36]. Aspalathin
is unique to Rooibos, while nothofagin has only been identified in
one other species, Nothofagus fusca [37,38].
The aim of this study was to determine the influence of Rooi-
bos and the dihydrochalcones, aspalathin and nothofagin, on
the catalytic activities of CYP17A1 and CYP21 expressed in non-
steroidogenic COS-1 cells, as well as on steroidogenesis in H295R
cells, a human adrenal carcinoma cell line. Although previous
studies have investigated the inhibitory effect of flavonoid com-
pounds on adrenal enzyme activities, specific metabolites in the
respective steroidogenic pathways, and on enzyme expression,
the effect of these compounds on steroid hormone biosynthesis
has not been fully addressed. Unsatisfactory analytical methods
have impeded the efficient analyses and quantification of metabo-
lites produced in adrenal steroidogenesis. In this study we report
a novel ultra performance liquid chromatography/tandem mass
spectrometry (UPLC–MS/MS) method for the identification and
quantification of twenty-one steroid metabolites. This method
enabled us to quantify not only the end metabolites of the min-
eralocorticoid, glucocorticoid and androgen precursor pathways,
but  also to simultaneously analyse the steroid profile of the inter-
mediate metabolites in basal and forskolin stimulated H295R cells.
2. Materials and methods
2.1.  Materials
Unfermented Rooibos was provided by the South African Rooi-
bos Council. Aspalathin and nothofagin were supplied by Prof.
W.C.A. Gelderblom (Medical Research Council, Western Cape,
South Africa) Nucleobond® AX plasmid preparation kits were
purchased from Machery-Nagel (Duren, Germany). COS-1 cells
were obtained from the American Type tissue Culture Collection
(Manassas, VA, USA) and Mirus TransIT®-LT1 transfection reagent
was purchased from Mirus Bio Corporation (Madison, WI,  USA).
Penicillin–streptomycin, fetal calf serum and trypsin–EDTA were
obtained from Gibco BRL (Gaithersburg, MD,  USA). Deuterated
cortisol (9,11,12,12-D4-cortisol) was  purchased from Cambridge
isotopes (Andover, MA,  USA). Steroids, forskolin, trilostane, Dul-
becco’s modified Eagle’s Medium (DMEM) and an MTT  assay kit
were purchased from Sigma–Aldrich (St. Louis, MA,  USA). DMSO
was obtained from Merck (Darmstadt, Germany). DMEM/F12 and
gentamicin were purchased from Invitrogen/Gibco (Grand Island,
New York, USA). Cosmic calf serum was  supplied by HyClone®,
Thermo Scientific (South Logan, Utah, USA). A bicinchoninic acid
(BCA) protein determination kit was purchased from Pierce (Rock-
ford, IL, USA). The UPLC BEH C18 column was  purchased from
Waters and the Kinetex PFP column was  purchased from Phe-
nomenex. All other chemicals were of the finest quality and
supplied by trustworthy scientific supply houses.
2.2. Methanol extractions of unfermented Rooibos
Rooibos is produced both as a fermented and unfermented prod-
uct, with the latter subjected to milder processes ensuring oxidative
changes to secondary plant metabolites are minimized. A Rooibos
extract was  prepared by extracting 30 g unfermented plant mate-
rial with 300 ml  chloroform for 8 h using a glass soxhlet extractor
fitted with a double wall condenser. The plant material was  sub-
sequently extracted with 300 ml  methanol for 8 h. The extract was
dried on a rotary evaporator and the vacuum released under nitro-
gen. The dried extract was resuspended in deionised water to a
final concentration of 86 mg  extract/ml and centrifuged at 6000 × g
for 5 min. The supernatant was  divided into aliquots and stored at
−20 ◦C. The Rooibos extract was  protected from light and oxygen
at all times to avoid any compositional changes.
2.3. Enzyme assays in transiently transfected COS-1 cells
COS-1  cells were grown at 37 ◦C and 5% CO2 in DMEM con-
taining 0.9 g/l glucose, 0.12% NaHCO3, 10% fetal calf serum and
1% penicillin–streptomycin. The cells were plated into 12 well
dishes with each well containing 1 × 105 cells in 1 ml, 24 h
prior to transfection. Cells were transiently transfected with
0.5 "g DNA (baboon CYP17A1/pCIneo, baboon CYP21/pCIneo and
baboon CYP11B1/pTarget) and 1.5 "l Mirus TransIT®-LT1 transfec-
tion reagent according to the manufacturer’s instructions. Control
transfection reactions were performed using the pCIneo vector con-
taining no DNA insert. Cells were incubated for 72 h after which
the appropriate steroid substrate, PREG, PROG, 17OH-PROG, DOC,
deoxycortisol or A4 was  added to the medium. Substrate conver-
sion in the presence of Rooibos was assayed by the addition of
50 "l extract (final concentration, 4.3 mg  extract/ml). Aspalathin
and nothofagin, dissolved in ethanol, were added to a final con-
centration of 10 "M.  At specific time intervals, 500 "l aliquots
were removed and the steroids extracted using a 10:1 volume of
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dichloromethane to culture medium. The medium was removed
and the dichloromethane phase dried under N2. The steroids were
resuspended in 150 !l methanol and analysed. After each exper-
iment, the cells were washed and collected in phosphate buffer
(0.1 M,  pH 7.4), disrupted via sonication and the total protein
content determined by the Pierce BCA method according to the
manufacturer’s instructions.
2.4.  Steroid metabolism in H295R cells
H295R cells were grown to confluency at 37 ◦C and 5% CO2
in growth medium, DMEM/F12, supplemented with l-glutamine,
15 mM HEPES, pyridoxine, 1.125 g NaHCO3/l, 1% penicillin strepto-
mycin, 0.01% gentamicin and 10% cosmic calf serum, after which
cells were plated into 12 well dishes (1 ml,  4 × 105 cells/ml). PREG
metabolism was assayed as follows: after an incubation period
of 48 h, the growth medium was aspirated off and replaced with
growth medium containing 0.1% cosmic calf serum. Cells were incu-
bated for a further 12 h after which the appropriate treatments
were added to the medium. Basal steroid metabolism was  assayed
in the presence of Rooibos by the addition of 50 !l extract (final
concentration, 1 mg  extract/ml). Aspalathin and nothofagin were
added to a final concentration of 10 !M.  Basal steroid metabolism
was stimulated with the addition of forskolin to a final concentra-
tion of 10 !M.  A4 metabolism was assayed as follows: 24 h after
plating cells the medium was replaced with growth medium con-
taining 10 !M trilostane. After 24 h, the medium was replaced with
growth medium containing 10 !M trilostane and 1 !M A4. Control
assays included the addition of 10 !M trilostane and 1 !M cortisol;
10 !M trilostane; and medium only. After 48 h the medium (500 !l)
was removed and the steroids extracted as described in Section
2.3. D4-cortisol (15 ng), was added to the dichloromethane/culture
medium mixture as an internal standard prior to extraction.
2.5.  Cell viability
2.5.1.  COS-1 cells
The  viability of the COS-1 cells was determined by investigating
the effect of the test compounds on the ability of the cells to con-
vert testosterone to A4 through endogenous 17"-hydroxysteroid
dehydrogenase (17"-HSD) type 2 activity [39]. Testosterone (1 !M)
was added to confluent COS-1 cells in the absence and presence of
the Rooibos extract (4.3 mg/ml), aspalathin (10 !M)  and nothofagin
(10 !M).  After a 24 h incubation period the steroids were extracted
as described in Section 2.3.
2.5.2.  H295R cells
Confluent  H295R cells were plated out in a 96 well plate
(100 !l, 4 × 105 cells/ml) and incubated with the Rooibos extract
(1 mg/ml), aspalathin (10 !M),  nothofagin (10 !M)  as well as
forskolin (10 !M)  for 48 h. Cell viability was subsequently assayed
using a MTT  toxicology assay kit according to the manufacturer’s
instructions.
2.6. Separation and quantification of steroid metabolites in COS-1
cells
Steroid metabolites were analysed by UPLC–MS/MS. Steroid
metabolites resulting from the conversion of PREG, PROG, 17OH-
PROG, deoxycortisol and A4 in COS-1 cells were separated by UPLC
(ACQUITY UPLC, Waters, Milford, USA) using a Waters UPLC BEH
C18 (2.1 mm × 50 mm,  1.7 !m)  column as previously described
[40]. The mobile phases consisted of 1% formic acid (A) and acetoni-
trile (B). Steroids were eluted at a flow rate of 0.4 ml/min, using a
linear gradient from 85% A to 80% B in 3.5 min, followed by a linear
gradient from 80% B to 100% B in 0.1 min. The injection volume
was  5 !l. A Xevo triple quadrupole mass spectrometer (Waters,
Milford, USA) was  used for quantitative mass spectrometric detec-
tion. All steroids were analysed in multiple reaction monitoring
(MRM)  mode using an electrospray in the positive ionization mode
(ESI+). The following settings were used: capillary voltage of 2.8 kV,
cone voltage 15–35 V, collision energy 4–32 eV, source temperature
100 ◦C, desolvation temperature 500 ◦C, desolvation gas 1000 l h−1
and cone gas 50 l h−1. Calibration curves were constructed by using
weighted (1/x2) linear least squares regression. Data was collected
with the MassLynx 4.0 software program.
2.7. Separation and quantification of steroid metabolites in
H295R  cells
2.7.1.  Preparation of standards
Stock  solutions of PREG, PROG, DOC, CORT, 18OH-CORT, ALDO,
11-DHC, 17OH-PREG, 17OH-PROG, 16OH-PROG, deoxycortisol,
cortisol, cortisone, DHEA, DHEA-S, A4, 11"OH-A4, testosterone,
DHT and "-estradiol were prepared in ethanol (2 mg/ml). Estrone
was dissolved in acetone (2 mg/ml). A series of standards (0.0002,
0.002, 0.02, 0.1, 0.2, 1, 2 and 4 ng/!l) were prepared in methanol
from the stock solutions. In addition, each standard contained an
internal standard, D4-cortisol (final concentration, 0.1 ng/!l).
2.7.2. UPLC–MS/MS conditions
Steroid  metabolites from conversion assays conducted in
the H295R cells were separated by UPLC (ACQUITY UPLC,
Waters, Milford, USA) using a Phenomenex UPLC Kinetex PFP
(2.1 mm × 100 mm,  2.6 !m)  column. The mobile phases consisted
of 1% formic acid (A) and 49%:49%:2% methanol:acetonitrile:
isopropanol  (B). Steroid metabolites were eluted at a flow rate
of 0.45 ml/min and the injection volume was set to 5 !l. Steroids
were quantified using a Xevo triple quadrupole mass spectrom-
eter (Waters, Milford, USA) as described above. The gradient of
the LC system is shown in supplementary Table 1, other relevant
information including the parent and daughter ions, cone (V) and
collision (eV) voltages, retention times and the validation of the
UPLC–MS/MS assay is shown in supplementary Table 2.
2.8.  Statistical analysis
All  experiments were performed in triplicate and results are
given as means ± SEM. Statistics were calculated by a one-way
ANOVA, followed by a Dunnett’s multiple comparison test using
GraphPad Prism (version 5) software (GraphPad Software, San
Diego, California). A value of P < 0.05 was considered statistically
significant.
3. Results and discussion
The  present study was undertaken to investigate the effect of
Rooibos on adrenal steroidogenesis, and in particular, on glucocor-
ticoid production. The influence of an unfermented Rooibos extract
and two  dihydrochalcone compounds, aspalathin and nothofa-
gin, was investigated on two key adrenal steroidogenic enzymes,
CYP17A1 and CYP21, by expression in non-steroidogenic COS-1
cells. We  subsequently examined the effect of Rooibos, aspalathin
and nothofagin on steroidogenesis in H295R cells.
3.1. Enzyme assays in COS-1 cells expressing CYP17A1 and CYP21
Both  CYP17A1 and CYP21 play a central role in adrenal steroido-
genesis with CYP17A1 catalysing the biosynthesis of androgen
precursors while CYP21 is essential for the biosynthesis of miner-
alocorticoids and glucocorticoids. The effect of Rooibos (4.3 mg/ml),
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Fig. 2. The influence of Rooibos and dihydrochalcones on substrate conversion in transiently transfected COS-1 cells. (A) Inhibition of PREG (1 !M) conversion by baboon
CYP17A1, (B) inhibition of PROG (1 !M)  conversion by baboon CYP21 and (C) inhibition of 17OH-PROG (1 !M)  conversion by baboon CYP21. Substrates were assayed in the
presence of Rooibos (4.3 mg/ml), aspalathin (10 !M)  and nothofagin (10 !M) after 4 h. Individual steroids were compared by a one-way ANOVA, followed by a Dunnett’s
multiple comparison test. Results are expressed as the mean ± SEM (***P < 0.001, n = 3).
aspalathin and nothofagin (10 !M)  were assayed on CYP17A1 activ-
ity with PREG (1 !M)  as substrate in non-steroidogenic COS-1
cells. After 4 h, PREG conversion was significantly inhibited in the
presence of Rooibos (48%), aspalathin (39%) and nothofagin (29%)
(Fig. 2A). The magnitude of CYP17A1 inhibition could significantly
alter the flux through the steroidogenic pathway. Inhibition of
CYP17A1 would likely result in decreased concentrations of glu-
cocorticoids, deoxycortisol and cortisol, and androgen precursors,
A4 and DHEA. Ohno et al. [26] previously found that formononetin,
genistein and diadzein, at a concentration 25 !M,  were unable to
inhibit CYP17A1, while 6-hydroxy-flavone inhibited CYP17A1 sig-
nificantly at the same concentration. Aspalathin and nothofagin
are therefore more potent inhibitors, as significant inhibition of
PREG conversion is observed at a lower concentration of 10 !M
(P < 0.001).
The effect of Rooibos (4.3 mg/ml), aspalathin and nothofagin,
(10 !M)  on the catalytic activity of CYP21 expressed in COS-1 cells
with both PROG (1 !M)  and 17OH-PROG (1 !M)  as substrates was
also investigated. After 4 h, significant inhibition of PROG conver-
sion was observed in the presence of Rooibos (57%), aspalathin
(32%) and nothofagin (41%) (P < 0.001) (Fig. 2B). Similar results
were obtained when 17OH-PROG was added as substrate, with
Rooibos (51%), aspalathin (34%) and nothofagin (43%) inhibiting
17OH-PROG conversion significantly (P < 0.001) (Fig. 2C). In both
assays, the presence of Rooibos showed the greatest inhibition, fol-
lowed by nothofagin and aspalathin. Inhibition of CYP21 would
inhibit the production of DOC and deoxycortisol, which in turn
will lead to a decrease in the glucocorticoids, CORT and cortisol,
as well as the mineralocorticoid, ALDO. Ohno et al. [26] previ-
ously demonstrated that the flavonoids 6-hydroxyflavone, diadzein
and genistein significantly inhibit CYP21 at concentrations ranging
from 12.5 to 25 !M (P < 0.01). Subsequent studies confirmed that
genistein and diadzein are competitive inhibitors of both 3"HSD
and CYP21 [26,41].
While  CYP21 is unique to the adrenal and essential for mineralo-
corticoid and glucocorticoid biosynthesis, the dual catalytic activity
of CYP17A1 and its competition for substrates with 3"HSD, places
this enzyme in a pivotal position in determining the steroidogenic
output of the adrenal cortex. Although the hydroxylation of PREG
and the subsequent lyase reaction of the intermediate, catalysed
by  CYP17A1, were not assayed as individual reactions, the data
clearly shows an inhibitory effect on the end products of the !5-
pathway. Both PREG and 17OH-PREG are substrates for 3"HSD
which catalyses the biosynthesis of CYP21 substrates. PROG and
17OH-PROG are thus channelled into the mineralocorticoid and
glucocorticoid pathways by CYP21. The role of 3"HSD, however,
cannot be ignored. Ohno et al. [41] showed significant inhibition of
3"HSD by genistein, diadzein and quercetin at a concentration of
10 !M (P < 0.01). We  found significant inhibition of PREG conver-
sion by 3"HSD using the same concentration of aspalathin (P < 0.01)
and nothofagin (P < 0.001) (data not shown).
The inhibitory effects observed on the catalytic activities of
these steroidogenic enzymes by Rooibos and the two dihydrochal-
cone compounds at the tested concentrations was not due to the
cells being compromised. The metabolism of testosterone was
not impaired in the presence of the Rooibos extract (4.3 mg/ml),
aspalathin (10 !M)  or nothofagin (10 !M),  confirming that the
observed effects resulted from inhibition of the catalytic activities
of the steroidogenic enzymes (data not shown).
3.2. Steroid metabolism in H295R cells
The H295R cell line is the first established cell line capable of
producing all the steroids from the three adrenal cortex zones
which include the mineralocorticoids, glucocorticoids and adrenal
androgen precursors. In addition, these cells also express 17"HSD
and aromatase (CYP19), and are thus capable of producing testos-
terone, estrone and "-estradiol, making this cell line an excellent
model system for studying adrenal steroidogenesis [3,42]. The
inter-conversion of the inactive keto-forms of estrogens and andro-
gens to their respective active hydroxyl-forms are catalysed by var-
ious 17"HSD enzymes which vary in substrate specificity and tissue
expression [43,44]. The accurate detection and quantification of
the intermediates and end products in the steroidogenic pathways,
however, still remains a challenge. In the most recent study to date,
three different LCMS methods were used to identify the steroid
metabolites produced in H295R cells [3]. In order to quantify the
steroid metabolites of interest, we  developed a novel UPLC–MS/MS
method enabling the separation and quantification of twenty-one
steroid metabolites, using a single chromatographic separation
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Fig. 3. UPLC–MS/MS chromatographic separation of 21 steroids. Chromatograms of steroid metabolites (5 !l each of a 2 !g/ml standard solution) and D4-cortisol are shown
in  multiple reaction monitoring (MRM)  mode. Retention times of steroid metabolites (shaded peaks) are indicated on the chromatograms.
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Table  1
Steroids produced in H295R cells. Cells were incubated in the absence and presence
of forskolin (10 !M)  for 48 h. Steroids were quantified by UPLC–MS/MS. Percentage
of  each steroid ± SEM was  calculated by dividing the amount of individual steroid
by  the total steroid. Fold change ± SEM in response to forskolin treatment, was
calculated  from the changes in absolute values of individual steroids (not shown)
compared  to basal values. P values were calculated using a one-way ANOVA with a
Dunnett’s post test.
Steroid metabolite Basal + Forskolin
% Total ± SEM % Total ± SEM Fold Change ± SEM
PREG 2.8 ± 1.7 0.7 ± 0.2
PROG 1.2 ± 1.1 0.0 ± 0.0
DOC 2.8 ± 0.2 3.0 ± 0.2 ↑3.5 ± 1.1**
CORT 6.2 ± 0.5 18.6 ± 0.4 ↑9.1 ± 2.0***
18OH-CORT 0.2 ± 0.0 0.9 ± 0.0 ↑11.9 ± 2.8***
ALDO 0.1 ± 0.0 0.2 ± 0.0 ↑14.1 ± 5.6***
11-DHC 0.3 ± 0.1 0.1 ± 0.0
17OH-PREG ND ND
17OH-PROG 1.5 ± 0.1 0.3 ± 0.0
16OH-PROG 1.7 ± 0.0 0.6 ± 0.0
Deoxycortisol 44.4 ± 1.4 24.6 ± 1.0 ↑1.7 ± 0.5*
Cortisol 14.6 ± 1.0 34.2 ± 1.2 ↑7.2 ± 1.9***
Cortisone 0.2 ± 0.1 0.1 ± 0.0
DHEA ND ND
DHEA-S  0.3 ± 0.2 0.0 ± 0.0
A4 20.5 ± 0.3 12.5 ± 0.4 ↑1.9 ± 0.6***
11BOH-A4 2.3 ± 0.1 3.5 ± 0.3 ↑4.5 ± 0.7***
Testosterone 1.0 ± 0.1 0.5 ± 0.0
DHT ND ND
Estrone ND ND
"-Estradiol  ND ND
Total  steroid (nM) 3947 11141 ↑2.8***
ND, not detectable (n = 3).
*
**
***
without prior derivatisation. The chromatographic separation of
the steroid metabolites is shown in Fig. 3. The conditions and vali-
dations of this method are shown in supplementary material. This
method enabled the detection and quantification of sixteen steroid
metabolites from the medium of H295R cells after 48 h under basal
conditions and in response to forskolin treatment. Forskolin was
used as a general inducer of steroidogenesis since H295R cells
are insensitive to ACTH [3]. Forskolin is a diterpene which mim-
ics the effects of ACTH via the activation of adenyl cyclase (cAMP)
pathways in adrenal cells [45]. While we did not detect DHEA, "-
estradiol, estrone or 17OH-PREG, for which Xing et al. [3] detected
low levels, we were however, able to detect and quantify ALDO,
11-DHC, cortisone, 16OH-PROG, 18OH-CORT and DHEA-S after 48 h
under basal and forskolin-stimulated conditions in H295R cells.
Under basal conditions, the major steroid metabolites detected
after 48 h were deoxycortisol (44.4%), A4 (20.5%), cortisol (14.6%)
and CORT (6.2%) (Table 1). The higher concentration of deoxycor-
tisol compared to that of cortisol is in accordance with data by
Xing et al. [3] suggesting low expression of CYP11B1. However,
in comparison, DOC levels are significantly lower than CORT
levels, possibly due to metabolism of DOC by both CYP11B1
and CYP11B2. Forskolin stimulation significantly increased the
production of ALDO (14.1-fold), 18OH-CORT (11.9-fold), CORT
(9.1-fold), cortisol (7.2-fold), 11"OH-A4 (4.5-fold), DOC (3.5-fold),
A4 (1.9-fold) and deoxycortisol (1.7-fold). After stimulation, cor-
tisol (34.2%) was the most abundant steroid metabolite, followed
by deoxycortisol (24.6%), CORT (18.6%) and A4 (12.5%). These
results are in agreement with those obtained by Xing et al. [3]
under similar experimental conditions. However, although cortisol
and deoxycortisol were the most abundant metabolites under
stimulated conditions, analyses of the steroid metabolites showed
that there was a greater fold increase in the intermediates of the
mineralocorticoid pathway, ultimately resulting in the 14-fold
increase observed in ALDO levels.
In addition to altering the steroid profile of the cells, stimula-
tion of forskolin resulted in a 2.8-fold increase in the total amount
of steroid detected when compared to basal levels, with the total
steroid concentration increasing from 4.0 !M to 11.1 !M (Table 1).
It has previously been reported that the majority of agents that
stimulate steroid hormone biosynthesis also upregulate steroid
acute regulatory (StAR) protein expression. StAR is responsible for
the transportation of cholesterol to the inner mitochondrial mem-
brane where CYP11A1 metabolizes it to PREG [46]. King et al. [47]
demonstrated that StAR mRNA levels increased by 260% after 24 h
in the presence of 40 !M forskolin. Our data shows that the steroid
flux through the glucocorticoid pathway is greater than the flux
through the androgen precursor pathway under basal conditions,
with even fewer metabolites being channelled through the miner-
alocorticoid pathway. Although the flux through the glucocorticoid
pathway remains the highest upon forskolin stimulation, quantifi-
cation of the intermediates shows that ALDO precursors are present
in higher concentrations than that of the C19 metabolites.
Forskolin-stimulation also resulted in a significant increase in
11"OH-A4 production (0.09–0.39 !M)  (Table 1). Rainey et al. [48]
previously showed 11"OH-A4 to be one of the major steroids pro-
duced following forskolin stimulation. It is possible that 11"OH-A4
may be produced in the adrenal by either the lyase of cortisol or
the hydroxylation of A4, with early studies favouring the hydrox-
ylation of A4 [5,49]. In vivo and in vitro studies conducted by
Axelrod et al. [50] showed A4 to be the major precursor of 11"OH-
A4 in human and baboon adrenals. Conversion assays in human
and baboon tissue showed that 1.3 and 1.4% 3H-cortisol and 32
and 46% 3H-A4 was incorporated into 11"OH-A4, respectively.
Liakos et al. [51] later showed that transforming growth factor
"1 (TGF"1) inhibited the expression of CYP11B1 and CYP11B2 in
H295R cells, resulting in a decrease in ALDO, cortisol and 11"OH-A4
production.
In this study we  investigated the biosynthesis of 11"OH-A4
by H295R cells in the absence and presence of trilostane (10 !M),
a selective inhibitor of 3"HSD. Neither A4 nor 11"OH-A4 was
detected after 48 h in the presence of trilostane. The addition of A4
(1 !M)  together with trilostane (10 !M)  resulted in a significant
increase in 11"OH-A4 levels, indicating that this metabolite is a
product of the 11"-hydroxylation of A4 (Fig. 4). No 11"OH-A4
was detected following the addition of cortisol (1 !M)  together
with trilostane (10 !M).  In addition, we assayed the conversion
of cortisol in COS-1 expressing recombinant human CYP17A1, in
the absence and presence of cytochrome b5, which augments the
lyase reaction, and did not detect 11"OH-A4 after 8 h by UPLC
MS/MS analyses (data not shown). While the conversion of A4 to
11"OH-A4 by CYP11B1 has been demonstrated for non-primate
species [52,53], to our knowledge, the 11"-hydroxylation of A4 by
primate CYP11B1 has only been indirectly implied. We  therefore
assayed the metabolism of A4, deoxycortisol and DOC in COS-1
cells transiently co-transfected with baboon CYP11B1 and human
adrenodoxin (ADX). The data clearly shows that CYP11B1 catalyses
the conversion of A4 to 11"-OHA4 with negligible substrate
remaining after 8 h (Fig. 5). In the assay in which both deoxycor-
tisol (1 !M)  and A4 (1 !M)  were added together, the substrates
did not appear to inhibit the conversion of each other after 8 h,
although the rate of the conversions are yet to be determined.
A conversion profile similar to that of deoxycortisol and A4 was
obtained when DOC was  added as substrate, with negligible
substrate remaining after 8 h (results not shown). From our data
it is clear that the production of 11"OH-A4 observed in the H295R
cells could be attributed to the conversion of A4 by CYP11B1.
Furthermore, the 4.5-fold increase observed in 11"OH-A4 lev-
els under forskolin-stimulated conditions (Table 1) is therefore
P < 0.05.
P < 0.01.
P < 0.001.
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Fig. 4. Analysis of 11!OH-A4 production in H295R cells. Basal 11!OH-A4 pro-
duction  was  assayed in the absence and presence of trilostane (10 "M)  while the
conversion of A4 (1 "M)  and cortisol (1 "M)  to 11!OH-A4 was assayed in the pres-
ence  of trilostane after 48 h. Results are expressed as the mean ± SEM (n = 3).
to be expected since forskolin upregulates not only CYP11B1
mRNA but also the hydroxylase activity in H295R cells [51,54]. In
addition, the significant increase in A4 levels in the H295R cells
suggests that CYP17A1 activity was stimulated in the presence
of forskolin, as was previously reported by Rainey et al. [48],
thereby increasing the precursor metabolite for the biosynthesis of
11!OH-A4.
3.2.1. The influence of Rooibos and flavonoids on H295R
metabolism
Since the goal of this study was to investigate the effect of Rooi-
bos on the outcome of adrenal steroidogenesis, and in particular, on
Fig. 5. Cortisol and 11!OH-A4 formation in transiently transfected COS-1 cells. Con-
version of deoxycortisol and A4 was assayed after 8 h in COS-1 cells co-expressing
baboon  CYP11B1 and human ADX. Results are expressed as the mean ± SEM (n = 3).
Fig. 6. Basal and forskolin-stimulated steroid production in H295R cells. Steroids
were  assayed with and without forskolin (10 "M)  stimulation, in the presence of
Rooibos (1 mg/ml), aspalathin (10 "M)  and nothofagin (10 "M)  after 48 h. Data was
analysed by a one-way ANOVA, followed by a Dunnett’s multiple comparison test.
Results are expressed as the mean ± SEM (*P < 0.05, ***P < 0.001, n = 3).
glucocorticoid production, PREG metabolism was investigated in
H295R cells. We  assayed the effect of Rooibos (1 mg/ml), aspalathin
(10 "M)  and nothofagin (10 "M)  on both basal and forskolin
(10 "M)  stimulated steroid metabolism. The total amount of steroid
detected, decreased significantly under basal conditions in the
presence of Rooibos (2-fold), aspalathin (1.6-fold) and nothofagin
(2-fold) (Fig. 6). Similarly, under forskolin stimulated conditions,
treatment with Rooibos, aspalathin and nothofagin decreased the
total amount of steroid detected by 4.0-, 1.4- and 1.4-fold, respec-
tively (Fig. 6). MTT  assays conducted in the presence of 1 mg/ml
Rooibos extract, 10 "M dihydrochalcone compounds and 10 "M
forskolin showed that the inhibitory effects observed in the H295R
assays were not due to a decrease in cell viability (data not shown).
The greater inhibition observed by the addition of the Rooibos
extract in the presence of forskolin may  be attributed to com-
pounds which could affect upstream processes. Genistein together
with diadzein, have been shown to inhibit ACTH-stimulated corti-
sol production in cultured fetal and postnatal adrenal cortical cells
at concentrations ranging from 0.4 to 40 "M. Both genistein and
diadzein also inhibited cAMP-stimulated cortisol synthesis in H295
cells [27].
It  is possible that the decrease in steroid production by Rooibos
may be due to the inhibition of either CYP11A1 or the transport
of cholesterol to the inner mitochondrial membrane. We  have
shown that Rooibos, aspalathin and nothofagin significantly inhibit
CYP17A1 and CYP21 in COS-1 cells and inhibition of these key
enzymes would ultimately influence the steroid outcome of the
adrenal gland. Under basal conditions, the addition of Rooibos and
the dihydrochalcone compounds resulted in a small increase in the
production of the mineralocorticoid, ALDO (Table 2). Significant
reductions were, however, observed in the levels of A4 (Rooibos,
2.7-fold; aspalathin, 2.4-fold and nothofagin, 3.5-fold) and testos-
terone (Rooibos, 8.8-fold; aspalathin, 4.3-fold and nothofagin,
7.1-fold). The reduction of A4, and consequently of testosterone,
is most likely due to inhibition of 3!HSD as human CYP17A1
does not readily catalyse the lyase of 17OH-PROG to A4. In addi-
tion, increased DHEA-S production (1.6-fold) was  observed in the
presence of Rooibos, which could also imply inhibition of 3!HSD.
The increase in PREG and 17OH-PROG levels in the presence of
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Table  2
Steroids produced in H295R cells under basal conditions in the presence of Rooibos and dihydrochalcones. Cells were incubated for 48 h with Rooibos (1 mg/ml), aspalathin
(10 !M)  and nothofagin (10 !M).  Steroids were quantified by UPLC–MS/MS. Percentage of each steroid ± SEM was calculated by dividing the amount of individual steroid by
the  total steroid. Fold change ± SEM in response to Rooibos, aspalathin and nothofagin treatment, was calculated from the changes in absolute values of individual steroids
(not shown) compared to basal values. P values were calculated using a one-way ANOVA with a Dunnett’s post test.
Steroid metabolite Basal + Rooibos + Aspalathin + Nothofagin
% Total ± SEM % Total ± SEM Fold change ± SEM % Total ± SEM Fold change ± SEM % Total ± SEM Fold change ± SEM
PREG 2.8 ± 1.7 5.4 ± 1.7 2.0 ± 0.4 0.9 ± 0.5
PROG 1.2 ± 1.1 0.5 ± 0.1 0.2 ± 0.0 0.3 ± 0.1
DOC 2.8 ± 0.2 2.8 ± 0.1 9.0 ± 0.8 11.6 ± 1.5
CORT 6.2 ± 0.5 7.7 ± 0.4 10.4 ± 0.6 11.3 ± 1.0
18OH-CORT 0.2 ± 0.0 0.7 ± 0.3 0.6 ± 0.1 0.7 ± 0.2
ALDO 0.1 ± 0.0 0.3 ± 0.0 0.2  ± 0.0 0.2  ± 0.0
11-DHC 0.3 ± 0.1 0.5 ± 0.0 0.2  ± 0.0 0.3 ± 0.0
17OH-PREG ND ND ND ND
17OH-PROG 1.5 ± 0.1 4.5 ± 0.1 ↑1.6 ± 0.4* 0.7 ± 0.2 ↓3.6 ± 1.1** 0.7 ± 0.2 ↓4.8 ± 1.3**
16OH-PROG 1.7 ± 0.0 0.7 ± 0.1 ↓5.0 ± 0.7*** 1.2 ± 0.0 ↓2.3 ± 0.4*** 1.0 ± 0.1 ↓3.6 ± 0.7***
Deoxycortisol 44.4 ± 1.4 27.2 ± 1.6 ↓3.5 ± 0.6** 44.3 ± 0.3 42.4 ± 0.6 ↓2.3 ± 0.6*
Cortisol 14.6 ± 1.0 23.8 ± 2.0 14.8 ± 0.1 15.3 ± 1.4
Cortisone 0.2 ± 0.1 0.3 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
DHEA ND ND ND ND
DHEA-S 0.3 ± 0.2 0.5 ± 0.1 ↑1.6 ± 0.7** 0.1 ± 0.0 0.1 ± 0.0
A4 20.5 ± 0.3 16.3 ± 0.4 ↓2.7 ± 0.6** 13.9 ± 0.9 ↓2.4 ± 0.4** 13.0 ± 0.4 ↓3.5 ± 0.8***
11BOH-A4 2.3 ± 0.1 8.7 ± 0.4 ↑1.9 ± 0.4** 1.8 ± 0.1 1.7 ± 0.2 ↓3.0 ± 0.6*
Testosterone 1.0 ± 0.1 0.3 ± 0.0 ↓8.8 ± 2.0*** 0.4 ± 0.1 ↓4.3 ± 1.0*** 0.3 ± 0.0 ↓7.1 ± 2.6***
DHT ND ND ND ND
Estrone ND ND ND ND
"-Estradiol ND ND ND ND
Total steroid (nM) 3947 1890 ↓2.1* 2429 ↓1.6 1952 ↓2.0*
ND, not detectable (n = 3).
*
**
***
Rooibos under stimulated conditions, suggest the inhibition of
3"HSD, CYP17A1 and CYP21. 16OH-PROG, a dead end product,
was also reduced in the presence of Rooibos, suggesting either
a reduction of PROG levels due to 3"HSD inhibition or inhibi-
tion of CYP17A1. Under basal conditions, cortisol and cortisone
levels were not significantly affected, while basal deoxycortisol lev-
els decreased significantly in the presence of Rooibos (3.5-fold)
and nothofagin (2.3-fold), possibly due to inhibition of CYP21.
Under basal conditions, both aspalathin and nothofagin signif-
icantly reduced 17OH-PROG, 16OH-PROG, A4 and testosterone
levels, confirming our findings in COS-1 cells.
The effect of Rooibos was notably more pronounced during
forskolin treatment than under basal conditions. Rooibos sig-
nificantly decreased the levels of the glucocorticoids, cortisol
(4.9-fold), cortisone (5.2-fold) and CORT (5.2-fold), as well as
the glucocorticoid precursors, deoxycortisol (5.1-fold) and DOC
(3.4-fold) under stimulated conditions (Table 3). Aspalathin and
nothofagin also decreased cortisol levels by 1.3-fold and 1.7-fold,
respectively. While no effect was observed in ALDO levels in the
presence of Rooibos, there was a significant reduction of the precur-
sor metabolites. Androgen precursor production was  significantly
affected by Rooibos, aspalathin and nothofagin under stimulated
conditions. A4, testosterone and 11"OH-A4 levels decreased, while
DHEA-S levels remained unchanged. A4 is the primary precursor of
testosterone and A4 produced in the adrenal contributes to testos-
terone biosynthesis either by secretion or peripheral conversion
of the precursor [3]. A reduction in circulating levels of A4 and
testosterone by Rooibos may  have clinical implications. However,
in a study conducted in human test subjects, an increase in testos-
terone levels after Rooibos consumption for 6 weeks was observed.
In addition, DHEA-S levels in men  remained unchanged, while a
considerable increase in DHEA-S levels were detected in women
(results unpublished).
To  date the function of 11"OH-A4 in human adrenal steroido-
genesis remains uncertain. In a recent study investigating the
inhibition  of estrogen biosynthesis in gonadal masculinization of
rainbow trout, Vizziano et al. [55] showed that masculinization was
induced by the inhibition of CYP19 in genetic all-female popula-
tions following the administration of 11"OH-A4. The production
of this steroid metabolite, exhibiting weak androgenic activity [56]
and inhibitory effects on CYP19, which catalyses the biosynthesis
of estrone and "-estradiol, could have implications in the output
of adrenal steroidogenesis. In this study we  found that 11"OH-
A4 comprised only 2.3% of the total steroids assayed while A4
comprised 20.5% under basal conditions (Table 1). Upon forskolin
stimulation, the production of 11"OH-A4 significantly increased
(4.5-fold), comprising 3.5% of the total steroids. Although Xing et al.
[3] reported a 5-fold increase in 11"OH-A4 levels upon forskolin
stimulation, they found that in adult adrenal cells under basal con-
ditions, A4 and 11"OH-A4 levels comprised 4- and 9% of the total
steroids respectively. However, a 17-fold increase was observed
in 11"OH-A4 levels following ACTH stimulation. Nevertheless,
11"OH-A4 appears to be stimulated by Rooibos, with a significant
increase (1.9-fold) being detected under basal conditions. The pro-
duction of this metabolite is significantly inhibited by nothofagin
(3-fold) only, demonstrating the complex nature of the extract. Fol-
lowing forskolin stimulation, 11"OH-A4 production was inhibited
significantly by Rooibos and dihydrochalcone compounds, with a
concomitant decrease in A4 levels.
The data shows that while aspalathin and nothofagin are of the
most abundant flavonoids in Rooibos [57] and demonstrated sim-
ilar inhibitory effects, they did not in all cases reflect the effects
brought about by Rooibos, clearly indicating that other compounds
contribute to the effects of Rooibos on adrenal steroidogenesis.
The observation that Rooibos is able to significantly reduce glu-
cocorticoid production during forskolin treatment, but not under
basal conditions, may  have therapeutic applications for Rooibos
in the management of stress-related conditions. In addition, Rooi-
bos resulted in a much greater inhibition (4-fold) in the total
amount of steroids detected under forskolin stimulated conditions
P <  0.05.
P < 0.01.
P < 0.001.
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Table  3
Steroids produced in forskolin-stimulated H295R cells in the presence of Rooibos and dihydrochalcones. Cells were incubated for 48 h with forskolin (10 !M),  Rooibos
(1 mg/ml), aspalathin (10 !M)  and nothofagin (10 !M).  Steroids were quantified by UPLC–MS/MS. Percentage of each steroid ± SEM was  calculated by dividing the amount
of individual steroid by the total steroid. Fold change ± SEM in response to Rooibos, aspalathin and nothofagin treatment, was calculated from the changes in absolute values
of  individual steroids (not shown) compared to forskolin values. P values were calculated using a one-way ANOVA with a Dunnett’s post test.
Steroid metabolite Forskolin Forskolin + Rooibos Forskolin + aspalathin Forskolin + nothofagin
% Total ± SEM % Total ± SEM Fold change ± SEM % Total ± SEM Fold change ± SEM % Total ± SEM Fold change ± SEM
PREG 0.7 ± 0.2 8.7 ± 1.1 ↑4.2 ± 1.6* 0.6 ± 0.2 1.1 ± 0.1
PROG  0.0 ± 0.0 0.9 ± 0.1 0.0 ± 0.0 0.1 ± 0.0
DOC 3.0 ± 0.2 3.7 ± 0.2 ↓3.4 ± 0.6** 3.2 ± 0.1 5.8 ± 0.3
CORT  18.6 ± 0.4 14.1 ± 0.4 ↓5.2 ± 0.3*** 20.8 ± 0.8 21.6 ± 0.4
18OH-CORT 0.9 ± 0.0 1.8 ± 0.0 ↓2.1 ± 0.3*** 1.0 ± 0.0 1.1 ± 0.1
ALDO 0.2  ± 0.0 0.6 ± 0.0 0.3  ± 0.0 0.4  ± 0.0
11-DHC 0.1 ± 0.0 0.3 ± 0.0 0.1  ± 0.0 0.1 ± 0.0
17OH-PREG ND ND ND ND
17OH-PROG 0.3 ± 0.0 6.3 ± 0.1 ↑4.9 ± 0.2*** 0.3 ± 0.0 0.2 ± 0.1
16OH-PROG 0.6 ± 0.0 0.8 ± 0.1 ↓3.1 ± 0.4*** 0.7 ± 0.0 0.7 ± 0.0
Deoxycortisol 24.6 ± 1.0 19.4 ± 0.1 ↓5.1 ± 0.6*** 23.7 ± 1.8 28.5 ± 0.4
Cortisol 34.2 ± 1.2 27.8 ± 1.2 ↓4.9 ± 0.2*** 34.7 ± 1.3 ↓1.3 ± 0.1*** 28.8 ± 0.6 ↓1.7 ± 0.2***
Cortisone 0.1 ± 0.0 0.1 ± 0.0 ↓5.2 ± 1.2** 0.1 ± 0.0 0.1 ± 0.0 ↓2.6 ± 0.4*
DHEA ND ND ND ND
DHEA-S 0.1 ± 0.0
A4 12.5 ± 0.4 9.3 ± 0.5 ↓5.5 ± 0.7*** 10.3 ± 0.2 ↓1.7 ± 0.2*** 9.1 ± 0.3 ↓2.0 ± 0.2***
11BOH-A4 3.5 ± 0.3 6.0 ± 0.5 ↓2.3 ± 0.0*** 3.8 ± 0.2 ↓1.3 ± 0.1** 2.1 ± 0.1 ↓2.5 ± 0.4***
Testosterone 0.5 ± 0.0 0.1 ± 0.0 ↓22.8 ± 5.2*** 0.4 ± 0.0 ↓1.7 ± 0.2*** 0.3 ± 0.0 ↓2.4 ± 0.2***
DHT ND ND ND ND
Estrone ND ND ND ND
"-Estradiol ND ND ND ND
Total steroid (nM) 11,141 2788 ↓4.0*** 8248 ↓1.4* 7786 ↓1.4*
ND, not detectable (n = 3).
*
**
***
compared to the 2-fold inhibition observed under basal conditions.
A recent study by Beltrán-Debóna et al. [58] showed negligible
effects of Rooibos in animals with no metabolic disturbance, while
significant reductions in serum cholesterol, triglyceride and free
fatty acid concentrations were observed in hyperlipemic mice.
Although  the addition of Rooibos led to a reduction in over-
all biosynthesis of steroid hormones, the data shows that under
basal conditions the steroid metabolites in the mineralocorticoid
pathway are not significantly affected by the extract or by the two
dihydrochalcones, while a decrease in the flux is evident upon
forskolin stimulation in the presence of the extract only. While
cortisol and cortisone levels are unchanged, the glucocorticoid
intermediates are decreased under basal conditions by Rooibos and
both compounds. However, upon stimulation with forskolin the
inhibitory effect of Rooibos on the flux through the pathway, which
results in significant inhibition of cortisol and cortisone production,
is greater than that of aspalathin and nothofagin. Similarly, it would
appear that a reduction of the flux through the androgen precursor
pathway is more pronounced in the case of forskolin stimulation in
the presence of the Rooibos extract.
In conclusion, our data indicates that Rooibos and the flavonoid
compounds, aspalathin and nothofagin, interact with, and inhibit
the steroidogenic enzymes influencing the shunt of metabolites in
the mineralocorticoid, glucocorticoid and androgen pathways. The
UPLC–MS/MS method developed for this study can be applied in the
analysis and accurate quantification of adrenal steroid metabolites
and the steroid flux through these precursor pathways. In addition,
this method would be applicable in the assessment of inhibition
profiles of compounds impacting steroidogenesis.
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Supplementary table 1: Gradient specifications of the LC system. 
 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0.00 85 15 1 
2 0.04 85 15 6 
3 3.12 65 35 5 
4 4.67 62 38 6 
5 5.45 61 39 6 
6 7.00 60 40 7 
7 8.50 53 47 6 
8 9.50 30 70 6 
9 9.55 0 100 6 
10 10.00 0 100 6 
11 10.10 85 15 6 
12 13.00 85 15 6 
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     Supplementary table 2: Parameters for the detection and quantification of 21 steroids by UPLC-MS/MS: retention times  
     (RT, min), cone voltages (CV), collision energy (CE), limit of detection (LOD) and limit of quantification (LOQ).  
 
 
Steroid metabolite RT (min) 
Precursor 
ion CV
 Product 
ion A CE
 Product 
ion B CE
 Product 
ion C CE
 LODa 
(ng/ml) 
LOQb 
(ng/ml) 
Calibration range 
(ng/ml) 
Linearity 
(r2) 
PREG 9.09 317.2 16 159.1 18 281.2 12   100 100 100 - 4000 0.995 
PROG 9.11 315.2 30 96.9 15 297.2 15   0.2 0.2 0.2 - 4000 0.997 
DOC 6.89 331.2 30 97.0 15 108.9 15   2 2 2 - 4000 0.997 
CORT 4.44 347.0 30 121.0 15 329.1 15   20 20 20 - 4000 0.998 
18OH-CORT 2.98 363.2 30 147.0 22 251.2 20 269.2 15 2 2 2 - 4000 0.999 
ALDO 2.90 361.4 30 97.9 32 315.1 20 343.2 18 0.2 0.2 0.2 - 4000 0.997 
11-DHC 4.09 345.3 30 121 20 301.2 25   2 2 2 - 4000 0.997 
17OH-PREG 6.81 297.2 30 165.6 25 256.0 10 297.2 4 200 500 500 - 4000 0.990 
17OH-PROG 7.41 331.2 30 97.0 15 108.9 15   20 20 20 - 4000 0.998 
16OH-PROG 5.11 331.2 30 97.0 15 108.9 15   20 20 20 - 4000 0.998 
Deoxycortisol 4.82 347.0 30 97.9 15 108.9 15   2 2 2 - 4000 0.997 
Cortisol 3.15 363.0 30 121.0 20     2 2 2 - 4000 0.999 
Cortisone 3.38 361.2 30 163.0 30     0.2 0.2 0.2 - 4000 0.999 
DHEA 6.63 271.2 30 243.0 15 253.2 15   100 100 100 - 4000 0.994 
DHEA-S 5.69 367.2 50 97.0 35     0.2 0.2 0.2 - 4000 0.998 
A4 6.71 287.2 30 96.9 15 108.8 15   2 2 2 - 4000 0.998 
11BOH-A4 4.07 303.2 30 121 30 267.2 15   2 20 20 - 4000 0.998 
Testosterone 6.30 289.2 30 97.2 22 109.0 22   2 2 2 - 4000 0.994 
DHT 7.66 291.2 25 255.0 15 273.0 20   100 100 100 - 4000 0.994 
Estrone 6.87 271.2 30 243.0 15 253.2 15   100 100 100 - 4000 0.986 
β-Estradiol 5.74 255.2 15 133.0 15 159.0 15   100 100 100 - 4000 0.967 
          
         a Limit of detection was defined as a S/N ratio > 3 
         b Limit of quantification was defined as a S/N ratio > 10 
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Abstract: Major rooibos flavonoids—dihydrochalcones, aspalathin and nothofagin, 
flavones—orientin and vitexin, and a flavonol, rutin, were investigated to determine their 
influence on the activity of adrenal steroidogenic enzymes, 3ȕ-hydroxysteroid dehydrogenase 
(3ȕHSD2) and cytochrome P450 (P450) enzymes, P450 17Į-hydroxylase/17,20-lyase 
(CYP17A1), P450 21-hydroxylase (CYP21A2) and P450 11ȕ-hydroxylase (CYP11B1). All 
the flavonoids inhibited 3ȕHSD2 and CYP17A1 significantly, while the inhibition of 
downstream enzymes, CYP21A2 and CYP11B1, was both substrate and flavonoid specific. 
The dihydrochalcones inhibited the activity of CYP21A2, but not that of CYP11B1. 
Although rutin, orientin and vitexin inhibited deoxycortisol conversion by CYP11B1 
significantly, inhibition of deoxycorticosterone was <20%. These three flavonoids were 
unable to inhibit CYP21A2, with negligible inhibition of deoxycortisol biosynthesis only. 
Rooibos inhibited substrate conversion by CYP17A1 and CYP21A2, while the inhibition 
of other enzyme activities was <20%. In H295R cells, rutin had the greatest inhibitory 
effect on steroid production upon forskolin stimulation, reducing total steroid output  
2.3-fold, while no effect was detected under basal conditions. Nothofagin and vitexin had a 
greater inhibitory effect on overall steroid production compared to aspalathin and orientin, 
respectively. The latter compounds contain two hydroxyl groups on the B ring, while 
nothofagin and vitexin contain a single hydroxyl group. In addition, all of the flavonoids 
are glycosylated, albeit at different positions—dihydrochalcones at C3' and flavones at C8 
on ring A, while rutin, a larger molecule, has a rutinosyl moiety at C3 on ring C. Structural 
differences regarding the number and position of hydroxyl and glucose moieties as well as 
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structural flexibility could indicate different mechanisms by which these flavonoids 
influence the activity of adrenal steroidogenic enzymes. 
Keywords: Aspalathus linearis; rooibos polyphenols; adrenal steroidogenesis;  
cytochrome P450 enzymes; UPLC-MS/MS; adrenal H295R cells; cortisol; metabolic disorder; 
structure-activity relationship; stress 
 
1. Introduction 
Flavonoids are a diverse group of plant-derived polyphenols that occur naturally in fruits, 
vegetables, teas and herbs. These secondary plant metabolites have been shown to exhibit potent  
anti-oxidant activities, scavenging reactive radicals that cause cellular damage associated with many 
diseases and clinical conditions. Flavonoids, often referred to as phytoestrogens due to their structural 
similarity to estrogen and ability to bind the estrogen receptor, may have implications in various 
clinical conditions and hormone-dependent cancers [1,2]. Although flavonoid polyphenols are 
generally associated with beneficial health properties, it has been suggested that when consumed in 
high dosages, flavonoids may act as pro-oxidants and mutagens resulting in cytotoxicity. One such 
flavonoid, apigenin, a common dietary flavone which exhibits anti-inflammatory, anti-oxidant and 
anti-carcinogenic properties, was recently shown to induce oxidative stress, causing liver damage in 
Swiss mice following administration of high dosages of the compound [3,4]. Flavonoids have also 
been shown to modulate key enzymes in adrenal steroidogenesis, affecting steroid hormone 
biosynthesis in the mineralocorticoid, glucocorticoid and adrenal androgen pathways [5–8]. Abnormal 
adrenal steroid hormone levels impact on human health, leading to a broad spectrum of clinical 
conditions. Chronically elevated cortisol levels have, for example, been associated with metabolic 
disorders such as visceral obesity, insulin resistance, hypertension, cardiovascular disease and type 2 
diabetes [9]. Clinical strategies employed in the treatment of diseases associated with endocrine 
disorders and cancers include selective inhibitors of either the enzymes catalysing adrenal steroid 
biosynthesis and metabolism or antagonist activity at steroid receptor level [10]. Diets supplemented 
with flavonoid-rich plant based foods and beverages may influence the endocrine system and impact 
on metabolic diseases. 
Rooibos, a polyphenol-rich herbal tea prepared as an infusion from the stems and leaves of the plant 
Aspalathus linearis, has traditionally been used to aid in the alleviation of sleeplessness, anxiety and 
nervous tension, ailments related to stress and physiological conditions generally associated with high 
cortisol levels. Our previous studies showed that rooibos and specific flavonoids inhibit cytochrome 
P450 (P450) enzymes and cortisol production [8,11]. 
In vitro studies in COS-1 cells have shown that unfermented rooibos extract as well as the two rare 
dihydrochalcones, aspalathin and nothofagin, significantly inhibited P450 17Į-hydroxylase/17,20 lyase 
(CYP17A1) and P450 21-hydroxylase (CYP21A2), while also significantly reducing the levels of 
cortisol in forskolin stimulated adrenal H295R cells. Even though aspalathin and nothofagin are the 
two most abundant flavonoids in unfermented rooibos, they did not in all cases reflect the same 
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inhibitory effect on steroid levels in H295R cells as brought about by the rooibos extract, suggesting 
that other compounds contribute to the overall effect of rooibos on adrenal steroidogenesis [8]. 
In the present study we continued our investigation into the influence of rooibos and polyphenolic 
compounds, belonging to three distinct classes of flavonoids, on adrenal steroidogenic enzymes.  
The five major rooibos flavonoids used in this study included the dihydrochalcones, aspalathin and 
nothofagin, their flavone analogues, orientin and vitexin, as well as the flavanol, rutin (Table 1).  
Due to the structural differences of the flavonoids, these compounds may interact differently with the 
steroidogenic enzymes thus affecting steroid hormone biosynthesis in the adrenal. We therefore 
determined the inhibitory effect of rooibos flavonoids on enzymes that play a key role in adrenal 
steroidogenesis, 3ȕ-hydroxysteroid dehydrogenase (3ȕHSD2), CYP17A1, CYP21A2 and 11ȕ-hydroxylase 
(CYP11B1), as well as on overall steroid hormone production in the human adrenal H295R cell line 
under both basal and forskolin stimulated conditions.  
Table 1. Chemical structures of the major rooibos flavonoids. 
Structure Compound Substitution 
Dihydrochalcones 
 
Aspalathin R1=OH, R2=C-ȕ-D-glucopyranosyl 
Nothofagin R1=H, R2=C-ȕ-D-glucopyranosyl 
Flavones 
 
Orientin R1=OH, R2=C-ȕ-D-glucopyranosyl  
Vitexin R1=H, R2=C-ȕ-D-glucopyranosyl  
Flavonol 
 
Rutin R=rutinosyl 
2. Results and Discussion 
It has been widely reported that polyphenols exhibit a diverse range of beneficial biological effects, 
and as such, their consumption as part of the daily diet cannot be ignored. Although teas and herbal 
infusions contribute to the daily intake of dietary flavonoids, the pharmacological actions of these 
extracts cannot directly be attributed to single compounds within these beverages, unless identified and 
assayed in isolation. Flavonoids modulate steroid hormone biosynthesis and metabolism due to their 
interaction with steroidogenic enzymes, either inhibiting or stimulating specific enzymes [7,8]. We 
recently showed that unfermented rooibos extract influenced the steroid flux in the mineralocorticoid, 
glucocorticoid and androgen precursor pathways in human adrenal H295R cells under both basal and 
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forskolin stimulated conditions [8]. While the effect of flavonoid compounds on the flux through the 
adrenal steroidogenic pathways can be determined, the influence on specific enzymes in these 
pathways is less obvious due to upstream inhibition of steroid intermediates. In the present study, we 
assayed the effect of flavonoid compounds on individual steroidogenic enzymes as well as on steroid 
metabolite levels in H295R cells using ultra performance liquid chromatography/tandem mass 
spectrometry (UPLC-MS/MS). 
2.1. The Influence of Rooibos and Selected Flavonoid Compounds on Adrenal Steroidogenic Enzymes 
Expressed in Non-Steroidogenic COS-1 Cells 
CYP17A1 plays a central role at the branch point in adrenal steroid biosynthesis, and together with 
3ȕHSD2, determines the shunt of steroid metabolites in the glucocorticoid, mineralocorticoid and 
adrenal androgen pathways (Scheme 1). 
Scheme 1. Steroid hormones produced in human adrenal cells. 
 
CYP17A1 catalyses the 17Į-hydroxylation of pregnenolone (PREG), yielding 17OH-pregnenolone 
(17OH-PREG), which is in turn converted to dehydroepiandrosterone (DHEA). These three 
metabolites are substrates for 3ȕHSD2, which catalyzes their conversion to progesterone (PROG), 
17OH-progesterone (17OH-PROG), and androstenedione (A4), respectively, thereby shunting metabolites 
into the respective pathways. In addition, CYP17A1 also catalyses the conversion of PROG to  
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17OH-PROG and 16OH-progesterone (16OH-PROG), with the latter not being further metabolized in 
the adrenal. PREG conversion by CYP17A1 was inhibited by all the flavonoid compounds assayed, 
with the compounds exhibiting similar inhibitory effects (Figure 1A). Although PREG conversion by 
3ȕHSD2 was also inhibited by all the flavonoids assayed, rutin exhibited the greatest inhibitory effect, 
while vitexin had the lowest inhibitory effect, 2-fold lower than that of rutin (Figure 1B). 
Figure 1. Substrate conversion (1 µM) in transiently transfected COS-1 cells in the 
absence and presence of rooibos extract (4.3 mg/mL) and selected flavonoids (10 µM). 
CYP17A1 and CYP21A2 data adapted from [8]. 
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CYP21A2 catalyzes the conversion of PROG and 17OH-PROG to DOC and deoxycortisol, 
respectively. In contrast to CYP17A1 and 3ȕHSD2, only the dihydrochalcones inhibited the activity of 
CYP21A2 significantly, with the flavones and rutin not influencing the conversion of PROG by 
CYP21A2 (Figure 1C). In the conversion of 17OH-PROG, however, these compounds displayed 
inhibitory effects below 20% (Figure 1D). Neither aspalathin nor nothofagin inhibited the conversion 
of DOC and deoxycortisol by CYP11B1 to their corresponding products, CORT and cortisol, 
respectively. The main structural difference between the dihydrochalcones and the other flavonoids 
assayed in this study is the structural flexibility of the molecules and the glucose moiety at C3' on ring 
A of the dihydrochalcones, which could interfere with the binding of the compounds to CYP11B1. 
Inhibition of CYP11B1 by vitexin, orientin and rutin, however, was substrate specific. While 
inhibition of DOC conversion was negligible (Figure 1E), inhibition of deoxycortisol conversion was 
significantly higher in the presence of rutin, orientin and vitexin (Figure 1F). The higher binding 
affinity of CYP11B1 for DOC compared to deoxycortisol may account for the negligible inhibition of 
the flavonoids on the conversion of DOC. CYP11B1 has been shown to exhibit a lower Km for DOC 
and its catalytic conversion is also characterized by a lower Kcat, 2-fold less than that of deoxycortisol 
conversion, clearly indicating that a single hydroxyl group influences the enzyme’s affinity for its 
substrate, as well as the substrate turnover. It was suggested that the presence of the C17 hydroxyl 
group of deoxycortisol obstructs the entrance of deoxycortisol into the enzyme’s active pocket [12]. 
While the rooibos extract exhibited the greatest inhibitory effect on CYP17A1 and CYP21A2, 
inhibition of the other enzymes was negligible. The inhibition of PREG conversion by CYP17A1 
(Figure 1A) as well as the conversion of PROG (Figure 1C) and 17OH-PROG (Figure 1D) by 
CYP21A2 was similar (±50%) in the presence of the extract. However, the inhibitory effect of rooibos 
on PREG conversion by 3ȕHSD2 (Figure 1B) and DOC (Figure 1E) and deoxycortisol (Figure 1F) 
conversion by CYP11B1, was less than 20%. The inhibitory effects brought about by the individual 
flavonoid compounds (10 µM) was not reflected in the inhibitory effects of the whole extract in all 
instances, even though the flavonoid concentrations within the rooibos extract ranged between 27 µM 
and 1.4 mM. Although we assayed five of the major flavonoids present in rooibos, it is important to 
note that, to date, 46 flavonoid compounds have been identified in rooibos [13,14] which may possibly 
contribute to the data obtained in the presence of the extract. From the data it is clear, however, that the 
rooibos extract preferentially inhibits CYP17A1 and CYP21A2, two key enzymes at the branch point 
of adrenal steroidogenesis. 
2.2. The Influence of Selected Flavonoids on Steroid Metabolism in Adrenal H295R Cells under Basal 
and Forskolin Stimulated Conditions 
In H295R cells, the dihydrochalcones and the flavones decreased the total steroid output under both 
basal and stimulated conditions, while rutin’s effect was only detected in the presence of forskolin. 
Forskolin mimics the effects of ACTH by activating cAMP pathways in adrenal cells [15], stimulating 
steroidogenic enzymes and increasing steroid production. As expected, forskolin significantly 
increased the total steroid output to 11.1 µM (2.8 fold), with the greatest inhibition being detected  
in the presence of rutin (Table 2). Both aspalathin and nothofagin significantly reduced basal  
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17OH-PROG and 16OH-PROG levels due to the inhibition of CYP17A1 and 3ȕHSD2. Nothofagin 
also reduced deoxycortisol levels under basal conditions, possibly due to inhibition of CYP21A2 or 
due to lower levels of 17OH-PROG being available as the precursor substrate. Both dihydrochalcones 
reduced A4 levels significantly under basal and forskolin stimulated conditions, indicative of 3ȕHSD2 
inhibition. Interestingly, while nothofagin reduced basal levels of 11ȕ-hydroxyandrostenedione 
(11OHA4), the product of A4, it did not reduce basal production of cortisol, which is catalysed by the 
same enzyme, CYP11B1. Although this may suggest possible inhibition of CYP11B1, neither 
aspalathin nor nothofagin were shown to inhibit the enzyme at 10 µM in COS-1 cells, suggesting that 
the reduction in 11OHA4 was due to upstream inhibition. Under stimulated conditions, the production 
of both cortisol and 11OHA4 was inhibited in the presence of aspalathin and nothofagin, indicating 
upstream inhibition, resulting in reduced levels of precursor steroid metabolites. It should, however, 
also be noted that when comparing inhibitory effects of the flavonoid compounds under basal and 
stimulated conditions, the expression levels of steroidogenic enzymes are altered when cells are 
stimulated with forskolin, which would in turn alter steroid metabolite/precursor levels. From these 
results it is clear that the inhibitory effects of both dihydrochalcones are very similar, however, the 
inhibitory effect of nothofagin was notably greater than that of aspalathin. 
Table 2. Steroid metabolites produced in adrenal H295R cells under basal and forskolin 
(10 µM) stimulated conditions in the absence and presence of selected flavonoids (10 µM) 
after 48 h. 
Steroid 
metabolites 
Basal + Aspalathin a + Nothofagin a + Orientin + Vitexin + Rutin b 
Total ± SEM (nM) Fold change Fold change Fold change Fold change Fold change 
PREG 35.2 ± 2.2          Ĺ 1.4 **    
PROG 5.8 ± 1.7                
DOC 107.4 ± 13.0       Ĺ 1.2 * Ĺ 1.2 **    
CORT 241.1 ± 31.6       Ĺ 1.2 *       
18OH-CORT 9.3 ± 1.3       Ĺ 2.6 *       
ALDO 2.3 ± 0.5                
11-DHC 9.9 ± 0.3                
16OH-PROG 66.4 ± 10.3 Ļ 2.3 *** Ļ 3.6 *** Ļ 1.2 *** Ļ 1.8 ***    
17OH-PROG 56.8 ± 6.3 Ļ 3.6 ** Ļ 4.8 **    Ļ 1.4 *    
Deoxycortisol 1741.0 ± 234.1    Ļ 2.3 *    Ļ 1.3 ***    
Cortisol 670.2 ± 39.3          Ļ 1.3 **    
Cortisone 6.6 ± 2.2       Ļ 1.5 *** Ļ 1.8 ***    
A4 806.5 ± 115.6 Ļ 2.4 ** Ļ 3.5 *** Ļ 1.1 * Ļ 1.5 ***    
11OHA4 90.1 ± 11.1    Ļ 3.0 *    Ļ 1.5 ***    
Testosterone 39.22 ± 3.60 Ļ 4.3 *** Ļ 7.1 *** Ļ 1.3 ** Ļ 2.5 ***    
Total steroid (nM) 3947.0 Ļ 1.6  Ļ 2.0 * Ļ 1.0  Ļ 1.3 ** Ļ 1.0  
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Table 2. Cont. 
Steroid 
metabolites 
Forskolin + Aspalathin a + Nothofagin a + Orientin + Vitexin + Rutin b 
Total ± SEM (nM) Fold change Fold change Fold change Fold change Fold change 
PREG 47.5 ± 3.4       Ĺ 1.4 ** Ĺ 1.3 **    
PROG 5.1 ± 0.5       Ĺ 1.4 ** Ĺ 1.5 **    
DOC 343.2 ± 61.1       Ļ 1.2 * Ļ 1.1 *    
CORT 2062.0 ± 170.5          Ļ 1.3 ** Ļ 1.9 * 
18OH-CORT 104.8 ± 15.1             Ļ 2.0 ** 
ALDO 27.4 ± 3.4       Ļ 1.1 *** Ļ 1.4 *    
11-DHC 11.2 ± 1.4                
16OH-PROG 66.0 ± 4.7          Ļ 1.4 **    
17OH-PROG 36.0 ± 2.4             Ļ 3.1 * 
Deoxycortisol 2757.0 ± 393.1          Ļ 1.3 * Ļ 2.0 ** 
Cortisol 3793.0 ± 285.1 Ļ 1.3 *** Ļ 1.7 *** Ļ 1.3 *** Ļ 1.8 *** Ļ 3.0 *** 
Cortisone 11.6 ± 2.7    Ļ 2.6 *          
A4 1402.0 ± 180.0 Ļ 1.7 *** Ļ 2.0 *** Ļ 1.4 *** Ļ 1.5 *** Ļ 4.4 *** 
11OHA4 388.3 ± 16.3 Ļ 1.3 ** Ļ 2.5 *** Ļ 1.5 *** Ļ 1.7 *** Ļ 6.9 *** 
Testosterone 50.5 ± 6.1 Ļ 1.7 *** Ļ 2.4 *** Ļ 1.7 *** Ļ 2.3 *** Ļ 5.8 *** 
Total steroid (nM) 11,141.0 Ļ 1.4 * Ļ 1.4 * Ļ 1.1  Ļ 1.3 ** Ļ 2.3 ** 
* p < 0.05, ** p < 0.01, *** p < 0.001; a Adapted from [8]; b Adapted from [11]; ј (increase) or љ (decrease) in steroid levels (nM) under 
basal / forskolin stimulated conditions in the presence of flavonoids. 
Orientin, the flavone analogue of aspalathin, significantly increased the steroid flux in the 
mineralocorticoid pathway, increasing basal levels of DOC, CORT and 18OH-CORT, suggesting that 
inhibition of CYP17A1 resulted in more metabolites being channeled into the mineralocorticoid 
pathway. The data obtained clearly shows that the flavones inhibit CYP17A1, since PREG and PROG 
levels increased, while 16OH-PROG and 17OH-PROG levels decreased (Table 2). 
The inhibitory profile of vitexin was very similar to that of orientin, however, vitexin exhibited a 
greater inhibitory effect, reducing the total steroid output 1.3-fold under both basal and stimulated 
conditions, while the effect of orientin on total steroid production was negligible. Interestingly, under 
stimulated conditions, during which aldosterone synthase (CYP11B2) expression is upregulated [16], 
the effect of vitexin on the mineralocorticoid pathway was much more prominent compared to orientin, 
with a greater reduction in ALDO levels being observed, suggesting inhibition of either CYP11B2 or 
upstream enzymes. Under both basal and stimulated conditions, vitexin also had a much greater effect 
on the glucocorticoid pathway compared to orientin, reducing the levels of cortisol and its precursors 
significantly. In COS-1 cells, rutin as well as the flavones inhibited the biosynthesis of cortisol  
by CYP11B1, while the dihydrochalcones did not, suggesting that the reduced cortisol levels observed 
in H295R cells in the presence of aspalathin and nothofagin may be indicative of upstream  
inhibition only. 
While the dihydrochalcones and their flavone analogues reduced basal testosterone levels 
significantly, it was the former compounds which had the greatest effect, suggesting inhibition of 
17ȕHSD. However, the adrenal is not the primary site for 17ȕHSD expression, as is also the case for 
11ȕHSD2, which catalyses the formation of cortisone and 11-dehydrocorticosterone (11-DHC).  
The detected levels of these metabolites were very low, with the flavones reducing cortisone levels 
Stellenbosch University  https://scholar.sun.ac.za
Molecules 2014, 19 3689 
 
 
under basal conditions, while under stimulated conditions, it was inhibited in the presence of 
nothofagin only. Although 17ȕHSD and 11ȕHSD2 are expressed at very low levels in the adrenal [17], 
it would appear that these hydroxysteroid dehydrogenases, together with 3ȕHSD2, are sensitive to the 
flavonoid compounds present in Rooibos. 
In a recent pharmacophore-based virtual screening study investigating inhibitors of 17ȕHSD type 3 
and 5, key enzymes involved in adrenal androgen production, it was shown that the ligand binding 
domain of these enzymes is able to accommodate structurally highly diverse ligands which bind to 
different regions of the active site. An enlargement of the binding cavity was observed in the crystal 
structure of 17ȕHSD3/5 when rutin was bound to these enzymes. Furthermore, the X-ray structure of 
rutin bound to 17ȕHSD5 showed that water molecules formed a hydrogen bonding network with rutin 
bound at the base of the ligand binding domain [18]. 
Rutin, one of the more stable flavonoid compounds in both fermented and unfermented Rooibos, 
had no significant effect on any of the steroid hormones under basal conditions. However, upon 
forskolin stimulation, rutin had the greatest inhibitory effect of all the flavonoid compounds assayed, 
reducing the total steroid output 2.3-fold. In the mineralocorticoid pathway, CORT and 18OH-CORT 
levels were significantly lower, suggesting inhibition of CYP11B2. In the glucocorticoid pathway, 
significant reductions in the levels of 17OH-PROG, deoxycortisol and cortisol indicate inhibition of 
CYP17A1 and CYP11B1, as was also shown in COS-1 cells (Figure 1). Upstream inhibition also 
contributed to the reduced deoxycortisol levels, since rutin did not inhibit CYP21A2. In the adrenal 
androgen precursor pathway, rutin reduced the levels of A4, testosterone and 11OHA4, suggesting 
inhibition of CYP17A1 and/or 3ȕHSD2. 
The data obtained in the H295R cell line did not in all cases reflect results obtained in COS-1 cells. 
The expression levels of the individual enzymes assayed in COS-1 cells are comparable, as the cells 
were transiently transfected with equal concentrations of the appropriate cDNA. Furthermore, the 
conversion of substrates in COS-1 cells allowed assays to be conducted under very specific conditions. 
A fixed substrate concentration and no competition from other enzymes for the same substrates, as is 
the case in the adrenal H295R cell model, allowed us to investigate the effect of flavonoids on the 
catalytic activity of specific steroidogenic enzymes. In contrast, enzymes are expressed at different 
levels in adrenal H295R cells and vary from enzyme to enzyme under both basal and forskolin 
stimulated conditions, with specific enzymes being upregulated when cells are stimulated. It was 
recently shown that under basal conditions in H295R cells, CYP11A1 is expressed at the highest 
levels, followed by CYP21A2, CYP17A1, SULT2A1, 3ȕHSD2, CYP11B2 and CYP11B1, while 
under forskolin stimulated conditions, CYP17A1 is expressed at the highest levels, followed by 
CYP21A2, CYP11A1, 3ȕHSD2, SULT2A1, CYP11B2, and CYP11B1 [16]. 
Overall, from these results it is clear that orientin and vitexin had the greatest effect on the 
mineralocorticoid pathway under both basal and forskolin stimulated conditions. The dihydrochalcones 
had no significant effect on any of the metabolites in the mineralocorticoid pathway, while rutin’s 
effect was only detected under stimulated conditions, with significantly reduced levels of ALDO 
precursors, CORT and 18OH-CORT. The influence of rutin was most evident in the glucocorticoid 
and adrenal androgen pathways under stimulated conditions, with the other flavonoids decreasing 
metabolites under both basal and stimulated conditions in these pathways. 
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2.3. Structure Activity Analyses 
Analyses regarding the influence of structural differences of flavonoid compounds on their ability 
to inhibit steroidogenic enzymes are hampered due to the uncertainty of the manner in which these 
compounds would interact with the active site of these enzymes. As the type of inhibition of the 
steroidogenic cytochromes P450 by the flavonoids is not known, it is possible that binding could also 
occur at sites other than the active pocket. Furthermore, molecular docking studies reporting on 
structural aspects of flavonoid compounds impacting on substrate inhibition in terms of steroidogenic 
enzymes are limited. It has, however, been shown by Ohno et al. that the isoflavone, diadzein, was 
able to competitively inhibit the binding of DHEA and PROG to 3ȕHSD2 and CYP21A2, respectively. 
The authors suggested, having assayed a range of flavone compounds, that it was the hydroxyl groups 
at C6 on ring A and C4' on ring B which played an important role in the inhibition of steroidogenic 
P450 enzymes. They showed, in cAMP-stimulated H295R cells, at a concentration of 12.5 µM, that  
6-hydroxyflavone, 4'-hydroxyflavone and apigenin, which contains hydroxyl groups at C5, C7 and C4', 
inhibited cortisol production significantly [7]. In the present study, vitexin, with a C4' hydroxyl group 
and orientin with C3' and C4' hydroxyl groups, both also containing a glucose moiety at C8, 
significantly inhibited cortisol biosynthesis at a concentration of 10 µM. In COS-1 cells, it was the 
flavones and rutin that inhibited CYP11B1 significantly, while the dihydrochalcones did not inhibit the 
activity of CYP11B1 towards DOC or deoxycortisol. It is interesting to note that the flavones as well 
as rutin, containing glucose moieties on ring A and ring C respectively, showed negligible inhibition of 
CYP21A2. In contrast, while aspalathin and nothofagin significantly inhibited substrate conversion by 
CYP21A2, these compounds had no influence on the conversion of either DOC or deoxycortisol by 
CYP11B1, possibly due to the glucosyl moiety at C3' on ring A. Our data thus far suggests that a 
glucosyl moiety at this position may prevent compounds inhibiting the catalytic activity of CYP11B1, 
while the C8 glucosyl and C3 rutinosyl moieties on the pyran ring of the other flavonoids do not. 
Substitutions at C3 and C4 (dihydrochalcones) and C3' and C4' (flavones and flavonol) on the B ring 
may, however, also play a role. The type of inhibition that these compounds elicit need to be 
determined, while homology models may pinpoint the effect of functional groups on the binding of the 
compounds in the active pocket of the relevant enzymes. 
In a more recent study by Hasegawa et al. [5], it was also shown in H295R cells that a range of 
flavones with hydroxyl groups at positions C4' or C3' and C4' on ring B significantly reduced the 
levels of DOC and A4, suggesting inhibition of 3ȕHSD2, while apigenin was more potent than the 
other polyphenols assayed, increasing the levels of PREG and 17OH-PROG, suggesting inhibition of 
CYP17A1, CYP21A2 and 3ȕHSD2. Apigenin was also shown to downregulate the expression levels 
of CYP17A1, CYP21A2 and 3ȕHSD2 mRNA significantly [5]. 
From our data it appears that the enzymes 3ȕHSD2 and CYP17A1 are most susceptible to inhibition 
by the rooibos flavonoids assayed in this study. The natural substrates for these two enzymes, PREG, 
17OH-PREG and DHEA contains a hydroxyl group on C3 of the steroid backbone structure involved 
with substrate binding in the active pocket [19,20]. It is possible that the hydroxyl group on position 
C4' of the flavonoid is involved in the binding of these compounds to the active pocket of 
steroidogenic P450 enzymes, with hydrogen bonds stabilizing the orientation of flavonoid compounds 
in the active site. However, since limited data is available on the molecular docking of flavonoids, no 
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conclusions can be drawn regarding the orientation of these compounds within the active pocket.  
In addition, as the mechanism of inhibition is uncertain, the binding of these compounds to the same 
site that the substrate would occupy cannot be assumed. A recent study by Androutsopoulos et al. [21], 
investigating the binding mode of selected flavonoids to the heme group using the CYP1A2 crystal 
structure as a template, predicted that flavonoids bind in the active pocket with the B-ring orientated 
towards the heme group. In an earlier study, Shimada et al. [22] investigated the inhibition of a range 
flavonoid compounds towards five human P450 enzymes by assessing inhibitory activity together with 
molecular docking studies. These studies clearly showed that the position and number of hydroxy and 
methoxy groups impacted on the orientation of the compounds in the active pocket of the different 
enzymes. It was shown that ring B of the compounds was not, in all cases, oriented towards the heme 
group and that hydroxy/methoxy substitutions influenced positioning of the flavonoid compounds and 
thus also affected the mechanisms of inhibition for the enzymes assayed. 
The compounds assayed in this study all contained glucose moieties on either ring A or C, which 
would, if bound in the active site of the enzyme, affect the orientation of the molecule, impacting on 
the mechanism of inhibition. It would seem that while a hydroxy group on B ring plays a role in 
flavonoid inhibitory activity, a second hydroxy group does not significantly affect inhibition or 
contribute towards increasing inhibition, possibly due to rotation between rings A and B resulting in a 
degree of flexibility. It should, however, also be noted that aspalathin and nothofagin have a more 
flexible structure compared to rutin, orientin and vitexin. It is interesting to note that the dihydrochalcones 
inhibit the catalytic activity of CYP21A2 towards both substrates, while exhibiting no inhibitory effect 
on CYP11B1, regardless of the substrate. In contrast, the inhibition of the activity of these enzymes 
towards their substrates differs in the presence of flavone/flavonol compounds, with the inhibitory 
effect of these compounds being greater when the substrate is hydroxylated at the C17 position. 
3. Experimental 
3.1. Reagents and Instruments 
Unfermented rooibos plant material was provided by the South African Rooibos Council (Rooibos 
LTD-BPK, Clanwilliam, South Africa). Aspalathin and nothofagin were obtained from Prof. W.C.A. 
Gelderblom (Medical Research Council, Western Cape, South Africa). Orientin and vitexin were 
purchased from Extrasynthese (Genay Cedex, France). Rutin, steroid metabolites, forskolin, Dulbecco’s 
modified Eagle’s Medium (DMEM) and an MTT assay kit were purchased from Sigma-Aldrich  
(St. Louis, MO, USA). Nucleobond® AX plasmid preparation kits were purchased from Machery-Nagel 
(Duren, Germany). Mirus TransIT®-LT1 transfection reagent was purchased from Mirus Bio 
Corporation (Madison, WI, USA). Penicillin–streptomycin, fetal calf serum and trypsin-EDTA were 
obtained from Gibco BRL (Gaithersburg, MD, USA). Deuterated cortisol (9,11,12,12-D4-cortisol) was 
purchased from Cambridge isotopes (Andover, MA, USA). DMEM/F12 and gentamicin were 
purchased from Invitrogen/Gibco (Grand Island, New York, USA). Cosmic calf serum was supplied 
by HyClone®, Thermo Scientific (South Logan, Utah, USA). A bicinchoninic acid (BCA) protein 
determination kit was purchased from Pierce (Rockford, IL, USA). The UPLC BEH C18 column was 
purchased from Waters (Milford, MA, USA). The Kinetex PFP column was obtained from 
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Phenomenex (Torrance, CA, USA). All chemicals were of the highest quality and supplied by 
reputable scientific suppliers. 
3.2. Substrate Conversion Assays in Transiently Transfected COS-1 Cells 
COS-1 cells were grown at 37 °C and 5% CO2 in DMEM containing 0.9 g/L glucose, 0.12% 
NaHCO3, 10% fetal calf serum and 1% penicillin streptomycin. The cells were plated into 12 well 
dishes (1 × 105 cells/mL, 1 mL/well), 24 h prior to transfection. Cells were transiently transfected with 
0.5 ȝg cDNA (baboon CYP17A1/pCIneo, baboon 3ȕHSD2/pCIneo, baboon CYP21A2/pCIneo) and 
1.5 µL Mirus TransIT®- LT1 transfection reagent according to the manufacturer’s instructions.  
Co-transfections with baboon CYP11B1/pTarget and human ADX/pCIneo cDNA were carried out 
using 0.25 µg of each plasmid. Control transfection reactions were performed using the pCIneo vector 
containing no cDNA insert. Cells were incubated for 72 h prior to substrate addition. Substrate 
conversion (1 µM) was assayed in the absence and presence of aspalathin, nothofagin, rutin, orientin 
and vitexin, assayed at 10 µM, and unfermented rooibos extract, assayed at 4.3 mg/mL. The methanolic 
extract of unfermented rooibos plant material used in this study was prepared and analysed as 
previously described [8,11]. At specific time intervals, 500 µL aliquots were removed and the steroids 
were extracted using a 10:1 volume of dichloromethane to culture medium. The mixture was vortexed 
for 30 s, centrifuged at 500 ×g for 5 min and the medium removed via aspiration. The dichloromethane 
phase, containing the steroid metabolites, was dried under N2, resuspended in 150 ȝL methanol and 
stored at í20 °C prior to analyses.  
3.3. Steroid Metabolism in Adrenal H295R Cells 
H295R cells were grown at 37 °C and 5% CO2 in DMEM/F12, supplemented with L-glutamine,  
15 mM HEPES, pyridoxine, 1.125 g NaHCO3/l, 1% penicillin streptomycin, 0.01% gentamicin, and 
10% cosmic calf serum (growth medium). The cells were plated into 12 well dishes (4 × 105 cells/mL,  
1 mL/well) and incubated for 48 h. The medium was subsequently replaced with experimental medium 
(growth medium containing 0.1% cosmic calf serum) and cells were incubated for a further 12 h prior 
to substrate addition. Steroid metabolism was assayed in the presence of selected flavonoid 
compounds, aspalathin, nothofagin, rutin, orientin and vitexin (10 µM), under both basal and forskolin 
(10 µM) stimulated conditions. After 48 h, the medium (500 µL) was removed and 15 ng D4-cortisol 
added as an internal standard. The steroids were extracted as described in Section 3.2. 
3.4. Cell Viability 
COS-1 cells were plated out in a 96 well plate (100 µL, 1 × 105 cells/mL) and incubated with 
selected flavonoid compounds (10 µM) for 8 h. H295R cells were plated out in a 96 well plate  
(100 µL, 4 × 105 cells/mL) and incubated with selected flavonoids (10 µM) and forskolin (10 µM) for 
48 h. Cell viability was assayed using an MTT toxicology assay kit according to the manufacturer’s 
instructions. Color-standardized controls (media containing either 1 mg/mL or 4.3 mg/mL Rooibos 
extract) were included to compensate for the possible interference of the Rooibos color with the assay. 
None of the abovementioned test compounds had a significant effect on COS-1 or H295R cell viability. 
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3.5. Separation and Quantification of Steroid Metabolites Using UPLC-MS/MS 
All steroid metabolites were analysed and quantified using UPLC–MS/MS (ACQUITY UPLC, 
Waters, Milford, MA, USA). Steroid metabolites from conversion assays in COS-1 cells were 
separated using a Waters UPLC BEH C18 (2.1 mm × 50 mm, 1.7 µm) column, while steroid 
metabolites produced in H295R cells were separated using a Phenomenex UPLC Kinetex PFP  
(2.1 mm × 100 mm, 2.6 µm) column, as previously described [11]. A Xevo triple quadrupole mass 
spectrometer (Waters, Milford, USA) was used for quantitative mass spectrometric detection. All steroids 
were analysed in multiple reaction monitoring (MRM) mode using an electrospray in the positive 
ionization mode (ESI+). Gradients of the LC system and other relevant information including the mobile 
phases, flow rates, injection volumes, parent and daughter ions, cone (V) and collision (eV) voltages, 
retention times and the validation of the UPLC–MS/MS assays has been described previously [11]. 
Calibration curves were constructed by using weighted (1/x2) linear least squares regression. Data was 
collected with the MassLynx 4.0 software program. The data obtained in assays conducted COS-1 
cells are depicted as % inhibition of substrate conversion, while the data obtained in H295R cells are 
expressed as absolute values (nM) ± SEM. 
3.6. Statistical Analysis 
All results are representative of two independent experiments, performed in triplicate, with the data 
being expressed as the mean ± SEM. After each assay a protein determination by the Pierce BCA 
method was performed in order to normalize steroid levels to protein concentrations. Statistical 
analyses were calculated with GraphPad Prism (version 5) software (GraphPad Software, San Diego, 
CA, USA) using a one-way ANOVA, followed by a Dunnett’s multiple comparison test. A value of  
p < 0.05 was considered to be statistically significant (* p < 0.05, ** p < 0.01, *** p < 0.001).  
4. Conclusions 
This study included five of the major flavonoid compounds present in rooibos. These flavonoids, 
regardless of structural differences, all inhibited the activitiy of CYP17A1 and 3ȕHSD2, branch point 
enzymes in adrenal steroidogenesis. The dihydrochalcones and the flavone/flavonol compounds, 
however, showed marked differences in their inhibition of the activity of downstream enzymes, 
CYP21A2 and CYP11B1, expressed in COS-1 cells. In addition, these compounds also exhibited 
distinct differences in terms of specific substrates. It is clear that structural differences regarding the 
number and position of hydroxyl and glucose moieties, and structural flexibility, impact on the 
inhibitory effect of these flavonoids, possibly indicating different mechanisms. Rooibos extract, which 
contains a wide spectrum of flavonoid compounds, some of which are present at higher levels than was 
assayed, did not in all cases exhibit the same degree of inhibition. It is thus plausible that, of the array 
of compounds present in rooibos, some may inhibit while others may stimulate or have no effect at all. 
Overall, it is clear that, although the mechanism of inhibition is uncertain, the major rooibos flavonoid 
compounds assayed in this study significantly influence adrenal steroidogenic enzyme activities and 
steroid hormone levels. 
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Scope: To determine the effect of Rooibos (Aspalathus linearis) on glucocorticoid biosynthesis
and inactivation in vivo and in vitro.
Methods and results: Ultra-performance liquid chromatography/tandem mass spectrometry
(UPLC-MS/MS) analyses of in vivo studies showed that humanRooibos consumption increased
cortisone plasma levels in males (p = 0.0465) and reduced cortisol:cortisone ratios in males
and females (p = 0.0486) at risk for cardiovascular disease. In rats, corticosterone (CORT)
(p = 0.0275) and deoxycorticosterone (p = 0.0298) levels as well as the CORT:testosterone
ratio (p = 0.0009) decreased following Rooibos consumption. The inactivation of cortisol was
investigated in vitro by expressing 11!-hydroxysteroid dehydrogenase type 1 (11!HSD1) and
type 2 (11!HSD2) in CHO-K1 cells. Rooibos inhibited 11!HSD1, which resulted in a signif-
icant reduction in the cortisol:cortisone ratio (p < 0.01). No significant effect was detected
on 11!HSD2. In vitro studies in adrenal H295R cells showed that Rooibos and rutin, one of
the more stable flavonoid compounds present in Rooibos, significantly reduced the levels of
cortisol and CORT in cells stimulated with forskolin to mimic a stress response.
Conclusion: In vivo studies demonstrate that Rooibos significantly decreased glucocorticoid
levels in rats and steroid metabolite ratios linked to metabolic disorders—cortisol:cortisone in
humans and CORT:testosterone in rats. Results obtained at cellular level elucidate possible
mechanisms by which these effects were achieved.
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1 Introduction
Rooibos is a popular tisane or herbal teamade from the stems
and leaves of the fynbos plant, Aspalathus linearis, which is
unique to the Western Cape region of South Africa. Rooi-
bos has gained popularity globally as a health drink, and
while Germany and the Netherlands have for many years
commanded the greatest export market, export of Rooibos
to the UK, USA, and Japan has risen steadily, Website:
oxycorticosterone; H6PDH, hexose-6-phosphate dehydrogenase;
UPLC-MS/MS, ultra-performance liquid chromatography/tandem
mass spectrometry
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www.ppecb.com [1, 2]. Although local Rooibos sales have
also increased [2], it is consumed mainly as an herbal “tea,”
competing with coffee and varieties of Camellia sinensis. In
1997, functional teas already comprised 25% of tea sales
in the USA [3] and Rooibos has since joined the healthy
dietary trends as a functional beverage in the USA, (Web-
site: www.PreparedFoods.com) [4]. While Rooibos is caffeine
free with very low tannin levels, it is also a rich source of
polyphenols. Within this group of compounds, flavonoids
have been shown to exhibit a wide range of activities, with
the daily consumption of tea contributing substantially to-
ward dietary flavonoid intake. Rooibos contains a unique
flavonoid profile, which is altered due to oxidation during
fermentation, with the process resulting in a significant loss
of antioxidant activity [5]. Rooibos is manufactured both as
a fermented and unfermented product. The former is pro-
duced by first fermenting shredded plant material for 12–
14 h in mounds in which the temperature increases to ±
40!C. This process results in the leaves becoming reddish
brown in color, after which the material is sun-dried. Unfer-
mented Rooibos is generally produced by spreading shredded
plant material in thin layers to minimize drying time in the
sun, thus maintaining the green color and reducing oxida-
tive changes. While fermentation decreases antioxidant activ-
ity, aspalathin and nothofagin are the two compounds most
affected by the fermentation process [6].
Anecdotal evidence suggests that Rooibos aids in the al-
leviation of depression, anxiety and insomnia—ailments as-
sociated with stress and which are generally linked to the
endocrine system. To date, very little clinical data are avail-
able on the biological effects of Rooibos on the endocrine
system. Although soy flavonoids have been shown to inhibit
cortisol production in H295R cells, an adrenal cell model, the
effect of phytochemicals on steroidogenesis in vivo remained
undetermined [7]. Our recent report showed that Rooibos sig-
nificantly influenced the outcome of steroid hormone biosyn-
thesis in H295R cells stimulated with forskolin to mimic a
stress response [8].
In the adrenal, the biosynthesis of glucocorticoids, min-
eralocorticoids, and adrenal androgens from the com-
mon precursor, cholesterol, is catalyzed by the cytochrome
P450 (P450) enzymes and 3"-hydroxysteroid dehydrogenases
(3"HSD), with cytochrome P450 11"-hydroxylase (CYP11B1)
catalyzing the production of corticosterone (CORT) and cor-
tisol from their respective precursors, deoxycorticosterone
(DOC) and deoxycortisol. CORT can also be further metabo-
lized to aldosterone by aldosterone-synthase in the mineralo-
corticoid pathway [9]. Glucocorticoids mediate their effects
via the glucocorticoid receptor, with their availability being
dependent on the activity of the 11"-hydroxysteroid dehydro-
genase (11"HSD) isozymes. The conversion of cortisol and
CORT to their inactive keto-metabolites, cortisone and 11-
dehydrocorticosterone (11-DHC), respectively, is catalyzed by
11"HSD type 2 (11"HSD2) (Fig. 1). This enzyme is expressed
mainly in mineralocorticoid target tissues such as the kidney
and colon, where it protects the mineralocorticoid receptor
Figure 1. Interconversion of cortisol and cortisone as well as
CORT and 11-DHC by 11"HSD type 1 and 2.
from cortisol, which binds with a high affinity. Impaired ac-
tivity of 11"HSD2 has been shown to result in sodium reten-
tion, ultimately leading to hypertension [10]. 11"HSD type 1
(11"HSD1) is a bidirectional enzyme expressed in the liver,
bone, and adipose tissue, catalyzing the interconversion of
cortisone and 11-DHC to cortisol and CORT, respectively.
11"HSD1 has been identified as a therapeutic target, since
it is implicated in various clinical conditions such as obe-
sity, metabolic syndrome, and type 2 diabetes mellitus [11].
The maintenance of normal glucocorticoid levels is therefore
critical in maintaining hormonal homeostasis.
In this study we investigated the influence of Rooibos
consumption on glucocorticoid plasma levels in human test
subjects at risk for CVD and in male Wistar rats. The influ-
ence of Rooibos on the inactivation of cortisol was further
investigated in Chinese hamster ovary (CHO-K1) cells ex-
pressing 11"HSD. The influence of rutin was subsequently
investigated at cellular level in the H295R cell model.
2 Materials and methods
2.1 Materials and reagents
Unfermented Rooibos was provided by the South African
Rooibos Council (Rooibos LTD-BPK, Clanwilliam, South
Africa). Nucleobond R© AX plasmid preparation kits were
purchased from Machery-Nagel (Duren, Germany). Mirus
TransIT R©-LT1 transfection reagent was purchased from
Mirus Bio Corporation (Madison, WI, USA). Penicillin–
streptomycin, fetal calf serum, and trypsin–EDTA were ob-
tained from Gibco BRL (Gaithersburg, MD, USA). Deuter-
ated cortisol (9,11,12,12-D4-cortisol) was purchased from
Cambridge isotopes (Andover, MA, USA). Steroids, rutin,
forskolin, Dulbecco’s modified Eagle’s Medium (DMEM),
and an MTT assay kit were purchased from Sigma-Aldrich
(St. Louis, MA, USA). DMEM/F12 and gentamicin were pur-
chased from Invitrogen/Gibco (Grand Island,NY,USA). Cos-
mic calf serumwas supplied byHyClone R©, ThermoScientific
(South Logan, UT, USA). A bicinchoninic acid (BCA) protein
determination kit was purchased from Pierce (Rockford, IL,
USA). The UPLC BEH C18 column was purchased fromWa-
ters (Milford, MA, USA). The Kinetex PFP column and SPE
columns (Strata-X 33# Polymetric Reversed Phase, 200mg/3
mL) were obtained from Phenomenex (Torrance, CA, USA).
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All other chemicals were of the highest grade and supplied
by trustworthy scientific supply houses.
2.2 Methanolic extractions of unfermented Rooibos
UnfermentedRooibos plantmaterial (30 g)was extractedwith
chloroform (300 mL) for 8 h using a glass soxhlet extractor
fitted with a double wall condenser, followed by a methanol
(300mL) extraction for 8 h. Extracts were protected from light
and oxygen at all times to avoid any compositional changes.
The methanolic extract was dried on a rotary evaporator and
the vacuum released under nitrogen. One gram of Rooibos
leaves yielded 0.158 g extract. The dried extract was resus-
pended in deionized water, centrifuged at 6000× g for 5 min
and stored in aliquots at −20!C. Extracts were prepared at
a concentration of 20 mg dried extract/mL for in vitro as-
says and at a concentration of 160 mg dried extract/mL for
administration to rats. The extracts were subsequently ana-
lyzed using the HPLC-DAD method as previously published
by Beelders et al. [12].
2.3 Preparation of human blood samples
Plasma samples were obtained from the study conducted by
Marnewick et al. [13]. In this study, the effect of Rooibos was
assessed on oxidative stress in 40 adult subjects at risk for
CVD. Briefly, the study included 24 females and 16 males
between the ages of 30 and 60 years, with at least two or more
risk factors for coronary heart disease that included hyper-
cholesterolemia, hypertension, or an increased BMI, while
not being medicated. A single group intervention design was
followed, consisting of two intervention periods. Subjects
first entered a 2-week washout period (control), during which
food and beverages with high flavonoid content were elim-
inated, followed by a 6-week intervention period (Rooibos
intervention) in which the same subjects consumed six cups
of fermented Rooibos per day (15 g Rooibos leaves/subject).
Fasting (10 AM-12 AM) blood samples were collected on
completion of each period and centrifuged at 1000 × g for
10 min at 4!C. The plasma samples (500 "L) were subse-
quently diluted with deionized water (1:1), followed by the
addition of 15 ng D4-cortisol. Diluted plasma samples, 1 mL,
were vortexed with 1 mL ACN and 4 mL ethyl acetate for
10 min. Phases were separated by centrifugation at 500 × g
for 10 min, the organic phase removed and evaporated under
nitrogen. The dried residue was resuspended in 250 "L
methanol, followed by the addition of 1 mL deionized water
prior to SPE of steroid metabolites. Plasma samples were
applied to Strata-X SPE columns, preconditioned with 3 mL
methanol and 3 mL deionized water. Columns were washed
with 3 mL deionized water and 3 mL 30% methanol.
Steroids were eluted with 1 mL methanol and the eluent
dried under nitrogen. The dried residue of each sample was
resuspended in 150 "L methanol and stored at −20!C until
ultra-performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) analysis.
2.4 Rat study
This study was cleared the by the University of Stellen-
bosch Animal Research Ethics Committee (reference nr.
2009B02007) and conformed to the “Guide for the Care and
Use of Laboratory Animals” published by the National In-
stitutes of Health (NIH publication 85–23, revised 1996).
Twenty adult male Wistar rats were housed in standard rat
cages (5 rats/cage) and fed standard rat chow and tap water
ad libitum. Conditions were kept at 21!C with lights set to
a 12:12-h reversed light-dark cycle (lights on at 7 PM). Rats
were divided into two weight-matched experimental groups
(n= 10 each) assigned as follows: (i) control group, subjected
to two daily placebo treatments (1 mL water/kg body mass)
for a period of 10 consecutive days, administered via oral
gavage; (2) Rooibos group, maintained as the control group,
receiving Rooibos treatments instead of placebo treatments.
Methanolic extracts of unfermented Rooibos were prepared
as described in Section 2.2. Rats received a dosage equivalent,
in terms of soluble solids, to the Rooibos infusion consumed
by human subjects (15 g Rooibos leaves/subject daily). A
dose translation factor of 6.16 [14] was used to calculate the
rat dosage of 0.25 g Rooibos leaves/rat daily. The rats were
administered twice the calculated dose due to the Rooibos
leaf extract retaining moisture when dried on the rotary evap-
orator. The rats, with an average mass of 250 g, thus received
a total of 0.5 g Rooibos leaves/rat (80 mg Rooibos extract/rat),
which was administered twice daily in a dosage of 0.25 g
Rooibos leaves/rat (40 mg Rooibos extract/rat) in a volume of
250"Lper gavage. Prior to the interventionprotocol, ratswere
accustomed to the investigator by handling and weighing the
animals twice daily (7 AM and 7 PM), 7 times per week for
4weeks. During the experimental protocol, rats were weighed
once daily (7AM), and received two oral treatments daily
(7 AM and 7 PM) for 10 consecutive days. On the 11th day of
the intervention, rats were sacrificed via decapitation between
8 AM and 11 AM. Trunk blood was collected via a hep-
arinized funnel into lithium heparin tubes and centrifuged
at 1000 × g for 10 min at 4!C. Plasma samples, 1.5 mL,
were subsequently diluted as described in Section 2.3, and
following the addition of 15 ng D4-cortisol, the samples
were incubated for 1 h at 60!C. Samples were centrifuged at
1000× g for 10 min at 4!C, after which steroids were isolated
from the resulting supernatant using SPE as described in
Section 2.3.
2.5 Enzyme assays in transiently transfected
CHO-K1 cells
CHO-K1 cells were grown at 37!C and 5% CO2 in DMEM
containing 0.9 g/L glucose, 0.12% NaHCO3, 10% fetal
bovine serum, and 1% penicillin–streptomycin. Cells were
plated into 12 well plates (1 mL/well, 1 × 105 cells/mL)
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24 h prior to transfection. CHO-K1 cells were transiently
cotransfected with a total of 1 !g DNA (0.5 !g human
11"HSD1/pCR3 and 0.5 !g human hexose-6-phosphate de-
hydrogenase (H6PDH)/pcDNA3.2 or 0.5 !g pCIneo with no
DNA insert) using 3 !L Mirus TransIT R©LT1 transfection
reagent per mL according to the manufacturer’s instructions.
H6PDH was added to stimulate the oxoreductase activity of
11"HSD1. CHO-K1 cells were also cotransfected with 0.5 !g
human 11"HSD2/pCR3 plasmid DNA and 0.5 !g pCIneo,
using the same protocol. Cells were incubated for 72 h af-
ter which cortisol (1 !M) and cortisone (1 !M) were added
to the medium. 11"HSD1 and 11"HSD2 activities were as-
sayed in the absence and presence of Rooibos by the addition
of 50 !L unfermented Rooibos extract (final concentration,
1 mg dried extract/mL). After 24 h, the medium (500 !L)
was removed and steroids extracted from the media using
a 10:1 volume of dichloromethane to culture medium. The
mixture was vortexed for 2 min, centrifuged at 500 × g for
5 min. The dichloromethane phase was dried under nitro-
gen, resuspended in 150 !L methanol and stored at −20#C
until UPLC-MS/MS analysis. After each assay the cells were
washed with PBS (10 mM, pH 7.4), collected in the same
buffer and sonicated prior to protein determination by the
Pierce BCA R© method.
2.6 Steroid metabolism in H295R cells
H295R cells were grown to confluency at 37#C and 5%
CO2 in growth medium (DMEM/F12, supplemented with L-
glutamine, 15 mM HEPES, pyridoxine, 1.125 g NaHCO3/L,
1% penicillin streptomycin, 0.01% gentamicin, and 10% cos-
mic calf serum). Steroid metabolism was assayed as fol-
lows: Cells were plated into 12 well plates (1 mL/well,
4 × 105 cells/mL) and incubated for 48 h. The medium was
subsequently replaced with experimental medium (growth
medium containing 0.1% cosmic calf serum) and cells were
incubated for 12 h after which the appropriate treatments
were added in experimental medium. Steroid metabolism
was assayed in the presence of Rooibos, by the addition
of 50 !L extract per well (final concentration, 1 mg dried
extract/mL) and in the presence of rutin, added to a final
concentration of 10 !M, under basal and forskolin (10 !M)
stimulated conditions. After 48 h, the medium (500 !L) was
removed and 15 ng D4-cortisol was added as an internal stan-
dard. Steroids were extracted and the protein content deter-
mined as described in Section 2.5. After each assay, the cells
were washed with, and collected in PBS (10mM, pH 7.4), and
sonicated prior to protein determination by the Pierce BCA R©
method.
2.7 UPLC-MS/MS separation and quantification of
steroid metabolites
Steroid metabolites from human plasma, and conversion
assays in CHO-K1 and H295R cells, were separated by
UPLC (ACQUITY UPLC, Waters, Milford, MA, USA) using
a Phenomenex UPLC Kinetex PFP (2.1 mm × 100 mm,
2.6 !m) column as previously described [8]. Steroid metabo-
lites from rat plasma were separated by UPLC (ACQUITY
UPLC) using a Waters UPLC BEH C18 (2.1 mm × 50
mm, 1.7 !m) column as previously described by Storbeck
et al. [15]. A Xevo triple quadrupole mass spectrometer
(Waters, Milford, MA, USA) was used for quantitative
mass spectrometric detection. All steroids were analyzed in
multiple reaction monitoring mode using an electrospray in
the positive ionization mode (ESI+). The following settings
were used: capillary voltage of 2.8 kV, cone voltage 15–50
V, collision energy 3–32 eV, source temperature 100#C,
desolvation temperature 500#C, desolvation gas 1000 L/h
and cone gas 50 L/h. Calibration curves were constructed
using weighted (1/x2) linear least squares regression. Data
were collected with the MassLynx 4.1 software program.
2.8 Cell viability
Confluent CHO-K1 cells were plated out in a 96 well plate
(100!L, 1× 105 cells/mL) and incubatedwith Rooibos extract
(1 mg/mL) for 24 h. Confluent H295R cells were plated out
in a 96 well plate (100 !L, 4 × 105 cells/mL) and incubated
with Rooibos extract (1 mg/mL), rutin (10 !M), and forskolin
(10!M) for 48h.Cell viabilitywas subsequently assayedusing
an MTT toxicology assay kit according to the manufacturer’s
instructions. A color-standardized control (media containing
1 mg/mL Rooibos extract) was included to compensate for
the possible interference of the Rooibos color with the assay.
The following absorption values were obtained: cells exposed
to media only ($A, 0.335), cells exposed to media containing
1 mg/mL Rooibos extract ($A, 0.334) and cells exposed to
media containing 10 !M rutin ($A, 0.305). Since Rooibos
and rutin did not have a significant influence on cell viability,
the effects of these compounds on steroid production in vitro
were assayed at abovementioned concentrations.
2.9 Statistical analysis
Data from in vivo studies are summarized as boxplots to il-
lustrate and compare the distribution of the steroid hormone
levels for rats, stratified by group (control or+Rooibos) and in
humans, stratified by treatment (control or+Rooibos) within
gender. Boxplots show the minimum, maximum (whiskers),
first and third quartiles (bottom and top of box) and median
(line inside box) of each group. If there were outliers, they
are depicted as dots and the whiskers extended to the next
ordered value. Some distributions were skewed, illustrated
by the outliers, and therefore those outcomes (testosterone,
CORT:testosterone, cortisol:cortisone, cortisol:testosterone
and cortisol:DHEA-S) were log-transformed to approximate
normality, prior to analysis, for validity. The association of age
with basic characteristics, after adjusting for gender,were also
tested. General linear models were used to compare variables
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Table 1. Major phenolic compounds (!g) present in the methanolic extract of unfermented Rooibos plant material and in the extract
administered to rats and cells
Flavonoid compounds Rooibosa) Ratsb) Cellsc)
Aspalathin 23 560.0 ± 1035.0 11 930.0 ± 523.8 149.1 ± 6.5
Nothofagin 4915.0 ± 408.7 2488.0 ± 206.9 31.1 ± 2.6
Rutin 621.9 ± 28.1 314.9 ± 14.3 3.9 ± 0.2
Quercetin-3-O-robinobioside 1138.0 ± 53.6 576.1 ± 27.1 7.2 ± 0.3
Orientin 2356.0 ± 61.2 1193.0 ± 30.9 14.9 ± 0.4
Isoorientin 3153.0 ± 17.7 1597.0 ± 8.9 20.0 ± 0.1
Vitexin 435.7 ± 27.6 220.6 ± 14.0 2.8 ± 0.2
Isovitexin 477.7 ± 25.7 242.1 ± 13.2 3.0 ± 0.2
Values are expressed as the mean ± SEM.
a) Flavonoids extracted from 1 g unfermented Rooibos leaves (methanolic extraction).
b) Flavonoids present in Rooibos extract administered per rat per day.
c) Flavonoids present in Rooibos extract administered to CHO-K1 cells (24 h) and H295R cells (48 h) per mL media.
between groups of rats as well as general characteristics of the
human group between genders. Since the same human sub-
jectswere tested for both the control andRooibos intervention
period, the correlation between these pairs of measurements
were taken into account by including random effects for indi-
viduals in mixed-effects linear models. We tested for gender
differences in the effect of Rooibos (statistical interaction be-
tween gender and Roooibos group) and where there was no
interaction, we tested for difference between Rooibos groups,
adjusted for gender. All p-values, effect sizes, and confidence
intervals reported are from these models. In vivo data were
analyzed in base R and R package nlme, freely available from
www.r-project.org. The data from CHO-K1 cells were ana-
lyzed with an unpaired t-test, while the H295R data were
analyzed with a one-way ANOVA, followed by a Newman–
Keuls multiple comparison test using GraphPad Prism (ver-
sion 5) (GraphPad Software, San Diego, CA, USA). A value of
p < 0.05 was considered statistically significant.
3 Results
3.1 Analysis of methanolic extracts of unfermented
Rooibos
The methanolic extract of unfermented Rooibos used in the
rat study and in our in vitro experiments (H295R and CHO-
K1 cells) was analyzed for polyphenols using HPLC-DAD as
previously published [12]. Quantification of the major phe-
nolic compounds (Table 1) showed that, per gram unfer-
mented Rooibos leaves, the dihydrochalcones were the most
abundant flavonoids present in the extract, with aspalathin
being 4.8-fold higher than nothofagin. Within the group of
flavones, isoorientin, and orientin levels were considerably
higher (6-fold) than those of vitexin and isovitexin. Analyses
of the flavonols showed that the rutin isomer, quercetin-3-O-
robinobiocide was present at levels 1.8-fold higher than that
of rutin. The rats, with an averagemass of 250 g, each received
a total of 18.56 mg of the major phenolic compounds daily,
while the final concentration of these compounds ranged
from 6.4 to 330 !M in the media to which the CHO-K1 and
H295R cells were exposed.
In order to ascertain the major phenolic compounds
present in fermented Rooibos, these compounds were subse-
quently also quantified in a methanolic extract of fermented
Rooibos as well as aqueous extracts of fermented and un-
fermented Rooibos (Supporting Information Table 1). The
analyses show that the greatest difference between the aque-
ous extract of fermented Rooibos and the methanol extract of
unfermented Rooibos lies in aspalathin and nothofagin levels
being higher, 45.7-fold and 38.9-fold, respectively, in unfer-
mented Rooibos. The flavones, orientin, isoorientin, vitexin,
and isovitexin were ± 2.0-fold higher in unfermented Rooi-
bos, while the flavonols were also detected at higher levels,
rutin (5.5-fold), and quercetin-3-O-robinobiocide (1.6-fold).
3.2 Analysis of plasma steroid levels in human
subjects following Rooibos consumption
Human plasma was analyzed for the levels of cortisol, corti-
sone, dehydroepiandrosterone-sulfate (DHEA-S) and testos-
terone. The effect of Rooibos on cortisol (Fig. 2A), testos-
terone (Fig. 2C), and DHEA-S (Fig. 2D) levels in both male
and female subjects did not reach statistical significance.
Rooibos consumption did, however, significantly increase the
levels of cortisone in males by 9.1 nmol/L (95% CI: 1.3–17.0
nmol/L; p = 0.0465) but not in females (Fig. 2B). The corti-
sol:cortisone ratio, however, was significantly lower in both
male and female subjects followingRooibos consumption, re-
sulting in an estimated reduction of 6.7% (95%CI: 0-12.9%; p
= 0.0486) after adjusting for gender (Fig. 3A). No significant
effects were detected on the cortisol:testosterone (Fig. 3B) or
cortisol:DHEA-S (Fig. 3C) ratios in male or female subjects.
3.3 Analysis of plasma steroid levels in male Wistar
rats following Rooibos consumption
Rat plasma was analyzed for the levels of CORT, DOC,
11-DHC, and testosterone. A significant reduction of
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Figure 2. Boxplots of human plasma (A) cortisol, (B) cortisone, (C) testosterone, and (D) DHEA-S levels in male and female subjects in the
absence (control) and presence of Rooibos (+Rooibos). The estimated effect of Rooibos on cortisone was an increase of 9.1 nmol/L (95%
CI: 1.3–17.0 nmol/L) in male subjects only. No other significant effects were detected.
131.6 nmol/L was observed in CORT plasma levels of rats
receiving Rooibos treatments (95% CI: 16.3–246.8 nmol/L;
p = 0.0275) compared to the control group (Fig. 4A). In ad-
dition, plasma DOC levels were 1.75 nmol/L lower in rats
consuming Rooibos (95% CI: 0.19–3.32 nmol/L; p = 0.0298;
Fig. 4B). The influence of Rooibos on the levels of 11-DHC
(Fig. 4C) and testosterone (Fig. 4D) did not reach statistical
significance. Although Rooibos only decreased the CORT:11-
DHC ratio to a level approaching significance (p = 0.0624;
Fig. 5A), it caused a 57% reduction in the CORT:testosterone
ratio (95% CI: 32–72%; p = 0.0009; Fig. 5B).
3.4 Cortisol and cortisone conversion assays by
11!HSD in transiently transfected CHO-K1 cells
The influence of Rooibos (1 mg extract/mL) on the inter-
conversion of cortisol and cortisone by 11!HSD1 as well
as on the conversion of cortisol to cortisone by 11!HSD2
was assayed in CHO-K1 cells. 11!HSD1 was assayed with
and without H6PDH, the cofactor regenerating system that
stimulates the oxoreductase activity of 11!HSD1. After a
24 h incubation period with cortisone (reductase/forward re-
action) in cells co-expressing 11!HSD1 and H6PDH, the ad-
dition of Rooibos resulted in a significant reduction (68%,
p < 0.01) in the cortisol:cortisone ratio (Fig. 6A). After the
same incubation period with cortisone in cells expressing
11!HSD1 alone, the addition of Rooibos also resulted in
a significant decrease in the cortisol:cortisone ratio (56%,
p < 0.01) even though the ratio of cortisol:cortisone in the
absence of Rooibos was lower than that in cells co-expressing
11!HSD1 and H6PDH. The increased cortisol:cortisone ra-
tios in the presence of H6PDH is due to stimulated oxo-
reductase activity, resulting in increased levels of cortisol. The
same experimentwas carried out using cortisol as substrate to
assay the dehydrogenase/reverse reaction of 11!HSD1. After
24 h, Rooibos significantly reduced the cortisol:cortisone ratio
in cells co-expressing 11!HSD1 andH6PDH (39%, p< 0.01)
as well as in cells expressing 11!HSD1 only (33%, p < 0.01;
Fig. 6B). No effect was observed on the enzymatic activity of
11!HSD2 when the cortisol:cortisone ratio was determined
in the presence of Rooibos (Fig. 6C).
3.5 Analysis of steroid metabolites in adrenal H295R
cells
The effect of rutin (10 "M) on steroid metabolism in H295R
cells was investigated (Table 2) and compared with the effect
previously observed in the presence of Rooibos (1 mg/mL
extract) under basal and forskolin-stimulated (10 "M) con-
ditions [8]. While Rooibos significantly reduced the levels of
deoxycortisol (P < 0.01), DHEA-S (p < 0.01), A4 (p < 0.01),
11!OHA4 (p< 0.01) and testosterone (p< 0.001) under basal
conditions, the effect of rutin was negligible. Upon forskolin
stimulation, however, Rooibos significantly decreased the
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Figure 3. Boxplots of human plasma (A) cortisol:cortisone, (B)
cortisol:testosterone and (C) cortisol:DHEA-S ratios in male and
female subjects in the absence (control) and presence of Rooi-
bos (+Rooibos). The estimated effect of Rooibos on the corti-
sol:cortisone ratio was a decrease of 6.7% (95% CI: 0–12.9%) in
both genders. No other significant effects were detected.
levels of DOC (p < 0.01), deoxycortisol (p < 0.001), CORT
(p < 0.001), cortisol (p < 0.001) and cortisone (p < 0.01),
while rutin significantly reduced the levels of deoxycortisol
(p< 0.01), CORT (p< 0.05) and cortisol (p< 0.001). Rooibos
and rutin both reduced the levels of A4 (p< 0.001), 11!OHA4
(p< 0.001) and testosterone (p< 0.001) under stimulated con-
ditions, however, the levels of DHEA-S was reduced in the
presence of rutin only (p < 0.001).
4 Discussion
Fermented Rooibos, which exhibits significantly lower an-
tioxidant activity and contains lower levels of aspalathin and
nothofagin than unfermented Rooibos [6], was consumed for
6 weeks during the human study, after which we analyzed
plasma steroid levels. Unfermented Rooibos was used in the
rat study and in vitro experiments and analyses of the major
polyphenols in our methanolic extract (Table 1) detected sig-
nificantly higher levels of aspalathin, nothofagin and rutin,
while the other flavonoids analyzed were± 2-fold higher than
the compounds in the aqueous extract of fermented Rooibos
(Supporting Information Table 1). It should be noted that the
aqueous extract was prepared with a different batch of fer-
mented Rooibos as that which was consumed in the human
study.While it can be assumed that aspalathin andnothofagin
levels would differ most significantly to that of unfermented
Rooibos, there may also be variation in fermented Rooibos
samples due to factors such as the product originating from
different plantmaterial, the fermentation and drying process,
as well as natural variation [12]. Interestingly, when compar-
ing the aqueous extract and the methanolic extract of un-
fermented Rooibos, the flavone extraction was higher in the
organic extract. Although the aglycones were not analyzed,
these hydrophobic compounds may also be present in the
methanolic extract, however, it is also possible that they were
removed in the chloroform fraction during the extraction pro-
cess. Comparisons of fermented and unfermented Rooibos
showed that aspalathin and nothofagin levels are significantly
reduced in fermented Rooibos, as has also been reported by
other groups [6, 12].
We first analyzed the effect of Rooibos consumption in
vivo—on circulating glucocorticoid levels, cortisol and its in-
active keto-metabolite, cortisone, in the human study. Our
analyses showed that cortisone levels increased significantly
(p= 0.0465) inmale subjects following Rooibos consumption
(Fig. 2B), while the effect on cortisol levels in both male and
female participants was negligible (Fig. 2A). Since in vivo an-
imal studies have fewer limitations and are conducted under
more controlled and standardized conditions than is possi-
ble for human studies, the influence of Rooibos on adrenal
steroidogenesis was further investigated in male Wistar rats,
minimizing the risk of effects being masked by confounding
factors. Due to the lack of adrenal cytochrome P450 17"-
hydroxylase/17,20-lyase (CYP17A1) expression, CORT is the
principal plasma glucocorticoid in rats [9] and the measure-
ment thereof is generally used an indicator of stress. Plasma
levels of CORT (p= 0.0275; Fig. 4A) and its precursormetabo-
lite, DOC (p = 0.0298; Fig. 4B), were reduced significantly
in rats receiving Rooibos, compared to the control group.
The effect of Rooibos on the inactive metabolite of CORT,
11-DHC (Fig. 4C), however, did not reach statistical signifi-
cance. The reduction observed in CORT and DOC levels indi-
cates that Rooibos reduced glucocorticoid production in rats,
likely due to inhibition of CYP11B1, and possibly upstream
steroidogenic enzymes such as 3!HSD and cytochrome P450
21-hydroxylase (CYP21A2). We have previously shown that
Rooibos extracts inhibit CYP17A1 and CYP21A2 [8], while a
study by Ohno et al. [7], showed that 3!HSD and CYP21A2
weremore sensitive to an array of flavonoid compoundswhen
compared to other adrenal steroidogenic enzymes.
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Figure 4. Boxplots of plasma (A) CORT, (B) DOC, (C) 11-DHC and (D) testosterone levels in male Wistar rats in the absence (control) and
presence of Rooibos (+Rooibos). The estimated effect of Rooibos on CORT was a decrease of 131.6 nmol/L (95% CI: 16.3–246.8 nmol/L)
and an estimated decrease of 1.75 nmol/L (95% CI: 0.19–3.32 nmol/L) was observed on the levels of DOC. No other significant effects were
detected.
Figure 5. Boxplots of plasma (A) CORT:11-DHC and (B)
CORT:testosterone ratios in male Wistar rats in the absence (con-
trol) and presence of Rooibos (+Rooibos). The estimated effect of
Rooibos on the CORT:testosterone ratio was a decrease of 57%
(95% CI: 32–72%). No other significant effects were detected.
We subsequently analyzed the effect of Rooibos on steroid
metabolite ratios, since ratios rather than absolute con-
centrations alone are generally used to better characterize
clinical conditions linked to stress related diseases. Corti-
sol:cortisone (humans) and CORT:11-DHC (rats) ratios in
circulating blood reflect the interconversion of active gluco-
corticoids and their inactive keto-metabolites by 11!HSD1
and 11!HSD2. In the human study, a significant reduction
in the cortisol:cortisone ratio of both male and female sub-
jects (p = 0.0486) was detected following Rooibos consump-
tion (Fig. 3A), suggesting that Rooibos favors the inactivation
of cortisol. It is possible that the reduced cortisol:cortisone
ratio could be attributed to altered 11!HSD activity, since in
vivo cortisol levels remained within the normal range. Sig-
nificantly decreased cortisol levels may lead to an increase
in the activity of the HPA axis and undesired stimulation of
the adrenal by ACTH to produce cortisol [16]. In rats, the
CORT:11-DHC ratio decreased to a level approaching signifi-
cance (p= 0.0624) following Rooibos consumption (Fig. 5A).
Although Rooibos significantly reduced rat CORT levels, the
effect on 11-DHC was negligible, possibly contributing to
lowering the effect observed on the CORT:11-DHC ratio.
The reduction observed in the cortisol:cortisone ratio in
human subjects following Rooibos consumption prompted
us to examine the effect of Rooibos on glucocorticoid inac-
tivation by the two 11!HSD isozymes at cellular level. Co-
transfection of 11!HSD1 and H6PDH in CHO-K1 cells sim-
ulates in vivo conditions in which the oxoreductase activity
of 11!HSD1 predominates, while virtually eliminating the
dehydrogenase activity [17]. High ratios of NADPH:NADP,
required for the oxoreductase activity of 11!HSD1, are main-
tained by H6PDH, which converts glucose-6-phosphate to 6-
phospho-gluconolactone, regenerating NADPH from NADP
[18]. Enzyme activity was assayed in the absence and pres-
ence of Rooibos extract (1 mg/mL) using either 1 "M corti-
sone or 1 "M cortisol as substrate. The addition of H6PDH
resulted in a 1.7-fold increase in the oxoreductase activ-
ity, eliminating the dehydrogenase activity completely, with
no cortisone being detected after 24 h (results not shown),
which is in agreement with data obtained by Bujalska et al.
[17]. In the present study, Rooibos significantly reduced the
cortisol:cortisone ratio in cells expressing 11!HSD1, both in
the absence and presence of H6PDH, suggesting that Rooi-
bosmodulates 11!HSD1 and does not interfere withH6PDH
and the cofactor regenerating system. From the data it is
clear that Rooibos reduces the cortisol:cortisone ratio when
either cortisone (Fig. 6A) or cortisol (Fig. 6B) conversion is
assayed in cells expressing 11!HSD1, in the absence and
presence of H6PDH. 11!HSD2 activity was, however, unaf-
fected by Rooibos with no effect on the cortisol:cortisone ratio
being detected after 24 h (Fig. 6C). It is widely reported that
11!HSD1 plays a pivotal role in the regulation of glucocor-
ticoid action, with dysregulation and subsequent long-term
glucocorticoid excess being strongly associated with numer-
ous clinical conditions linked to themetabolic syndrome [19].
Selective 11!HSD1 inhibitors tested in rodents have been
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Figure 6. Cortisol:cortisone ratios after 24 h in CHO-K1 cells transiently transfected with 11!HSD1 and 11!HSD2. 11!HSD1 expression,
with and without H6PDH, was assayed with (A) 1 "M cortisone as substrate and (B) 1 "M cortisol as substrate, while 11!HSD2 expression
was assayed with (C) 1 "M cortisol as substrate, in the absence and presence of Rooibos extract (1 mg/mL). The data was analyzed with
an unpaired t-test and results are expressed as the mean ± SEM (**p < 0.01). The data is representative of two independent experiments,
performed in triplicate.
shown to increase insulin sensitivity and decrease endoge-
nous glucose production, together with a reduction in body
mass and circulating lipid levels [18]. It is therefore evident
that 11!HSD1 inhibitors may play a key role in the treatment
of metabolic syndrome and type 2 diabetes.
Since flavonoids have been shown to modulate the ac-
tivity of P450 enzymes and affect steroid hormone biosyn-
thesis [7, 20], we compared the effect of rutin, 10 "M, on
steroid metabolism in H295R cells with the effect previously
observed in the presence of 1 mg/mL Rooibos extract, which
contained rutin at 3.9 "g/mL (6.4 "M), and quercetin-3-O-
robinobiocide at 7.2 "g/mL (11.8 "M) (Table 1). Rutin and
its isomer are reported to form part of the major phenolic
compounds present in Rooibos, however, there is marked
variation between Rooibos production batches [21, 22], with
our analyses also showing rutin to be present in higher lev-
els in unfermented than in fermented aqueous extracts of
Rooibos (Supporting Information Table 1). Analysis of the
Rooibos extract added to the cells, showed that the cells were
exposed to ± 0.5 mM flavonoids. These flavonoids however,
represent only a fraction of the total phenolic compounds
present in Rooibos.
TheH295R cell line is an excellentmodel system for study-
ing the effect of nutraceuticals, dietary supplements and food
additives on steroid hormone biosynthesis, since these cells
express all the steroidogenic enzymes and are capable of pro-
ducing the mineralocorticoids, glucocorticoids, and adrenal
androgens. These cells can also be manipulated by the ad-
dition of forskolin, a diterpene that mimics the effects of
ACTHvia the activation of adenyl cyclase (cAMP) pathways in
adrenal cells, thus imitating a stress response [23]. Analyses of
the total steroid output showed that the influence of rutin was
not as pronounced as that of Rooibos under both basal and
stimulated conditions. Rutin did not influence basal steroid
production significantly, however, upon forskolin stimula-
tion, rutin significantly reduced the total steroid output from
11.1 to 4.9 "M (p< 0.01). While neither rutin nor Rooibos in-
hibited basal CORT or cortisol production significantly, upon
stimulation, rutin reduced the levels of CORT (p < 0.05)
and cortisol (p < 0.001), however, markedly less than the in-
hibitory effect observed in the presence of Rooibos (Table 2).
Rutin also significantly reduced the levels of deoxycortisol
(p < 0.01) under stimulated conditions, however not to the
same extent as Rooibos (p < 0.001). Regarding the inactive
glucocorticoid metabolites, cortisone and 11-DHC, the effect
of both Rooibos and rutin was negligible under basal con-
ditions, however, nonsignificant decreases in 11-DHC and
cortisone production were observed upon forskolin stimula-
tion.However, the contribution of the adrenal toward circulat-
ing levels of inactive glucocorticoid metabolites is negligible,
since the expression of the 11!HSD isoforms is low in the
adrenal [24]. From these results it is clear that rutin inhibits
glucocorticoid production, as well as the respective precursor
metabolites under stimulated conditions. Interestingly, while
rutin decreased cortisol levels significantly in the presence of
forskolin, the effect of Rooibos on cortisol levels was more
prominent, reducing cortisol levels to the levels detected un-
der basal conditions.
We previously showed that Rooibos not only reduced the
flux through the glucocorticoid pathway, but also through
the androgen pathway in forskolin stimulated H295R cells,
prompting us to analyze the plasma levels of testosterone and
DHEA-S in our in vivo investigations. In addition, we also re-
ported that Rooibos inhibited CYP17A1, expressed in COS-1
cells, possibly accounting for the decreased androgen levels
observed in H295R cells [8]. It must be noted that, while the
testes is themajor site of testosteroneproduction inmales, the
adrenal also produces low levels of testosterone in bothmales
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Table 2. Steroid metabolism in H295R cells under basal and forskolin (10 !M) stimulated conditions in the presence of Rooibos (1 mg/mL)
and rutin (10 !M) after 48 h
Steroids Basala) +Rooibosa) +Rutin
Steroid levels (nM) Steroid levels (nM) Steroid levels (nM)
DOC 107.4 ± 13.0 54.0 ± 8.0 125.7 ± 7.0
Deoxycortisol 1741.0 ± 234.1 506.4 ± 23.0** 1998.0 ± 128.9
CORT 241.1 ± 31.6 144.9 ± 13.5 280.2 ± 34.6
Cortisol 670.2 ± 39.3 381.7 ± 63.7 550.3 ± 28.1
11-DHC 9.9 ± 0.3 9.0 ± 0.9 11.8 ± 1.4
Cortisone 6.6 ± 2.2 4.9 ± 0.3 6.0 ± 0.3
DHEA-S 3.5 ± 0.3 9.1 ± 1.0** 5.5 ± 1.1
A4 806.5 ± 115.6 307.4 ± 27.5** 890.9 ± 74.4
11"OHA4 90.1 ± 11.1 162.7 ± 10.6** 83.0 ± 10.7
Testosterone 39.22 ± 3.60 4.79 ± 0.70*** 44.70 ± 3.49
Steroids Forskolina) Forskolin + Rooibosa) Forskolin + Rutin
Steroid levels (nM) Steroid levels (nM) Steroid levels (nM)
DOC 343.2 ± 61.1 104.0 ± 11.0** 510.1 ± 85.8
Deoxycortisol 2757.0 ± 393.1 539.8 ± 26.8*** 1409.0 ± 156.0**
CORT 2062.0 ± 170.5 394.9 ± 27.2*** 1267.0 ± 88.8*
Cortisol 3793.0 ± 285.1 772.1 ± 40.5*** 1246.0 ± 32.3***
11-DHC 11.2 ± 1.4 8.4 ± 1.4 7.1 ± 1.8
Cortisone 11.6 ± 2.7 2.3 ± 0.4** 5.7 ± 2.7
DHEA-S 5.2 ± 0.5 3.8 ± 0.5 1.2 ± 0.6***
A4 1402.0 ± 180.0 259.3 ± 22.6*** 321.2 ± 34.6***
11"OHA4 388.3 ± 16.3 167.0 ± 5.7*** 57.9 ± 7.0***
Testosterone 50.5 ± 6.1 2.4 ± 0.5*** 8.9 ± 1.0***
Steroids are expressed as absolute values (nmol/L). Data was analyzed by a one-way ANOVA, followed by a Dunnett’s multiple comparison
test and results are expressed as the mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001). The data is representative of two independent
experiments, performed in triplicate.
a) Data regarding the influence of Rooibos on basal and forskolin stimulation in H295R cells was reproduced and modified from Schloms
et al. 2012, with permission from Elsevier.
and females due to the expression of 17"-hydroxysteroid de-
hydrogenase type 3 and 5 [24]. In the human study, Rooi-
bos consumption did not affect male or female testosterone
(Fig. 2C) and DHEA-S (Fig. 2D) levels significantly. Since
rat adrenals do not produce DHEA-S [9], we only analyzed
testosterone levels, which showed that the effect of Rooibos
consumption on these levels did not reach statistical signifi-
cance (Fig. 4D). In a study byRosmund et al. [25], it was shown
that altered cortisol:testosterone ratios are prevalent in clinical
conditions such as type 2 diabetes, hypertension, and CVD.
In addition, Smith et al. [26] showed that elevated circulating
cortisol:testosterone ratios are associated with an increased
risk of ischemic heart disease, mediated through insulin re-
sistance. The authors therefore hypothesized that agents ca-
pable of reducing the cortisol:testosterone ratio may improve
insulin resistance and lower the risk of coronary heart disease.
In the human study, Rooibos consumption had no significant
effect on the cortisol:testosterone ratio inmale or female sub-
jects (Fig. 3B), however, in the rat study, Rooibos consump-
tion significantly reduced theCORT:testosterone ratio by 57%
(p= 0.0009; Fig. 5B). We also studied the effect of Rooibos on
the cortisol:DHEA-S ratio in the human study, since it was
recently shown that this ratio is positively associated with the
metabolic syndrome [27]. Analyses of human plasma showed
that the effect of Rooibos on the cortisol:DHEA-S ratio did not
reach statistical significance, even though the subjects were at
risk for CVD, with negligible differences being observed after
the intervention period (Fig. 3C). The lack of statistical power
to detect significance in steroid levels in human plasma could
be attributed to the small number of participants in the study.
It is also possible that the interindividual variation among
the participants regarding steroid levels and age contributed
toward lowering the statistical power. Interestingly, under
stimulated conditions inH295R cells, both Rooibos and rutin
decreased the levels of the adrenal androgens, androstene-
dione (A4), 11"-hydroxyandrostenedione (11"OHA4), and
testosterone significantly (p < 0.001), and, in contrast
to Rooibos, rutin also significantly decreased DHEA-S
levels (p < 0.001; Table 2). DHEA-S, which is syn-
thesized primarily in the adrenal, is the major source
of testosterone in women, while in men, about half
of the total androgen pool is synthesized from these
steroids [28]. Under basal conditions in H295R cells,
Rooibos also reduced the levels of the androgens, A4
(p < 0.01), 11"OHA4 (p < 0.01), and testosterone (p <
0.001), however, the levels of DHEA-S increased significantly
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(p< 0.01). Rutin had no influence on basal androgen produc-
tion in H295R cells.
Fromour data it is clear that rutin did not in all cases result
in the same inhibitory effects brought about by Rooibos in the
adrenal cell model, indicating that the flavonoid composition
of Rooibos results in markedly different inhibitory effects
on adrenal steroidogenic enzymes. The H295R cells were,
however, exposed to higher levels of flavonoid compounds
(Table 1), with aspalathin being present at 330 !M
and nothofagin at 71 !M. We previously assayed both
compounds, and at 10 !M, both aspalathin and nothofagin
decreased 17OHPROG and 11"OHA4 levels, while Rooibos
increased basal production of these steroids. We have also
determined that aspalathin, nothofagin, rutin, and vitexin, at
10 !M, inhibit CYP17A1 and 3"HSD significantly. Interest-
ingly, the activity of CYP11B1 was inhibited significantly by
rutin when deoxycortisol was used as substrate, while vitexin
had no influence on the conversion. In contrast, when DOC
was added as substrate, vitexin’s inhibition was significant
while rutin did not affect the reaction (unpublished data). It is
evident that the phenolic compounds in Rooibos interact dif-
ferently with the enzymes catalyzing steroid hormone biosyn-
thesis, and while some may inhibit specific enzymes, others
may have no influence, with the effects observed also being
substrate dependent. In a recent study byHasegawa et al. [29],
a range of flavone, flavanone, and isoflavone compounds
were assayed inH295R cells. Catechin, amonomeric flavanol
also present in Rooibos, had no effect on any of the steroid
levels assayed, while apigenin increased CYP17A1 products,
PREG, DHEA, and 17OHPROG, and inhibited DOC and A4
production. In addition, the compound also decreased
CYP17A1, CYP21A2 and 3"HSD mRNA expression in
forskolin stimulated H295R cells—effects that were not ob-
served in unstimulated cells [29]. Although this aglycone
has not been identified in Rooibos, its glycosylated deriva-
tives, apigenin-6-C-glucoside (isovitexin), and apigenin-8-C-
glucoside (vitexin) have been identified [12]. Both vitexin and
isovitexin may be converted to apigenin by intestinal mi-
crobacteria, with vitexin having been identified in human
plasma [22]. It should be noted that, in our assays in H295R
cells, in which the cells were exposed to extracts or com-
pounds, the bioavailability and metabolism of the flavonoid
compounds were not taken into account, and data obtained
as such, may not reflect the effect on the system in vivo. Al-
though the influence of Rooibos on steroidogenesis cannot
be attributed to a single flavonoid compound, we showed
that aspalathin, nothofagin [8] and rutin are able to influ-
ence steroid production in H295R cells. Both rutin and as-
palathin have been shown to be present in human plasma
in their unchanged forms following Rooibos consumption.
However, recovery rates were low and marked interindivid-
ual variation in absorption patterns of the human subjects in
the study was evident [22]. Rutin has been shown to be me-
tabolized through the action of intestinal bacterial enzymes
to quercetin, which may be further metabolized to yield phe-
nolic acids [30] as well as methylated and glucuronidated
metabolites [31]. Quercetin may contribute toward the ef-
fect of Rooibos on steroid plasma levels, as it has been
shown to inhibit 3"HSD activity significantly at 10 !M [7].
While it was subsequently shown to have no significant in-
fluence on cortisol production in H295R cells [32], it was
shown to increase intracellular cAMP concentrations and to
induce aromatase activity [33]. While nothofagin was not de-
tected in plasma samples, it was detected in urine samples,
together with aspalathin, as conjugated and as unchanged
metabolites [21]. Whether these phenolic compounds reach
target tissues in their intact form, at physiologically relevant
concentrations, and whether effects are due to their native
structure, is perhaps questionable. However, more than 50
phenolic compounds have, to date, been identified in Rooi-
bos [6, 12]. These dietary polyphenols, and their conjugated
pool of flavonoids produced by intestinal and colonic micro-
biota, which may contribute to their bioavailability, as well
as postabsorption metabolism by hepatic enzymes, suggest
a key role for Rooibos flavonoids in the observed effects on
steroidogenesis.
Although the data obtained in this study does place Rooi-
bos in a favorable position in terms of health benefits, not all
the polyphenol compounds present in Rooibos are necessar-
ily beneficial. Plant polyphenols are ingested daily not only as
part of a normal diet, but also, in many instances, as dietary
supplements. Tea flavonoids have gained popularity as added
value products in the food supplement and health industries
and, being regarded as nutraceuticals, are used to promote
polyphenol-rich products. However, increasing the dosage
does not necessarily mean that the increase may be beneficial
or that more compounds, if any, will reach specific target tis-
sues. Health benefits regarding the ingestion of concentrated
polyphenols are being questioned, as limited in vivo data is
available on the metabolism and absorption thereof. Papers
reporting the beneficial effects of polyphenols, however, far
outweigh those reporting on the antinutritional and toxicity
aspects of polyphenols. Polyphenols taken in high dosages
have been linked to hepatotoxic effects, toxicity, drug interac-
tion as well as estrogenic effects [34], however, these effects
have only been reported when high dosages of concentrated
dietary supplements or purified tea preparations were taken,
which is not the case for the consumption of daily teas or
herbal infusions.
Taken together, our data shows that although the sub-
jects in the human study received a lower dose of flavonoid
compounds (per kg body mass) due to the consumption of
fermented tea, a significant effect on cortisol:cortisone ratios
was nevertheless achieved, indicating that the Rooibos con-
sumed resulted in changes in these steroid levels. This effect
was also observed in CHO-K1 cells when cortisol:cortisone
ratios were analyzed by assaying 11"HSD activity in the pres-
ence of unfermented Rooibos. Interestingly, the significant
decrease in cortisol levels obtained with unfermented Rooi-
bos in the adrenal cell model was not observed in humans,
possibly due to the lower flavonoid intake. In the rats, how-
ever, there was a reduction in plasma glucocorticoids, with
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CORT andDOC levels being reduced significantly, whichwas
also reflected in the data obtained in stimulated H295R cells
in the presence of unfermented Rooibos. While testosterone
levelswere decreased significantly inH295R cells, these levels
remained unchanged in rats, however, a significant decrease
was detected in the CORT:testosterone ratio.
From our data it would appear that Rooibos affects gluco-
corticoid biosynthesis by reducing glucocorticoid production
in the adrenal and/or by favoring the inactivation of glu-
cocorticoids to their inactive keto-metabolites by 11!HSD.
Although a degree of uncertainty exists with regards to the
absorption and bioavailability of the compounds present in
Rooibos, the daily consumption of Rooibos is not associated
with the ingestion of concentrated doses of polyphenols, and
has not been linked to toxic effects. Our in vivo and in vitro
studies suggest a role for Rooibos in the maintenance of nor-
mal glucocorticoid levels, which could suggest therapeutic
applications for Rooibos in the management of stress-related
conditions and metabolic diseases.
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Supporting Information Table S1: Major phenolic compounds present in aqueous and 
methanolic extractions of fermented and unfermented Rooibos. Values are expressed as 
the mean flavonoid content (µg) extracted from 1 g plant material ± SEM. 
 
Aqueous Rooibos extracts Methanol Rooibos extracts 
Flavonoids 
Fermented Unfermented Fermented Unfermented 
Aspalathin 514.8 ± 0.4 21120.0 ± 24.8 927.1 ± 2.4 23560.0 ± 1035.0 
Nothofagin 126.4 ± 3.2 3991.0 ± 1.2 248.1 ± 1.8 4915.0 ± 408.7 
Rutin 114.0 ± 1.2 614.8 ± 2.0 214.8 ± 0.4 621.9 ± 28.1 
Quercetin-3-O-
robinobioside 715.2 ± 6.4 1102.0 ± 7.2 1247.0 ± 5.1 1138.0 ± 53.6 
Orientin 1013.0 ± 4.0 1392.0 ± 2.8 2656.0 ± 1.4 2356.0 ± 61.2 
Isoorientin 1343.0 ± 19.2 2248.0 ± 8.0 3191.0 ± 0.4 3153.0 ± 17.7 
Vitexin 217.2 ± 1.2 268.0 ± 1.6 521.8 ± 1.4 435.7 ± 27.6 
Isovitexin 222.8 ± 2.8 337.2 ± 1.2 485.2 ± 0.9 477.7 ± 25.7 
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4.2 Summary 
 
The data obtained in COS-1 cells and in H295R cells clearly shows that 
Rooibos as well as the flavonoids, aspalathin, nothofagin, orientin, vitexin and rutin 
interact with and inhibit adrenal steroidogenic enzymes, which subsequently 
influences the shunt of metabolites through the mineralocorticoid-, glucocorticoid- 
and adrenal androgen precursor pathways.  
In COS-1 cells, Rooibos significantly inhibited the activities of CYP17A1 and 
CYP21A2, while the inhibitory effect on 3βHSD2 and CYP11B1 was less apparent. 
The five Rooibos flavonoids, regardless of their structural differences, inhibited the 
activities of CYP17A1 and 3βHSD2, while inhibition of downstream enzymes, 
CYP21A2 and CYP11B1 was both flavonoid and substrate specific. The 
dihydrochalcones, aspalathin and nothofagin, inhibited the activity of CYP21A2 
significantly, but not that of CYP11B1. In contrast, the flavones, orientin and vitexin, 
and the flavonol, rutin, inhibited deoxycortisol conversion by CYP11B1 significantly, 
while inhibition of DOC conversion by CYP11B1 as well as PROG and 17OH-PROG 
conversion by CYP21A2 was either negligible or absent. There are thus distinct 
differences between the inhibitory effects of the dihydrochalcones compared to that 
of the flavones and the flavanol, which could be attributed to differences in structural 
flexibility as well as the number and position of their hydroxyl and glucosyl moieties. 
In H295R cells, Rooibos significantly reduced total steroid production under 
both basal and forskolin stimulated conditions. The inhibitory effect was 2-fold greater 
under stimulated conditions, with Rooibos decreasing end products in the 
mineralocorticoid-, glucocorticoid- and adrenal androgen precursor pathways. The 
UPLC-MS/MS method developed for the quantification of steroid metabolites 
produced by H295R cells enabled the analyses of the steroid flux in the respective 
pathways. This novel method enabled the separation and quantification of 21 steroid 
metabolites in the steroidogenic pathways using a single chromatographic separation 
without prior derivitisation. This method has since proved suitable for the 
quantification of steroid metabolites both in vitro and in vivo, enabling analyses of the 
inhibitory profile of compounds and natural products on adrenal steroid hormone 
production.  
Vitexin had the most significant inhibitory effect on overall steroid production in 
H295R cells under basal conditions, followed by nothofagin, aspalathin and orientin. 
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Interestingly, while rutin had no effect under basal conditions, it had the greatest 
inhibitory effect on total steroid production under forskolin-stimulated conditions, 
followed by vitexin, nothofagin, aspalathin and orientin. Considering the steroid flux in 
the steroidogenic pathways, the dihydrochalcones reduced steroid hormone 
production significantly within the glucocorticoid- and adrenal androgen precursor 
pathways under both basal and stimulated conditions, while they had no effect on 
steroid hormone production within the mineralocorticoid pathway. The flavones 
affected steroid hormone production significantly within the three pathways, and 
compared to the dihydrochalcones and the flavonol, the flavones were the only 
compounds that inhibited ALDO production significantly under stimulated conditions. 
Upon stimulation with forskolin, rutin also reduced steroid production significantly in 
the three pathways, with the inhibitory effects within the glucocorticoid- and adrenal 
androgen precursor pathways being significantly greater compared to the inhibition 
by the other compounds. 
In terms of the influence of Rooibos on glucocorticoid production, Rooibos and 
all the flavonoid compounds investigated reduced glucocorticoid levels significantly 
under stimulated conditions, but not under basal conditions, with the exception of 
vitexin. In our analyses of cortisone levels, we detected increased levels of the 
metabolite in response to forskolin stimulation, while it has been shown to decrease 
in adrenal primary cultures when cells were stimulated with ACTH. In this study, 
Rooibos was shown to decrease cortisone significantly under forskolin-stimulated 
conditions. Reports that the human adrenal expresses both 11βHSD isoforms 
prompted further investigation into the effects of Rooibos on these enzymes.  
Rooibos significantly reduced the cortisol:cortisone ratio in CHO-K1 cells expressing 
11βHSD1, suggesting that Rooibos favours the dehydrogenase reaction of 
11βHSD1. These results were obtained both in the absence and presence of 
H6PDH, which suggests that Rooibos modulates the activity of 11βHSD1 without 
interfering with H6PDH. Conversely, Rooibos had no effect on the activity of 
11βHSD2. 
The two in vivo studies further highlighted the influence of Rooibos on adrenal 
steroidogenesis. The consumption of six cups of Rooibos per day by human subjects 
at risk for CVD showed that Rooibos significantly influenced glucocorticoid levels as 
well as steroid metabolite ratios linked to various metabolic diseases. The data 
obtained in experimental rats administered equivalent doses of Rooibos, underlined 
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these findings, showing significantly reduced plasma CORT and DOC levels, while 
also significantly reducing CORT:testosterone ratios. In the human study, the 
cortisol:cortisone ratio was reduced significantly in both males and females, while 
cortisone levels were significantly higher in males only. It is interesting to note that 
testosterone levels were increased in male subjects as well as in male rats receiving 
Rooibos, while increased DHEA-S levels were detected in female subjects.  
Taken together, the data shows that Rooibos affects glucocorticoid 
biosynthesis either by reducing glucocorticoid biosynthesis by the adrenal and/or via 
the inhibition of glucocorticoid activation by 11βHSD1. The observation that Rooibos 
significantly reduced glucocorticoid levels under forskolin stimulated conditions, but 
not under basal conditions in H295R cells, together with the significant reductions in 
glucocorticoid levels and ratios in vivo, strongly suggests therapeutic applications for 
Rooibos in the management of stress-related diseases. 
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CHAPTER 5 
General discussion and conclusion 
 
Chronically elevated glucocorticoid levels play a central role in hyperglycemia, 
T2D, insulin resistance, hypertension, suppression of the immune system, 
dyslipidemia, visceral obesity and CVDs, which are characteristic of clinical 
conditions such as MetS and Cushing’s syndrome (Chrousos and Gold 1998; Sen et 
al. 2008; Feelders et al. 2012; Gathercole et al. 2013). Of all the adverse systemic 
effects associated with elevated glucocorticoid levels, CVDs are the most deleterious 
and it is currently the leading cause of death globally, with diabetes, insulin 
resistance, dyslipidemia, obesity and hypertension being major risk factors for the 
development of CVDs (Arnaldi et al. 2003; Faggiano et al. 2003; Dekkers et al. 2007; 
Feelders et al. 2012). 
Numerous in vivo studies have reported that Rooibos consumption 
significantly improves glucose homeostasis, insulin resistance and lipid profiles, while 
also exhibiting potent anti-oxidant, anti-diabetic and cardio-protective properties, 
amongst others (Mose Larsen et al. 2008; Marnewick et al. 2011; Son et al. 2013; 
Ajuwon et al. 2014; Dludla et al. 2014). In addition, Rooibos has also been reported 
to modulate the activities of CYP17A1 and CYP21A2, two key enzymes involved in 
adrenal steroidogenesis (Richfield 2008; Perold 2009). These data suggests that 
Rooibos may have a functional role within most of the metabolic diseases associated 
with elevated glucocorticoid levels. The aim of this thesis was therefore to determine 
the influence of Rooibos on adrenal steroid hormone production in vitro and in vivo, 
and in particular, on the levels of the glucocorticoids, cortisol and CORT. 
Glucocorticoids are responsible for the regulation of carbohydrate, protein and 
lipid metabolism - increasing circulating glucose levels at the expense of protein and 
fat stores. In the liver, glucocorticoids promote gluconeogenesis and glycogen 
synthesis, while simultaneously stimulating protein catabolism in the muscle and 
lipolysis in adipose tissue to fuel gluconeogenesis. Furthermore, glucocorticoids also 
reduce glucose uptake and insulin sensitivity in tissues (Costanzo 2014). In response 
to the high blood glucose levels caused by the actions of glucocorticoids, insulin is 
secreted from pancreatic β-cells to promote glucose uptake, glycogenesis and 
lipogenesis, while lipolysis is inhibited. Patients with T2D, however, are insulin 
Stellenbosch University  https://scholar.sun.ac.za
! 101!
resistant and circulating glucose levels remain chronically elevated, which results in a 
wide range of pathological consequences. Treatment of T2D include drugs that target 
glucose-regulating processes in the pancreas, liver, skeletal muscle, gut or adipose 
tissue (Mohler et al. 2009). Rooibos was recently patented as an anti-diabetic agent 
due to the ability of Rooibos extract and two major Rooibos flavonoid compounds, 
aspalathin and rutin, to significantly reduce plasma glucose levels and improve 
impaired glucose tolerance in vivo (Mose Larsen et al. 2008; Kawano et al. 2009; 
Muller et al. 2012; Son et al. 2013). In addition, aspalathin was shown to suppress 
the expression of genes encoding enzymes involved in gluconeogenesis, 
glycogenolysis and lipogenesis in vivo, while also increasing glucose uptake in 
muscle cells and promoting insulin secretion from pancreatic β-cells in vitro (Kawano 
et al. 2009; Son et al. 2013). 
Various studies have reported that diabetes as well as CVDs are linked to 
oxidative stress, with the severity of diabetes being positively correlated to the 
formation of ROS (Brownlee 2005; Halliwell 2006; Houstis et al. 2006; Valko et al. 
2006). Rooibos, which is well known for its potent anti-oxidant properties, has been 
reported to reduce oxidative stress in vivo by counteracting the oxidative stress-
induced reduction in GSH:GSSH ratios, while also significantly reducing lipid-
peroxidation and pro-inflammatory cytokine secretion (Marnewick et al. 2003; Ajuwon 
et al. 2014; Hong et al. 2014). Macrophages that accumulate in adipose tissue are a 
major source of the pro-inflammatory cytokines, IL-6 and TNF-α. Inhibition of TNF-α 
production, which has been reported to be elevated in the blood and adipose tissue 
of obese animals, was shown to significantly improve insulin sensitivity (Hotamisligil 
1999; Shoelson et al. 2006). Furthermore, TNF-α and IL-6 released by adipocytes 
and macrophages are elevated in diabetic and insulin resistant patients (Senn et al. 
2002). The crosstalk between inflammation and ROS in diabetes is also evident, 
since ROS has been shown to promote the production of TNF-α and IL-6 (Rahman et 
al. 2002). It is therefore likely that agents capable of suppressing inflammation by 
reducing pro-inflammatory cytokine levels and/or their biological actions may have 
beneficial effects in the treatment of insulin resistance and/or diabetes (Kim et al. 
2004; Larsen et al. 2007; Sears and Ricordi 2012; Gómez-Zorita et al. 2013; 
Siriwardhana et al. 2013). Rooibos extract has been reported to exhibit potent anti-
inflammatory effects both in vitro (Hendricks and Pool 2010; Mueller et al. 2010) and 
in vivo (Baba et al. 2009) and preliminary results from our group have shown that 
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Rooibos decreased IL-6 production in rat adrenal tissue, while significantly increasing 
the levels of the anti-inflammatory cytokine, IL-10 (P<0.05) (unpublished data). It is 
therefore possible that the anti-diabetic properties of Rooibos could also be ascribed 
to its anti-inflammatory properties. 
As mentioned previously, hypertension as well as the aforementioned 
metabolic diseases are major risk factors for the development of CVDs (Arnaldi et al. 
2003; Faggiano et al. 2003; Dekkers et al. 2007; Feelders et al. 2012). Due to the 
strong association between the RAAS and blood pressure regulation, blockade of 
this system is a key therapeutic target for the treatment of hypertension, with ACE 
inhibitors currently being one of the most clinically relevant pharmacological agents 
for the treatment of hypertension and CVD (Persson et al. 2010; van Vark et al. 
2012). In a human study by Persson et al. (2010), a single oral dose of Rooibos was 
shown to significantly inhibit the activity of ACE at 30 min and 60 min after intake 
(Persson et al. 2010). It was subsequently shown that Rooibos exhibited its inhibitory 
action of ACE via the same mechanism as enalaprilat, a known ACE inhibitor 
(Persson 2012). 
In addition to hypertension, dyslipidemia, another major risk factor for CVD, is 
characterized by elevated plasma total cholesterol, LDL cholesterol and TGs and 
reduced levels of HDL cholesterol. In a study by Francisco (2010), a single oral dose 
of Rooibos significantly reduced total cholesterol, LDL cholesterol and TGs as well as 
inflammatory biomarkers and plasma glucose and insulin levels in normolipidemic 
subjects (Francisco 2010). These findings were corroborated in a subsequent study 
by Marnewick et al. (2011), reporting that Rooibos consumption significantly 
decreased plasma LDL cholesterol and TGs, while increasing the levels of HDL 
cholesterol in humans at risk for CVD (Marnewick et al. 2011). These findings 
suggest Rooibos to have positive modulatory effects in normal individuals as well as 
in disease states. In addition, Rooibos was shown to exhibit similar beneficial effects 
in a hyperlipidemic mouse model, as reflected in significant reductions in serum 
cholesterol, TG and FFA levels. Rooibos also protected the liver from lipid storage 
and prevented the accumulation of fat in adipocytes as well as the development of 
dietary-induced hepatic steatosis (Beltrán-Debón et al. 2011).  
Taken together, these data clearly demonstrate a role for Rooibos in the 
treatment and perhaps prevention of numerous metabolic disorders such as T2D, 
insulin resistance, hypertension, dyslipidemia and obesity, which are all major risk 
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factors for CVDs. Since these conditions are strongly linked with chronically elevated 
glucocorticoid levels, this study investigated whether Rooibos can reduce 
glucocorticoid levels through inhibiting the activities of steroidogenic enzymes 
involved in glucocorticoid homeostasis. 
The final step of glucocorticoid biosynthesis in the adrenal is catalysed by 
CYP11B1. However, glucocorticoid levels are not only dependent on the activity of 
CYP11B1, but also on the activities of upstream enzymes such as CYP21A2, 
3βHSD2 and CYP17A1, which catalyse a network of reactions to yield substrates for 
CYP11B1. Previous studies in our laboratory by Richfield (2008) and Perold (2009) 
showed that Rooibos significantly inhibited the activities of CYP17A1 and CYP21A2, 
expressed in COS-1 cells. (Richfield 2008; Perold 2009). In the present study, these 
investigations were continued by analysing the influence of Rooibos extract and five 
major Rooibos flavonoids (the dihydrochalcones, aspalathin and nothofagin, their 
flavone analogues, orientin and vitexin and the flavonol, rutin) on the activities of 
CYP17A1, 3βHSD2, CYP21A2 and CYP11B1, expressed in COS-1 cells. The results 
in the present study corroborated previous results by Richfield (2008) and Perold 
(2009), with Rooibos significantly inhibiting the catalytic activities of both CYP17A1 
and CYP21A2 in COS-1 cells, while the inhibitory effects on 3βHSD2 and CYP11B1 
were negligible. 3βHSD2 and CYP17A1 were inhibited in the presence of all the 
flavonoid compounds assayed, while inhibition of the downstream enzymes, 
CYP21A2 and CYP11B1 was both flavonoid and substrate specific. The 
dihydrochalcones inhibited the activity of CYP21A2 significantly, but not that of 
CYP11B1. In contrast, the flavones and the flavonol inhibited deoxycortisol 
conversion by CYP11B1 significantly, while inhibition of PROG and 17OH-PROG 
conversion by CYP21A2 as well as DOC conversion by CYP11B1 was either 
negligible or absent. From these results it is clear that there are distinct differences 
between the dihydrochalcones, flavones and the flavonol in terms of their inhibitory 
effects on adrenal steroidogenesis, which could be attributed to the structural 
differences of these flavonoid compounds in terms of the number and position of their 
hydroxyl and glucose moieties, as well as differences in the structural flexibility of 
these compounds. These data are in agreement with previous results by Ohno et al. 
(2002), showing that the flavonoids, daidzein, genistein and 6-hydroxyflavone 
selectively inhibited the activities of steroidogenic enzymes in H295R cells (Ohno et 
al. 2002).  
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After having studied the effects of Rooibos in isolated cell model systems, the 
influence of Rooibos and selected flavonoids were investigated on steroid hormone 
production in human adrenal H295R cells, under both basal and forskolin stimulated 
conditions, mimicking the effects of ACTH which increases glucocorticoid production 
in response to stress. In a recent study by Xing et al. (2011), the influence of ACTH 
on steroid production was determined in adult adrenal primary cultures. ACTH 
treatment increased the levels of the glucocorticoids, cortisol (63-fold), CORT (37-
fold), the glucocorticoid precursor, deoxycortisol (23-fold), as well as the adrenal 
androgen precursors, A4 (26-fold), DHEA (18-fold) and 11OHA4 (17-fold) 
significantly. Cortisol represented 30% of the total steroids detected in under basal 
conditions and 61% following ACTH treatment, confirming the ability of ACTH to 
stimulate glucocorticoid biosynthesis under the control of the HPA-axis. The authors 
continued their investigations in H295R cells, using forskolin instead of ACTH as an 
agonist. In terms of the total steroids detected in H295R cells, cortisol represented 
10% under basal conditions and 26% following forskolin stimulation (Xing et al. 
2011).  
In our analyses of steroid production by H295R cells, comparable results were 
obtained, with cortisol comprising 15% of the total steroids detected under basal 
conditions and 34% following stimulation with forskolin, confirming the ability of 
forskolin to increase cortisol production, mimicking the stress response in vitro. 
Under basal conditions, Rooibos had no effect on the levels of cortisol. However, 
upon forskolin stimulation, Rooibos significantly limited the forskolin-induced increase 
in cortisol levels (5-fold). With the exception of vitexin, which reduced basal cortisol 
levels 1.3-fold, none of the other flavonoids inhibited cortisol production under basal 
conditions. Under stimulated conditions, however, all the flavonoids significantly 
reduced cortisol levels between 1.3- and 3-fold when compared to untreated controls. 
Of all the flavonoids assayed, Rutin had the greatest inhibitory effect on cortisol 
biosynthesis, as it reduced stimulated cortisol levels from 3.8 µM to 1.2 µM, although 
these levels were still 2-fold higher than that of basal cortisol levels (0.7 µM). The 5-
fold reduction observed in the presence of Rooibos extract, on the other hand, 
reduced the levels of cortisol from 3.8 µM to 0.8 µM, similar to that of basal cortisol 
levels. Despite their varying inhibitory capacities, all the flavonoid compounds 
significantly reduced the levels of cortisol under stimulated conditions, although not to 
the same extent as the Rooibos extract. The reduction in cortisol levels by Rooibos 
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was, however, not due to inhibition of CYP11B1, but rather due to upstream inhibition 
of CYP17A1 and CYP21A1, resulting in decreased delivery of substrate to CYP11B1. 
Within the mineralocorticoid pathway, the levels of ALDO were unaffected 
under basal conditions, however, in response to forskolin treatment, the flavones, 
orientin and vitexin limited the elevation in ALDO levels significantly. In addition, the 
levels of the mineralocorticoid precursors were significantly lower in the presence of 
Rooibos and rutin under stimulated conditions. It is possible that, depending on levels 
of these compounds in Rooibos extracts and the degree of absorption in the gut, that 
these flavones may impact hypertension and CVD, together with the inhibition of 
ACE as previously reported (Persson et al. 2010; Persson 2012). It should, however, 
be noted that the levels of ALDO comprised 0.1% of the total steroids detected under 
basal conditions and 0.2% under forskolin-stimulated conditions. Stimulating the 
H295R cells with Ang II or KCl to increase the levels of ALDO would perhaps present 
a more appropriate model for an investigation into the effect of Rooibos on the 
mineralocorticoid pathway, allowing more definite conclusions to be drawn. 
In the adrenal androgen pathway, the levels of testosterone, as well as its 
precursor metabolite, A4, was significantly inhibited by Rooibos and all the flavonoid 
compounds assayed under both basal and forskolin stimulated conditions, with the 
exception of rutin, which did not have any inhibitory effect on steroid biosynthesis 
under basal conditions. Rooibos significantly reduced the steroid flux through the 
adrenal androgen precursor pathway, as is reflected in the increased levels of PREG. 
These results, suggesting inhibition of CYP17A1, were confirmed in COS-1 cells, as 
Rooibos reduced the activity of CYP17A1 by ±50%. In the human study, the levels of 
testosterone and DHEA-S, as well as the cortisol:testosterone and cortisol:DHEA-S 
ratios were unaffected following Rooibos consumption. These results were also 
reflected in rats, with testosterone levels not being affected by Rooibos. 
While Rooibos had negligible effect on circulating cortisol levels, Rooibos 
significantly reduced the cortisol:cortisone ratio (P=0.0486) in the plasma of both 
male and female subjects at risk for CVD. In addition, Rooibos also increased plasma 
cortisone levels in male subjects significantly (P=0.0465). In male Wistar rats, 
Rooibos reduced the CORT:11-DHC ratio to a level approaching significance 
(p=0.0624), with the levels of CORT (P=0.0275), and its precursor metabolite, DOC 
(P=0.0298), being significantly reduced following Rooibos consumption. In addition, 
Rooibos significantly reduced the CORT:testosterone ratio (P=0.0009) which, if 
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elevated, has been linked to the development of CVD (Rosmond et al. 2003; Smith et 
al. 2005).  
Since Rooibos did not inhibit the activity of CYP11B1, it is possible that the 
reduced cortisol:cortisone ratios observed in the human study could be attributed to 
altered activity of 11βHSD1 and/or 11βHSD2, since these isozymes catalyse the 
inter-conversion between cortisol and cortisone. In a recent study by Harno et al. 
(2013), it was proposed that intracellular glucocorticoids regenerated in the liver via 
11βHSD1, rather than circulating glucocorticoids, contribute towards the 
development of MetS, and that selective inhibition of 11βHSD1 seems to be a 
promising target for the treatment of MetS (Harno et al. 2013). Selective inhibition of 
11βHSD1 has been reported to prevent hyperglycemia, dyslipidemia and obesity, 
while also improving glucose homeostasis, lipid profiles, glucose tolerance and 
insulin tolerance (Masuzaki et al. 2003; Stewart 2003; Cooper and Stewart 2009; 
Anagnostis et al. 2013). Selective inhibition of 11βHSD1 is, however, crucial, since 
inhibition of 11βHSD2 results in inappropriate cortisol binding to the MRs in the 
kidney, which leads to “apparent mineralocorticoid excess” syndrome, hypertension, 
hypokalemia and suppression of the RAAS (Russo et al. 2000; Anagnostis et al. 
2010, 2013; Pant et al. 2010).  
In the present study it was demonstrated that Rooibos significantly inhibited 
the activity of 11βHSD1 expressed in CHO-K1 cells, in the absence and presence of 
H6PDH, as reflected in the significant reduction in the cortisol:cortisone ratio 
(P<0.01), while no effect on the cortisol:cortisone ratio was observed in cells 
expressing 11βHSD2.  
Taken together, the data presented in this thesis clearly shows that Rooibos 
and major Rooibos flavonoid compounds significantly inhibited the activities of key 
adrenal steroidogenic enzymes in vitro, which subsequently altered the steroid flux 
through the mineralocorticoid-, glucocorticoid- and adrenal androgen precursor 
pathways. The observation that Rooibos did not affect cortisol production under basal 
conditions in H295R cells, while significantly reducing elevated cortisol levels in 
response to forskolin treatment to levels characteristic of the basal milieu, strongly 
suggests a therapeutic role for Rooibos in the management of clinical conditions 
associated with elevated glucocorticoid levels. The significant reductions in cortisol 
levels appeared to be due to inhibition of upstream enzymes rather than CYP11B1. 
Rooibos did, however, significantly inhibit the activity of 11βHSD1 in vitro, as is 
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evident in the considerable reduction in the cortisol:cortisone ratios, while the activity 
of 11βHSD2 remained unaffected. These in vitro results were also reflected in vivo, 
as Rooibos significantly reduced the cortisol:cortisone ratios in human subjects at 
risk for CVD. While the reduction in the CORT:11-DHC ratio in rats only approached 
significance, Rooibos significantly reduced the levels of the glucocorticoid, CORT, 
and its precursor metabolite, DOC. It therefore appears that Rooibos affects 
glucocorticoid biosynthesis in one of two ways – either by reducing glucocorticoid 
levels in the adrenal via inhibition of upstream enzymes, or by favouring the 
inactivation of cortisol by 11βHSD1 in peripheral tissues. The data presented in this 
thesis, along with previous studies reporting on the anti-oxidant, anti-diabetic and 
cardio-protective properties of Rooibos, suggests a therapeutic role for Rooibos as a 
functional food to aid in the treatment of metabolic diseases associated with elevated 
glucocorticoid levels. 
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ADDENDUM A !
Table 1: Major flavonoid compounds (µg) present in the methanolic extract of 
unfermented Rooibos plant material and in the extract administered to COS-1 cells 
and H295R cells in the present study.  
Flavonoid compounds Rooibos a COS-1 cells b H295R cells c 
Dihydrochalcones          
Aspalathin 23562.0 ± 1035.0 641.1 ± 28.2 149.1 ± 6.5 
Nothofagin 4915.0 ± 408.7 133.8 ± 11.1 31.1 ± 2.6 
Flavones          
Orientin 2356.0 ± 61.2 64.1 ± 1.7 14.9 ± 0.4 
Iso-orientin 3153.0 ± 17.7 85.9 ± 0.5 20.0 ± 0.1 
Vitexin 435.7 ± 27.6 11.9 ± 0.8 2.8 ± 0.2 
Iso-vitexin 477.7 ± 25.7 13.0 ± 0.7 3.0 ± 0.2 
Luteolin-7-O-glucoside 144.1 ± 14.8 3.9 ± 0.4 0.9 ± 0.1 
Flavonols 
         
Rutin 621.9 ± 28.1 16.9 ± 0.8 3.9 ± 0.2 
Quercetin-3-O-robinobioside 1138.0 ± 53.3 31.0 ± 1.5 7.2 ± 0.3 
Iso-quercetrin 360.5 ± 20.6 9.8 ± 0.6 2.3 ± 0.1 
Hyperoside 319.3 ± 13.4 8.7 ± 0.4 2.0 ± 0.1 
 
Values are expressed as the mean ± SEM. 
a  Flavonoids extracted from 1g unfermented Rooibos plant material (methanolic extract). 
b  Flavonoids present in Rooibos extract administered to COS-1 cells / ml media. 
c  Flavonoids present in Rooibos extract administered to H295R cells / ml media. !
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